US PROVISIONAL PATENT APPLICATIONS IN EXCIPIENTS, DELIVERY AND RELEASE OF PHARMACEUTICAL COMPOSITIONS PUBLISHED IN 2011
This list includes Provisional Patent Applications published in the United States. The list was retrieved by searching the claims section of all patent applications. Salient search terms
included pharmaceutical formulations, excipients, strips, gums, cellulose, lozenge, tablets, capsules, suppositories; solid dosage, nasal inhalation; time, control or sustained drug release;
polysaccharides, polymeric excipients, hyaluronic acid, micro- and nano-spheres, carbomer, povidone, polyacrylates, polymerthacrylates; emulsions; enemas, vaginal, rectal, nasal, ocular
or buccal administration of medications, etc.
US Patent Applications in Excipients, Delivery and Release of
Pharmaceutical Compositions and Actives Published in 2011

Thank you for visiting FormulaScan . Please click on the Patent No to study the full patent document

US PATENT APPLICATIONS IN PHARMACEUTICAL EXCIPIENTS AND FORMULATION PUBLISHED IN 2011



Application No.: US20110002969A1  Published: 06/Jan/2011

Title: COSMETIC OR PHARMACEUTICAL COMPOSITIONS COMPRISING METALLOPROTEINASE INHIBITORS

Applicant/Assignee: LIPOTEC, S.A

Application No.: 12/920241   Filing Date: 27/Feb/2009

Abstract:

Peptides of general formula (I): R1AA1-AA2-AA3-AA4-R2 stereoisomers thereof, mixtures thereof or the cosmetically or pharmaceutically acceptable salts thereof, a method for obtaining them, cosmetic or pharmaceutical compositions containing them, and their use for the treatment and/or care of those conditions, disorders and/or pathologies of the skin, mucosae and/or scalp resulting from matrix metalloproteinases (MMP) overexpression or an increase in the MMP activity.

Priority: ES20080000597 Applic. Date: 2008-02-29; WO2009EP01419 Applic. Date: 2009-02-27

Inventor: SERRAIMA CRISTINA CARRENO [ES]; NEST WIM VAN DEN [ES]; PUCHE JUAN CEBRIAN [ES]; DOMENECH NURIA ALMINANA [ES]; MONTIEL ANTONIO FERRER [ES]; SANZ NURIA GARCIA [ES]


Application No.: US20110002977A1  Published: 06/Jan/2011

Title: LIPOSOMAL PHARMACEUTICAL PREPARATION AND METHOD FOR MANUFACTURING THE SAME

Applicant/Assignee:

Application No.: 12/521357   Filing Date: 29/Dec/2007

Abstract:

The present invention relates to a liposomal pharmaceutical preparation containing a multivalent ionic drug, a process for the preparation of the liposomal pharmaceutical preparation, and a use thereof in the treatment of diseases, in which the liposome has a size of about 30-80 nm, and the phospholipid bilayer has a phospholipid with a Tm higher than body temperature, so that the phase transition temperature of the liposome is higher than the body temperature.

Priority: CN20061102339 Applic. Date: 2006-12-29; WO2007CN71403 Applic. Date: 2007-12-29

Inventor: LI CHUNLEI [CN]; WANG JINXU [CN]; WANG CAIXIA [CN]; LI YANHUI [CN]; SHEN DONGMIN [CN]; GUO WENMIN [CN]; ZHANG LI [CN]; ZHANG LAN [CN]


Application No.: US20110003006A1  Published: 06/Jan/2011

Title: Orally Disintegrating Tablet Compositions Comprising Combinations of Non-Opioid and Opioid Analgesics

Applicant/Assignee:

Application No.: 12/772776   Filing Date: 03/May/2010

Abstract:

The present invention is directed to pharmaceutical compositions comprising a plurality of taste-masked non-opioid analgesic/opioid analgesic drug-containing microparticles, dosage forms comprising such pharmaceutical compositions (such as an orally disintegrating tablet), and methods of making the pharmaceutical compositions and dosage forms of the present invention. Dosage forms comprising the pharmaceutical compositions of the present invention are improved homogeneous blends of non-opioid and opioid analgesics which provide for more convenient and palatable administration of drug combinations, for example for treating pain.

Priority: US20090174780P Applic. Date: 2009-05-01; US20090174788P Applic. Date: 2009-05-01

Inventor: VENKATESH GOPI [US]; GOSSELIN MICHAEL [US]; CLEVENGER JAMES [US]; LAI JIN-WANG [US]


Application No.: US20110003008A1  Published: 06/Jan/2011

Title: MESENCHYMAL STEM CELL PARTICLES

Applicant/Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR)

Application No.: 12/918122   Filing Date: 21/Feb/2009

Abstract:

We describe a particle secreted by a mesenchymal stem cell and comprising at least one biological property of a mesenchymal stem cell. The biological property may comprise a biological activity of a mesenchymal stem cell conditioned medium (MSC-CM) such as cardioprotection or reduction of infarct size. The particle may comprise a vesicle or an exosome.

Priority: US20080066671P Applic. Date: 2008-02-22; WO2009SG00062 Applic. Date: 2009-02-21

Inventor: LIM SAI KIANG [SG]


Application No.: US20110003837A1  Published: 06/Jan/2011

Title: MODIFIED RELEASE FORMULATIONS OF HMG COA REDUCTASE INHIBITORS

Applicant/Assignee: LUPIN LIMITED

Application No.: 12/865448   Filing Date: 30/Jan/2009

Abstract:

Modified release formulations of HMG Co-A reductase inhibitors, which provide reduced incidence of rhabdomyolysis, renal toxicity and other side effects by increasing hepatic bioavailability and decreasing systemic availability upon oral administration. The modified release pharmaceutical formulation comprises a therapeutically effective amount of HMG CoA reductase inhibitor or a pharmaceutically acceptable salt(s), polymorph(s), solvate(s), hydrate(s), prodrug or metabolite thereof, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s), wherein the modified release formulation provides reduced incidence of adverse effects and improved efficacy when compared to the immediate release formulation upon oral administration.

Priority: IN2008KO00145 Applic. Date: 2008-01-30; WO2009IN00069 Applic. Date: 2009-01-30

Inventor: KULKARNI SHEETAL [IN]; DAS SRIRUPA [IN]; DESHMUKH ASHISH ASHOKRAO [IN]; DALAL SATISH KUMAR [IN]; KULKARNI SHIRISHKUMAR [IN]


Application No.: US20110003891A1  Published: 06/Jan/2011

Title: NOVEL USE OF ZINC N-ACETYLTAURINATE

Applicant/Assignee: TRI-INOV

Application No.: 12/918990   Filing Date: 25/Feb/2009

Abstract:

The subject matter of the present invention is Zn N-acetyltaurinate of formula: [CH3-CO-NH-CH2-CH2-SO3]2-Zn2+ for preventing and/or treating diseases with lipofuscin accumulation due in particular to aging or to oxidative stress, and for preparing a medicament that is of use in treating these diseases. Use: treatment of diseases related to aging or to oxidative stress, in particular age-related macular degeneration and diabetic retinopathy.

Priority: FR20080051233 Applic. Date: 2008-02-26; WO2009FR50297 Applic. Date: 2009-02-25

Inventor: DURLACH JEAN [FR]


Application No.: US20110008289A1  Published: 13/Jan/2011

Title: HYPERGLYCOSYLATED POLYPEPTIDE VARIANTS AND METHODS OF USE

Applicant/Assignee: ALIOS BIOPHARMA, INC

Application No.: 12/542561   Filing Date: 17/Aug/2009

Abstract:

The present invention provides synthetic Type I interferon receptor polypeptide agonists comprising consensus or hybrid Type I interferon receptor polypeptide agonists, containing one or more native or non-native glycosylation sites. The present invention provides synthetic Type I interferon receptor polypeptide agonists comprising consensus or hybrid Type I interferon receptor polypeptide agonists, containing one or more native or non-native glycosylation sites, as well as erythropoietin and darbepoetin alfa, each of which are linked to a penetrating peptide that facilitates translocation of a substance across a biological barrier as well as pharmaceutical compositions, including oral formulations, of the same. The present invention further provides oral formulations of hyperglycosylated or protease-resistant, hyperglycosylated polypeptide variants, which polypeptide variants lack at least one protease cleavage site found in a parent polypeptide, and thus exhibit increased protease resistance compared to the parent polypeptide, which polypeptide variants further include (1) a carbohydrate moiety covalently linked to at least one non-native glycosylation site not found in the parent protein therapeutic or (2) a carbohydrate moiety covalently linked to at least one native glycosylation site found but not glycosylated in the parent protein therapeutic. The present invention further provides compositions, including oral pharmaceutical compositions, comprising the synthetic Type I interferon receptor polypeptide agonist, the hyperglycosylated polypeptide variant, or the hyperglycosylated, protease-resistant polypeptide variant. The present invention further provides containers, devices, and kits comprising the synthetic Type I interferon receptor polypeptide agonist, the hyperglycosylated polypeptide variant, or the hyperglycosylated, protease-resistant polypeptide variant. The present invention further provides therapeutic methods involving administering an effective amount of an oral pharmaceutical composition comprising a synthetic Type I interferon receptor polypeptide agonist, a hyperglycosylated polypeptide variant, or a hyperglycosylated, protease-resistant polypeptide variant to an individual in need thereof.

Priority: US2006-351163 Applic. Date: 2006-02-08; US2006-330917 Applic. Date: 2006-01-11; US2005-200531 Applic. Date: 2005-08-08; US20040600202P Applic. Date: 2004-08-09; US20040600134P Applic. Date: 2004-08-09; US20040604280P Applic. Date: 2004-08-24; US20040604415P Applic. Date: 2004-08-24

Inventor: BLATT LAWRENCE M [US]; SEIWERT SCOTT D [US]; HONG JIN [US]


Application No.: US20110008291A1  Published: 13/Jan/2011

Title: Use of antifungal compositions to treat upper gastrointestinal conditions

Applicant/Assignee:

Application No.: 12/806564   Filing Date: 16/Aug/2010

Abstract:

The present invention provides a novel method for treating oral conditions and upper gastrointestinal conditions in a subject by providing an inventive oral dosage form of a pharmaceutical composition comprising an effective amount of at least one antifungal and optionally a flavor modifier and/or salivation component such as an herbal component. In the present invention, the subjects have either not been diagnosed or do not have active or recurrent fungal infections. Specifically, the present invention is directed to chewable dosage forms.

Priority: US2007-668764 Applic. Date: 2007-01-30; US20060764608P Applic. Date: 2006-02-01; US20060833433P Applic. Date: 2006-07-26; US20060862149P Applic. Date: 2006-10-19

Inventor: WEG STUART L [US]


Application No.: US20110008423A1  Published: 13/Jan/2011

Title: PHARMACEUTICAL COMPOSITIONS COMPRISING GRANULES OF PURIFIED MICROBIAL LIPASE AND METHODS FOR PREVENTING OR TREATING DIGESTIVE DISORDERS

Applicant/Assignee: ABBOTT PRODUCTS GMBH

Application No.: 12/811410   Filing Date: 02/Jan/2009

Abstract:

The present invention relates to pharmaceutical compositions comprising granules containing at least one recombinantly produced purified microbial lipase, the use of said pharmaceutical compositions for the manufacture of a medicament for the prevention or treatment of certain diseases or disorders like pancreatic endocrine insufficiency, and a process for the manufacture of said pharmaceutical compositions.

Priority: EP20080150018 Applic. Date: 2008-01-03; US20080018834P Applic. Date: 2008-01-03; WO2009EP50010 Applic. Date: 2009-01-02

Inventor: UNGER FLORIAN [DE]; SHLIEOUT GEORGE [DE]; KOERNER ANDREAS [DE]


Application No.: US20110008426A1  Published: 13/Jan/2011

Title: MODIFIED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING MYCOPHENOLATE AND PROCESSES THEREOF

Applicant/Assignee:

Application No.: 12/920512   Filing Date: 04/Mar/2009

Abstract:

Modified release pharmaceutical compositions comprising mycophenolate as the active agent or its pharmaceutically acceptable salts, esters, polymorphs, isomers, prodrugs, solvates, hydrates, or derivatives thereof, wherein the said composition exhibits a biphasic release profile when subjected to in-vitro dissolution and/or upon administration in-vivo are provided. The composition provides a drug release in a manner such that the drug levels are maintained above the therapeutically effective concentration (EC) constantly for an extended duration of time. Further, the difference between the maximum plasma concentration of the drug (Cmax) and the minimum plasma concentration of the drug (Cmjn), and in turn the flux defined as ((Cmax-Cmjn)/Cavg) is minimal. The present invention also provides process of preparing such dosage form compositions and prophylactic and/or therapeutic methods of using such compositions.

Priority: IN2008DE00549 Applic. Date: 2008-03-05; WO2009IN00148 Applic. Date: 2009-03-04

Inventor: JAIN RAJESH [IN]; SINGH SUKHJEET [IN]


Application No.: US20110008429A1  Published: 13/Jan/2011

Title: Anti-Retroviral Combination

Applicant/Assignee: CIPLA LIMITED

Application No.: 12/810301   Filing Date: 24/Dec/2008

Abstract:

A pharmaceutical composition comprising a solid unit dosage form comprising: (i) ritonavir or a pharmaceutically acceptable salt and ester thereof

(ii) darunavir or a pharmaceutically acceptable salt and ester thereof.

Priority: IN2007MU02538 Applic. Date: 2007-12-24; WO2008GB04291 Applic. Date: 2008-12-24

Inventor: LULLA AMAR [IN]; MALHOTRA GEENA [IN]


Application No.: US20110008454A1  Published: 13/Jan/2011

Title: IMMEDIATE RELEASE PHARMACEUTICAL GRANULE COMPOSITIONS AND A CONTINUOUS PROCESS FOR MAKING THEM

Applicant/Assignee: UNIVERSITEIT GENT

Application No.: 12/815781   Filing Date: 15/Jun/2010

Abstract:

Priority: GB20020005253 Applic. Date: 2002-03-06; US2004-933674 Applic. Date: 2004-09-03; WO2003BE00040 Applic. Date: 2003-03-05

Inventor: REMON JEAN PAUL [BE]; VERVAET CHRIS [BE]


Application No.: US20110008467A1  Published: 13/Jan/2011

Title: SODIUM THIOSULFATE-CONTAINING PHARMACEUTICAL COMPOSITIONS

Applicant/Assignee:

Application No.: 12/831331   Filing Date: 07/Jul/2010

Abstract:

Provided herein are pharmaceutically acceptable sodium thiosulfate and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-purgable organic carbon in a sodium thiosulfate-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium thiosulfate. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium thiosulfate.

Priority: US20090223993P Applic. Date: 2009-07-08

Inventor: SHERMAN CRAIG [US]; SMITH CATHERINE MARIE [US]; WIRTZ KEVIN ROBERT [US]; SCHULZE ERICH [US]


Application No.: US20110009362A1  Published: 13/Jan/2011

Title: SOLUBILITY-ENHANCED FORMS OF APREPITANT AND PHARMACEUTICAL COMPOSITIONS THEREOF

Applicant/Assignee: DR. REDDY'S LABORATORIES LTD, DR. REDDY'S LABORATORIES, INC

Application No.: 12/919331   Filing Date: 27/Feb/2009

Abstract:

Solubility-enhanced forms of aprepitant and processes for preparing such forms. The invention also provides solubility-enhanced forms of aprepitant that also possess stability against solid state conversions. Certain solubility-enhanced forms of aprepitant comprise a cyclodextrin or any of its derivatives. Other solubility-enhanced forms of aprepitant comprise fine particle preparations of aprepitant. The invention further provides non-nanoparticulate pharmaceutical formulations prepared using solubility-enhanced forms of aprepitant. The invention also provides taste-masked and orally disintegrating pharmaceutical formulations comprising aprepitant. Further, pharmaceutical formulations comprising solubilityenhanced forms of aprepitant and processes of preparation of such formulations, as well as methods of using them are provided.

Priority: IN2008CH00493 Applic. Date: 2008-02-27; IN2008CH00643 Applic. Date: 2008-03-14; IN2008CH02503 Applic. Date: 2008-10-14; US20080046571P Applic. Date: 2008-04-21; US20080048576P Applic. Date: 2008-04-29; US20080141460P Applic. Date: 2008-12-30; WO2009US35394 Applic. Date: 2009-02-27

Inventor: JOSHI MAHENDRA RAMACHANDRA [IN]; RADHAKRISHNAN NITHYA [IN]; DHIMAN MUNISH KUMAR [IN]; KARATGI PRADEEP JAIRAO [IN]; WAGH SANJAY CHHAGAN [IN]; PILLAI RAVIRAJ SUKUMAR [IN]; BHAGWATWAR HARSHAL PRABHAKAR [IN]; SREEDHARALA VENKATA NOOKARAJU [IN]


Application No.: US20110009416A1  Published: 13/Jan/2011

Title: PH INDEPENDENT FORMULATIONS OF 6-(5-CHLORO-2-PYRIDYL)-5-[(4-METHYL-1-PIPERAZINYL)CARBONYLOXY]-7-OXO-6,7-DIHYDRO-5H-PYRROLO[3,4-b]PYRAZINE

Applicant/Assignee: SEPRACOR INC

Application No.: 12/498751   Filing Date: 07/Jul/2009

Abstract:

Pharmaceutical compositions of zopiclone [(6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine)] that render the aqueous solubility/dissolution of the free base independent of the pH of the gastrointestinal tract are disclosed. The compositions are useful for oral administration.

Priority:

Inventor: HSIA RICHARD [US]; MISRA TUSHAR [US]; CAPILA PRIYA [US]; BAI GE [US]


Application No.: US20110014175A1  Published: 20/Jan/2011

Title: STIMULATION OF THE SYNTHESIS OF THE ACTIVITY OF AN ISOFORM OF LYSL OXIDASE-LIKE LOXL FOR STIMULATING THE FORMATION OF ELASTIC FIBRES

Applicant/Assignee: BASF BEAUTY CARE SOLUTIONS FRANCE S.A.S

Application No.: 12/824855   Filing Date: 28/Jun/2010

Abstract:

The invention relates to the stimulation of the synthesis and of the activity of an isoform of lysyl oxidase, and more particularly of the LOXL (lysyl oxidase-like) isoform. The invention relates notably to a method of identifying an active principle which stimulates the formation of elastic fibers. The aim of the invention is mainly to provide such a method of identification so as to provide compositions which enable stimulating the formation of elastic fibers.

Priority: FR20030007177 Applic. Date: 2003-06-13; US2004-852065 Applic. Date: 2004-05-24

Inventor: PERRIER ERIC [FR]; CENIZO VALERIE [FR]; BOUEZ CHARBEL [FR]; SOMMER PASCAL [FR]; DAMOUR ODILE [FR]; GLEYZAL CLAUDINE [FR]; ANDRE VALERIE [FR]; REYMERMIER CORINNE [FR]


Application No.: US20110014246A1  Published: 20/Jan/2011

Title: AMORPHOUS ARFORMOTEROL L-(+)-TARTRATE

Applicant/Assignee: ACTAVIS GROUP PTC EHF

Application No.: 12/919028   Filing Date: 27/Feb/2009

Abstract:

Disclosed herein is a novel and stable amorphous form of arformoterol L-(+)-tartrate, a process for its preparation, pharmaceutical compositions comprising amorphous arformoterol L-(+)-tartrate, and methods of treating with amorphous arformoterol L-(+)-tartrade.

Priority: IN2008CH00502 Applic. Date: 2008-02-28; IN2008CH02326 Applic. Date: 2008-09-24; WO2009IB05399 Applic. Date: 2009-02-27

Inventor: DIXIT GIRISH [IN]; GAIKWAD NANDKUMAR [IN]; PRADHAN NITIN SHARADCHANDRA [IN]; VALGEIRSSON JON [IS]


Application No.: US20110014248A1  Published: 20/Jan/2011

Title: Cosmetic use of microorganism(s) for the treatment of scalp disorders

Applicant/Assignee: L'OREAL, NESTEC SA

Application No.: 12/659597   Filing Date: 15/Mar/2010

Abstract:

The present invention relates to a use of an effective amount of at least one probiotic microorganism and/or a fraction thereof and/or a metabolite thereof for preventing and/or treating dandruff disorders of the scalp, as well as a cosmetic process for preventing and/or treating a dandruff condition including the administration a first cosmetic active agent and of at least a second cosmetic active agent, topically, the said first and second cosmetic active agents being formulated in separate compositions, the first cosmetic active agent being chosen from probiotic microorganisms, and mixtures thereof, and the second cosmetic active agent being chosen from antidandruff active agents.

Priority: FR20080057865 Applic. Date: 2008-11-19; FR20090053611 Applic. Date: 2009-06-02; US2009-509756 Applic. Date: 2009-07-27; US20080084582P Applic. Date: 2008-07-29; US20090213517P Applic. Date: 2009-06-16

Inventor: CASTIEL ISABELLE [FR]; GUENICHE AUDREY [FR]


Application No.: US20110015191A1  Published: 20/Jan/2011

Title: ORGANIC COMPOUNDS

Applicant/Assignee: SANDOZ AG

Application No.: 12/528483   Filing Date: 22/Feb/2008

Abstract:

Novel polymorph form III of Aprepitant and a method for preparation of novel form III is disclosed. New processes for the preparation of Aprepitant form II are disclosed. The processes involve transformation of form III to form II by heating in decalin and the precipitation of form II from a solvent or solvent mixture by cooling and/or addition of addition of seed crystals or an anti solvent. Solid dispersions containing Aprepitant form II in a suitable carrier are disclosed. A process for the preparation of the solid dispersion by evaporation of a solution of Aprepitant and the carrier in a suitable solvent is disclosed. Stable Aprepitant form II is disclosed. Further pharmaceutical compositions containing Aprepitant form II, III or solid dispersions containing Aprepitant form II in a suitable carrier are disclosed. A methanol solvate of Aprepitant is disclosed.

Priority: EP20070103150 Applic. Date: 2007-02-27; WO2008EP52192 Applic. Date: 2008-02-22

Inventor: LUDESCHER JOHANNES [AT]; WIESER JOSEF [AT]; PICHLER ARTHUR [AT]; GRIESSER ULRICH [AT]; BRAUN DORIS [AT]


Application No.: US20110015260A1  Published: 20/Jan/2011

Title: ANTI-MALARIAL PHARMACEUTICAL COMPOSITION

Applicant/Assignee: PROTOPHARMA LIMITED

Application No.: 12/739258   Filing Date: 27/Oct/2008

Abstract:

The invention provides pharmaceutical compositions for the treatment and prophylaxis of malaria, comprising artemether and a medium chain triglyceride formulated for transmucosal sublingual, buccal or nasal delivery, especially by a spray. Also provided are delivery devices containing the compositions.

Priority: GB20070020967 Applic. Date: 2007-10-25; GB20080006510 Applic. Date: 2008-04-10; WO2008GB50999 Applic. Date: 2008-10-27

Inventor: BOOLES CLIVE [GB]; ROSS CALVIN [GB]; SAMS MARTIN [GB]


Application No.: US20110020244A1  Published: 27/Jan/2011

Title: PHARMACEUTICAL COMPOSITIONS

Applicant/Assignee:

Application No.: 12/666001   Filing Date: 27/Jun/2008

Abstract:

The present invention relates to pharmaceutical compositions and in particular to suspension aerosol pharmaceutical compositions, processes to obtain them and their use in inhalation therapy.

Priority: GB20070012454 Applic. Date: 2007-06-27; WO2008GB50518 Applic. Date: 2008-06-27

Inventor: FLANDERS PAUL [GB]; THOMPSON JAMES [GB]


Application No.: US20110020265A1  Published: 27/Jan/2011

Title: USE OF OLIGOMERS OF LACTIC ACID IN THE TREATMENT OF GYNAECOLOGICAL DISORDERS

Applicant/Assignee: LACCURE AB

Application No.: 12/594147   Filing Date: 28/Mar/2009

Abstract:

Use of the one or more oligomers of lactic acid with the following formula (I) wherein n is an integer from 2 to 25 such as, e.g., from 2 to 20, from 3 to 25, from 3 to 20, from 2 to 15, from 3 to 15, from 2 to 10, from 3 to 10, from 4 to 10, or from 4 to 9 or a lactic acid oligomeric product for the prophylaxis and/or treatment of a disease or condition that benefit of an acidic environment especially a gynaecological infection such as a bacterial infection, such as bacterial vaginosis, unspecific colpitis, senile colpitis, cervicitis, and urethritis, a fungal infection, such as candidosis (Candida albicans), cryptococcosis, actinomycosis, or a viral infection, such as Human Immunodefiency Virus (HIV), Herpes Simplex Virus (HSV), Human Papilloma Virus (HPV).

Priority: DK20070000508 Applic. Date: 2007-03-30; WO2008EP02505 Applic. Date: 2008-03-28

Inventor: BATCHELLER GREG [BE]; HEDNER THOMAS [SE]; JOHNSSON JORGEN [SE]; SCHUBERT WERNER [SE]; SJOGREN CHRISTER [SE]; STERNER OLOV [SE]; AZNITOWSKA MALGORZAT [PL]


Application No.: US20110020299A1  Published: 27/Jan/2011

Title: METHOD AND COMPOSITION FOR THE REGENERATION OF TISSUE WITH THE AID OF STEM CELLS OR BONE MARROW CELLS

Applicant/Assignee:

Application No.: 12/935532   Filing Date: 24/Mar/2009

Abstract:

The invention relates to a novel polymerisable composition essentially consisting of blood or blood plasma, and also stem cells or bone-marrow cells, and to a method for tissue regeneration with the aid of such compositions. Mixtures of this type are able to polymerise under the influence of endogenous or exogenous polymerisation factors, such as thrombin, calcium ions or cell detritus, to give viscous gels, which are very advantageous for the development and differntiation of the stem cells or bone-marrow cells into tissue-specific cells. Polymers of this type, which, in particular, additionally comprise erythropoietin (EPO), or growth factors with a similar action, exhibit excellent properties on use for tissue regeneration or in the regeneration of bone defects.

Priority: EP20080006238 Applic. Date: 2008-03-31; WO2009EP02135 Applic. Date: 2009-03-24

Inventor: BADER AUGUSTINUS [DE]


Application No.: US20110020345A1  Published: 27/Jan/2011

Title: DRUG FUSIONS AND CONJUGATES

Applicant/Assignee:

Application No.: 12/935591   Filing Date: 27/Mar/2009

Abstract:

The present invention relates to drug fusions that have improved serum half lives. These fusions and conjugates comprise polypeptides, immunoglobulin (antibody) single variable domains and GLP and/or exendin molecules. The invention further relates to uses, formulations, compositions and devices comprising such drug fusions and conjugates.

Priority: US20080040796P Applic. Date: 2008-03-31; US20080086891P Applic. Date: 2008-08-07; WO2009EP53640 Applic. Date: 2009-03-27

Inventor: HERRING CHRISTOPHER [GB]; HOLT LUCY J [GB]; JESPERS LAURENT [GB]


Application No.: US20110020374A1  Published: 27/Jan/2011

Title: EXPRESSION SYSTEM FOR MODULATING AN IMMUNE RESPONSE

Applicant/Assignee: THE UNIVERSITY OF QUEENSLAND

Application No.: 12/738284   Filing Date: 02/Oct/2008

Abstract:

The present invention discloses methods and compositions for modulating the quality of an immune response to a target antigen in a mammal, which response results from the expression of a polynucleotide that encodes at least a portion of the target antigen, wherein the quality is modulated by replacing at least one codon of the polynucleotide with a synonymous codon that has a higher or lower preference of usage by the mammal to confer the immune response than the codon it replaces.

Priority: US20070980145P Applic. Date: 2007-10-15; WO2008AU01463 Applic. Date: 2008-10-02

Inventor: FRAZER IAN HECTOR [AU]


Application No.: US20110020397A1  Published: 27/Jan/2011

Title: HYDROPHOBIC MODIFIED PRES-DERIVED PEPTIDES OF HEPATITIS B VIRUS (HBV) AND THEIR USE AS HBV AND HDV ENTRY INHIBITORS

Applicant/Assignee: UNIVERSITATSKINIKUM HEIDELBERG

Application No.: 12/863663   Filing Date: 26/Jan/2009

Abstract:

The present invention relates to hydrophobic modified preS-derived peptides of hepatitis B virus (HBV) which are derived from a HBV preS consensus sequence and are N-terminal preferably acylated and optional C-terminal modified. These hydrophobic modified preS-derived peptides of HBV are very effective HBV entry inhibitors as well as HDV entry inhibitors and are, thus, suitable for the inhibition of HBV and/or HDV infection, prevention of primary HBV and/or HDV infection as well as treatment of (chronic) hepatitis B and/or D. The present invention further relates to pharmaceutical and vaccine compositions comprising these hydrophobic modified preS-derived peptides of HBV.

Priority: WO2008EP00591 Applic. Date: 2008-01-25; WO2009EP00476 Applic. Date: 2009-01-26

Inventor: MIER WALTER [DE]; URBAN STEPHAN [DE]


Application No.: US20110020408A1  Published: 27/Jan/2011

Title: MULTILAYERED MODIFIED RELEASE FORMULATION COMPRISING AMOXICILLIN AND CLAVULANATE

Applicant/Assignee: RANBAXY LABORATORIES LIMITED

Application No.: 12/600590   Filing Date: 16/May/2008

Abstract:

The present invention relates to multilayered modified release formulation comprising amoxicillin and clavulanate, process of preparation thereof and method of treating bacterial infection using these formulations. The multilayered modified release formulation comprises: an immediate release layer comprising amoxicillin and clavulanate

and a slow release layer comprising amoxicillin and one or more release retarding agents

and one or more non-release controlling inert barrier layers placed in between the immediate release layer and the slow release layer and comprising one or more pharmaceutically acceptable excipients.

Priority: IN2007DE01074 Applic. Date: 2007-05-17; WO2008IB51944 Applic. Date: 2008-05-16

Inventor: RAMARAJU KALAISELVAN [IN]; VERMA RAJAN KUMAR [IN]; RAMPAL ASHOK [IN]


Application No.: US20110020439A1  Published: 27/Jan/2011

Title: DELAYED RELEASE COMPOSITIONS OF DULOXETINE

Applicant/Assignee:

Application No.: 12/934148   Filing Date: 17/Mar/2009

Abstract:

A delayed release dosage form comprising core comprising duloxetine or its pharmaceutically acceptable salts or derivatives thereof, optionally, other pharmaceutically acceptable excipient(s) thereof

intermediate layer

and enteric layer

wherein the dosage form comprises one/more dissolution enhancer(s), wherein the enteric layer comprises one/more enteric polymers other than hydroxypropylmethyl acetate succinate. A process of preparing a delayed release dosage comprising mixing pharmaceutically acceptable excipients with duloxetine or its pharmaceutically acceptable derivatives thereof

granulating the product of previous step compressing the granulate formed in previous step to form core, coating said core with intermediate layer followed by coating with one/more enteric polymers and optional finishing coating. A delayed release dosage form comprising: core comprising duloxetine or its pharmaceutically acceptable derivative thereof, intermediate layer and enteric layer comprising one/more enteric polymers other than hydroxypropylmethyl acetate succinate

wherein dosage form contains one/more dissolution enhancer(s) and has improved dissolution.

Priority: IN2008KO00580 Applic. Date: 2008-03-24; WO2009IN00183 Applic. Date: 2009-03-17

Inventor: KOLE SHRENIK ANNASAHEB [IN]; SAHOO ASHOK KUMAR [IN]; AVACHAT MAKARAND KRISHNAKUMAR [IN]


Application No.: US20110020442A1  Published: 27/Jan/2011

Title: Taste Masked Oral Composition of Telithromycin

Applicant/Assignee: AVENTIS PHARMA S.A

Application No.: 12/899659   Filing Date: 07/Oct/2010

Abstract:

The invention relates to an oral compositions comprising telithromycin that have taste masking properties, a process for the preparation thereof, and methods of using the composition.

Priority: US2002-198115 Applic. Date: 2002-07-19

Inventor: BECOURT PHILIPPE [FR]; CIOLOCA NICOLETTA [FR]; BOLTRI LUIGI [IT]; DE LUIGI BRUSCHI STEFANO [IT]; MAPELLI LUIGI GIOVANNI [IT]; RABAGLIA LEONARDO [IT]; SCHWABE DETLEV [FR]


Application No.: US20110020445A1  Published: 27/Jan/2011

Title: EXTENDED RELEASE PHARMACEUTICAL COMPOSITIONS OF LEVETIRACETAM

Applicant/Assignee: SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI

Application No.: 12/838916   Filing Date: 19/Jul/2010

Abstract:

Extended release pharmaceutical compositions of levetiracetam or pharmaceutically acceptable salts thereof in the form of a tablet comprising glyceryl behenate and a polymethacrylate polymer with at least one pharmaceutically acceptable excipient.

Priority: TR20090005670 Applic. Date: 2009-07-22

Inventor: TURP HASAN ALI [TR]; YELKEN GULAY [TR]; SEZGIA ASIYE [TR]; TURKYILMAZ ALI [TR]; ONER LEVENT [TR]


Application No.: US20110020446A1  Published: 27/Jan/2011

Title: METHODS AND FORMULATIONS FOR MAKING PHARMACEUTICAL COMPOSITIONS CONTAINING BUPROPION

Applicant/Assignee:

Application No.: 12/900911   Filing Date: 08/Oct/2010

Abstract:

Embodiments of the invention generally provide pharmaceutical drug compositions, methods of preparing oral drug compositions, such as extended release dosage compositions, and methods for treating antidepressant or smoking cessation. In one aspect, the invention provides a pharmaceutical formulation comprising a core, including bupropion and its salt derivatives, and a coating. The coating may include from about 5% to about 99% by weight of the coating of a pharmaceutically acceptable pH-independent polymer. The coating may further include from about 0.001% to about 30% by weight of the coating of a surfactant. In another aspect, the invention provides methods for preparing and administering a pharmaceutical composition in oral dosage form, such as a tablet.

Priority: US2005-265918 Applic. Date: 2005-11-03; US20040626317P Applic. Date: 2004-11-08

Inventor: CHOW SAN-LAUNG [US]; WONG DAVID [US]; GARCIA DAMIAN [US]


Application No.: US20110020456A1  Published: 27/Jan/2011

Title: LANTHANUM COMPOSITION

Applicant/Assignee:

Application No.: 12/934296   Filing Date: 24/Mar/2009

Abstract:

The present invention discloses stable, solid oral pharmaceutical composition comprising Lanthanum carbonate having more than 6 molecules of water per molecule of lanthanum carbonate and pharmaceutically acceptable carriers or diluents, wherein said carrier or diluent excludes monosaccharide/s or disaccharide/s, such that the composition has comparable in-vitro dissolution profile similar to that of FOSRENOL TM . Also disclosed is a wet granulation process for making the same.

Priority: IN2008CH00737 Applic. Date: 2008-03-26; WO2009IN00195 Applic. Date: 2009-03-24

Inventor: AMMINABAVI NAGARAJ [IN]; BHUSHAN INDU [IN]; JAIN KUMAR [IN]; GORE SUBHASH [IN]; GUIDIPATI GNANADEVA [IN]; CHINNU BALAKRISHNAN [IN]; IYER SUBRAMANIAN [IN]; KUMAR MANOJ P [IN]; GUPTA RAJESHS [IN]


Application No.: US20110021426A1  Published: 27/Jan/2011

Title: METHODS FOR TREATMENT OF PAIN

Applicant/Assignee:

Application No.: 12/844721   Filing Date: 27/Jul/2010

Abstract:

The invention provides for methods and compositions for treatment of pain via craniofacial mucosal administration of an analgesic compound (e.g. a non-opioid analgesic peptide, an NOP agonist or N/OFQ). Intranasal administration of certain analgesic peptides such as N/OFQ results in global analgesic effects.

Priority: US20090228946P Applic. Date: 2009-07-27

Inventor: TOLL LAWRENCE R [US]; YEOMANS DAVID C [US]; ANGST MARTIN S [US]; JACOBS DANIEL I [US]


Application No.: US20110021478A1  Published: 27/Jan/2011

Title: COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND PDE4 INHIBITORS

Applicant/Assignee:

Application No.: 12/896232   Filing Date: 01/Oct/2010

Abstract:

Combinations comprising (a) a PDE4 inhibitor and (b) an antagonist of M3 muscarinic receptors which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid are useful, e.g., for the treatment of respiratory disease, e.g., asthma or chronic obstructive pulmonary diseases.

Priority: ES20040001312 Applic. Date: 2004-05-31; US2009-607409 Applic. Date: 2009-10-28; US2008-335849 Applic. Date: 2008-12-16; US2007-726982 Applic. Date: 2007-03-23; US2006-375308 Applic. Date: 2006-03-14; US2005-141169 Applic. Date: 2005-05-31

Inventor: GRAS ESCARDO JORDI [ES]; LLENAS CALVO JESUS [ES]; RYDER HAMISH [ES]; ORVIZ DIAZ PIO [ES]


Application No.: US20110021511A1  Published: 27/Jan/2011

Title: SUBSTITUTED 5H-PYRIMIDO[5,4-B]INDOLES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF FOR TREATING NON-SOLID MALIGNANT TUMORS OF THE BLOOD-PRODUCING SYSTEM

Applicant/Assignee: THE MEDICINES COMPANY (LEIPZIG) GMBH

Application No.: 12/520480   Filing Date: 21/Dec/2007

Abstract:

The invention relates to compounds of general formula 1 to processes for the production thereof, to pharmaceutical preparations containing said compounds and/or physiologically compatible salts and/or solvates which can be produced therefrom as well as to the pharmaceutical use of said compounds, the salts or solvates thereof as inductors of apoptosis in the case of non-solid malignant tumors of the hematopoietic system, in particular in the case of leukemias and lymphomas, more particularly in the case of leukemic B lymphocytes.

Priority: DE200610062203 Applic. Date: 2006-12-22; WO2007EP11387 Applic. Date: 2007-12-21

Inventor: REICHELT CLAUDIA [DE]; SCHULZE ALEXANDER [DE]; DAGHISH MOHAMMED [DE]; LUDWIG FRIEDRICH-ALEXANDER [DE]; HEINICKE JOCHEN [DE]; HERRMANN KONRAD [DE]; SCHUSTER MAJ [DE]; LETSCHERT SVEN [DE]; MUGRIDGE KENNETH [DE]; DEANGELO JOSEPH [US]


Application No.: US20110021535A1  Published: 27/Jan/2011

Title: Trazodone Composition for Once a Day Administration

Applicant/Assignee:

Application No.: 12/892454   Filing Date: 28/Sep/2010

Abstract:

The invention relates to a once a day formulation of trazodone or a trazodone derivative. The formulation contains trazodone or a trazodone derivative and a controlled release excipient so that, once administered orally, the trazodone or the trazodone derivative is maintained at a therapeutic plasma concentration from at least 1 hour to at least 24 hours after initial administration. After administration, the initial therapeutic action takes effect within the first hour and lasts at least about 24 hours. This therapeutic effect remains relatively and substantially stable for the remaining period of 24 hours. The formulations can be used for treating depression and/or sleeping disorders.

Priority: US2006-519194 Applic. Date: 2006-09-11; US20050715162P Applic. Date: 2005-09-09

Inventor: GERVAIS SONIA [CA]; SMITH DAMON [CA]; RAHMOUNI MILOUD [CA]; CONTAMIN PAULINE [FR]; OUZEROUROU RACHID [CA]; MA MY LINH [CA]; FERRADA ANGELA [CA]; SOULHI FOUZIA [CA]


Application No.: US20110021553A1  Published: 27/Jan/2011

Title: IMMUNOSUPPRESSIVE MACROLIDE POWDER FOR ORAL SUSPENSION

Applicant/Assignee:

Application No.: 12/866392   Filing Date: 05/Feb/2009

Abstract:

The present invention describes pharmaceutical compositions that comprise a tacrolimus powder for oral suspension that exhibits great stability as a powder for suspension and also, once prepared, as the extemporaneous suspension, without the formation of cake-like clusters, same having a satisfactory flavour and a pleasant aroma. The invention also describes the method for preparing the pharmaceutical compositions, same being a dry method that comprises mixing tacrolimus and pre-sieved pharmaceutically acceptable carriers for a suitable length of time, and the use of the pharmaceutical compositions for treating and preventing rejection of transplanted organs and atopic dermatitis.

Priority: CL20080000374 Applic. Date: 2008-02-05; WO2009IB50455 Applic. Date: 2009-02-05

Inventor: MONETTA RODRIGO IVAN RAMIREZ [CL]


Application No.: US20110023876A1  Published: 03/Feb/2011

Title: COMPOSITIONS FOR PULMONARY DELIVERY OF LONG-ACTING MUSCARINIC ANTAGONISTS AND ASSOCIATED METHODS AND SYSTEMS

Applicant/Assignee: PEARL THERAPEUTICS, INC

Application No.: 12/790448   Filing Date: 28/May/2010

Abstract:

Compositions, methods and systems are provided for pulmonary delivery of long-acting muscarinic antagonists and long-acting [beta]2 adrenergic receptor agonists via a metered dose inhaler. In particular embodiments, the compositions include a suspension medium, active agent particles, and suspending particles, in which the active agent particles and suspending particles form a co-suspension within the suspension medium.

Priority: US20090182565P Applic. Date: 2009-05-29; US20090258172P Applic. Date: 2009-11-04; US20100309365P Applic. Date: 2010-03-01; US20100345536P Applic. Date: 2010-05-17

Inventor: VEHRING REINHARD [CA]; HARTMAN MICHAEL STEVEN [US]; SMITH ADRIAN EDWARD [US]; JOSHI VIDYA B [US]; DWIVEDI SARVAJNA KUMAR [US]


Application No.: US20110027172A1  Published: 03/Feb/2011

Title: DRUG DELIVERY SYSTEM FOR PHARMACEUTICALS AND RADIATION

Applicant/Assignee:

Application No.: 12/747040   Filing Date: 10/Dec/2008

Abstract:

The present invention provides a drug delivery system for delivery of an agent and a radiopharmaceutical agent. The drug delivery system may specifically target an organ, tissue, cells, extracellular matrix, or intracellular compartment. Typically, the drug delivery system is a particle. Pharmaceutical compositions comprising the inventive particles are also provided. The present invention provides methods of preparing and using the inventive particles and pharmaceutical compositions. The inventive particles are useful in treating and diagnosing a variety of diseases including cancer. The inventive particles are also useful in tracking particles in vivo.

Priority: US20070012617P Applic. Date: 2007-12-10; WO2008US86255 Applic. Date: 2008-12-10

Inventor: WANG ZHUANG [US]; FAROKHZAD OMID C [US]; ZHANG LIANGFANG [US]; RADOVIC-MORENO ALEKSANDAR FILIP [US]; GU FRANK X [CA]; LANGER ROBERT S [US]


Application No.: US20110027359A1  Published: 03/Feb/2011

Title: Novel Pharmaceutical Compositions Comprising Levetiracetam

Applicant/Assignee: UCB, S.A

Application No.: 12/720768   Filing Date: 10/Mar/2010

Abstract:

The present invention relates to a pharmaceutical composition comprising levetiracetam as active ingredient, the invention relates specifically to a prolonged release formulation.

Priority: EP20060014537 Applic. Date: 2006-07-13; US2007-681490 Applic. Date: 2007-03-02; US20060807526P Applic. Date: 2006-07-17

Inventor: GOFFIN CAROLINE [BE]; BERWAER MONIQUE [BE]; BOONEN MICHAEL [BE]; DELEERS MICHEL [BE]; FANARA DOMENICO [BE]


Application No.: US20110027361A1  Published: 03/Feb/2011

Title: EXTENDED RELEASE DOSAGE FORM OF PALIPERIDONE

Applicant/Assignee: TORRENT PHARMACEUTICALS LTD

Application No.: 12/865801   Filing Date: 03/Feb/2009

Abstract:

The present invention relates to an extended release solid oral pharmaceutical composition comprising Paliperidone or its pharmaceutically acceptable salts and process for preparing the same.

Priority: IN2008MU00232 Applic. Date: 2008-02-04; WO2009IN00072 Applic. Date: 2009-02-03

Inventor: MURUGESAN GANESAN [IN]; ABRAHAM JAYA [IN]; GUPTA VINODKUMAR [IN]; SHAH BHAVESH [IN]


Application No.: US20110027377A1  Published: 03/Feb/2011

Title: IMMEDIATE RELEASE PHARMACEUTICAL GRANULE COMPOSITIONS AND A CONTINUOUS PROCESS FOR MAKING THEM

Applicant/Assignee: UNIVERSITEIT GENT

Application No.: 12/815715   Filing Date: 15/Jun/2010

Abstract:

Priority: GB20020005253 Applic. Date: 2002-03-06; US2006-276577 Applic. Date: 2006-03-06; US2004-933674 Applic. Date: 2004-09-03; WO2003BE00040 Applic. Date: 2003-03-05

Inventor: REMON JEAN PAUL [BE]; VERVAET CHRIS [BE]


Application No.: US20110028428A1  Published: 03/Feb/2011

Title: HIRSUTELLA SINENSIS MYCELIA COMPOSITIONS AND METHODS FOR TREATING SEPSIS AND RELATED INFLAMMATORY RESPONSES

Applicant/Assignee: WYNTEK CORP

Application No.: 12/750655   Filing Date: 30/Mar/2010

Abstract:

Compositions comprising Hirsutella sinensis mycelia extracts and chromatographically separated polysaccharide-enriched fractions thereof are provided. Methods for extracting Hirsutella sinensis mycelia are provided. Compositions for methods for their use in amelioration, prevention and treatment of sepsis, acute endotoxemia and inflammatory responses are disclosed.

Priority: US20090211495P Applic. Date: 2009-03-30

Inventor: WONG CHI-HUEY [US]; YU ALICE L [US]; YANG WEN-BIN [TW]; FAN EUGENE [US]; HSU HSIEN-YEH [TW]; LEE PEISHAN [TW]; TU TSENG-RONG [TW]; HUNG CHIN-CHUNG [TW]


Application No.: US20110028456A1  Published: 03/Feb/2011

Title: Solid Pharmaceutical Dosage Form

Applicant/Assignee: CIPLA LIMITED

Application No.: 12/812432   Filing Date: 12/Jan/2009

Abstract:

A pharmaceutical composition comprising a solid unit dosage form comprising: one or more of pharmaceutically active ingredients selected from valacyclovir, olanzapine, voriconazole, topotecan, artesunate, amodiaquine, guggulosterone, ramipril, telmisartan, tibolone, atorvastatin, simvastatin, amlodipine, ezetimibe, fenofibrate, tacrolimus, valgancyclovir, valsartan, clopidrogel, estradiol, trenbolone, efavirenz, metformin, pseudoephedrine, verapamil, felodipine, valproic acid/sodium valproate, mesalamine, hydrochlorothiazide, levosulpiride, nelfinavir, cefixime and cefpodoxime proxetil in combination with a water insoluble polymer and/or a water soluble polymer. Methods for making the pharmaceutical composition are also disclosed.

Priority: IN2008MU00089 Applic. Date: 2008-01-11; IN2008MU00489 Applic. Date: 2008-03-10; IN2008MU00619 Applic. Date: 2008-03-24; WO2009GB00083 Applic. Date: 2009-01-12

Inventor: LULLA AMAR [IN]; MALHOTRA GEENA [IN]


Application No.: US20110033526A1  Published: 10/Feb/2011

Title: PHARMACEUTICAL COMPOSITION OF ANTIBIOTICS AND PREBIOTICS FOR PREVENTING AND TREATING DYSBIOSIS DURING ANTIBACTERIAL THERAPY

Applicant/Assignee:

Application No.: 12/736169   Filing Date: 18/Mar/2008

Abstract:

The invention relates to medicine and pharmacology, in particular to pharmaceutical compositions containing the following antimicrobial preparations: antibiotics and sulphanylamides combined with prebiotic in the form of a lactulose. The composition is used for preventing enteral dysbiosis arising during antibiotic therapy using the wide range of preparations. The inventive pharmaceutical composition contains antibiotic or a sulphanylamide preparation and lactulose, wherein the antibiotic particle size ranges from 20 to 160 mkm, the sulphanylamide preparation particle size ranges from 40 to 150 mkm and the lactulose has a particle size equal to or less than 0.3 mm and the purity of at least 97%, with the ratio of the antibiotic and lactulose ranging from 1:0.1 to 1:100, and the ratio of the sulphanylamide preparation and lactulose of 1:12, said composition being internally administered. The inventive preparations contribute to the preservation of antibiotic-damaged intestinal flora by producing selective prebiotic action on the growth of dominant types of microflora of the large intestine, such as lactobacilli and bifidobacteria.

Priority: WO2008RU00152 Applic. Date: 2008-03-18

Inventor: DIKOVSKIY ALEKSANDER VLADIMIROVICH [RU]; DOROZHKO OLEG VALENTINOVICH [RU]; RUDOI BORIS ANATOLIEVICH [RU]


Application No.: US20110033535A1  Published: 10/Feb/2011

Title: PHARMACEUTICAL COMPOSITION AS SOLID DOSAGE FORM AND METHOD FOR MANUFACTURING THEREOF

Applicant/Assignee: FERRING B.V

Application No.: 12/730019   Filing Date: 23/Mar/2010

Abstract:

The present invention relates to a novel pharmaceutical composition as a solid dosage form comprising desmopressin as a therapeutically active ingredient, and to a method for manufacturing thereof. The invention relates to a pharmaceutical composition as a solid dosage form comprising desmopressin, or a pharmaceutically acceptable salt thereof, as a therapeutically active ingredient together with a pharmaceutically acceptable excipient, diluent or carrier, or mixture thereof, wherein the pharmaceutical composition is composed of a compressed granulate and contains lubricant in an amount of from 0.05 to less than 0.50 percent by weight of said pharmaceutical composition.

Priority: US2006-396899 Applic. Date: 2006-04-04; US2003-626857 Applic. Date: 2003-07-25

Inventor: LOMRYD HAKAN [SE]; NICKLASSON HELENA [SE]; OLSSON LARS-ERIK [SE]


Application No.: US20110033538A1  Published: 10/Feb/2011

Title: Pharmaceutical composition containing a pyrrolidone anticonvulsant agent and method for the preparation thereof

Applicant/Assignee: PHARMATHEN S.A

Application No.: 12/739475   Filing Date: 23/Apr/2010

Abstract:

The present invention relates to a pharmaceutical formulation of solid dosage forms comprising a therapeutically effective amount of a pyrrolidone anticonvulsant agent, and in particular Levetiracetam or a pharmaceutical acceptable salt or derivative thereof, in combination with an effective diluent, such as Dibasic Calcium Phosphate, and additional pharmaceutical excipients, and a process for the preparation thereof by wet granulation.

Priority: WO2007EP08952 Applic. Date: 2007-10-16

Inventor: KARAVAS EVANGELOS [GR]; KOUTRIS EFTHIMIOS [GR]; BIKIARIS DIMITRIOS [GR]; SAMARA VICKY [GR]; KOUTRI IOANNA [GR]; STATHAKI ELENI [GR]


Application No.: US20110034389A1  Published: 10/Feb/2011

Title: ACTIVE AGENTS, COMPOSITIONS, AND METHODS FOR INHIBITING AND REVERSING PLATELET FUNCTION

Applicant/Assignee: UNIVERSITY OF UTAH RESEARCH FOUNDATION

Application No.: 12/667119   Filing Date: 26/Oct/2009

Abstract:

Active agents, compositions, and methods for inhibiting and reversing platelet function are provided herein. In particular embodiments, the active agents provided herein inhibit or reverse platelet function. In particular embodiments, the compositions described herein are pharmaceutical formulations. Methods of inhibiting and reversing platelet function are also provided herein. In particular embodiments, methods as described herein include administration of a Sema3E polypeptide. Further, methods of treating pathologic conditions associated with platelet function (i.e., platelet activation) and methods of screening active agent candidates are also provided.

Priority: US20080108357P Applic. Date: 2008-10-24; WO2009US62107 Applic. Date: 2009-10-26

Inventor: LI DEAN Y [US]; SMITH MATTHEW [US]; WEYRICH ANDY [US]


Application No.: US20110034399A1  Published: 10/Feb/2011

Title: Liquid and Freeze Dried Formulations

Applicant/Assignee: IPSEN PHARMA S.A.S

Application No.: 12/936349   Filing Date: 03/Apr/2009

Abstract:

The present invention relates to stable parenteral formulations comprising a new class of compounds, which is a non proteinic compound, a method for preparing such formulations as well as the use of certain compounds for stabilizing these formulations.

Priority: EP20080290330 Applic. Date: 2008-04-04; WO2009IB05441 Applic. Date: 2009-04-03

Inventor: NOURRISSON DIDIER [FR]


Application No.: US20110034477A1  Published: 10/Feb/2011

Title: Crystalline Polymorph of Doxazosin Mesylate (Form IV) and Process for Preparation Thereof

Applicant/Assignee: CIPLA LIMITED

Application No.: 12/810297   Filing Date: 10/Jul/2008

Abstract:

Crystalline Form IV of doxazosin mesylate, a process for its preparation and uses thereof.

Priority: IN2007MU02537 Applic. Date: 2007-12-24; WO2008GB02362 Applic. Date: 2008-07-10

Inventor: KANKAN RAJENDRA NARAYANRAO [IN]; RAO DHARMARAJ RAMACHANDRA [IN]; GANGRADE MANISH GOPALDAS [IN]; MUDGAL SHRIKANT SURESH [IN]


Application No.: US20110038898A1  Published: 17/Feb/2011

Title: DISSOLUTION PROPERTIES OF DRUG PRODUCTS CONTAINING OLMESARTAN MEDOXOMIL

Applicant/Assignee:

Application No.: 12/921627   Filing Date: 02/Mar/2009

Abstract:

A pharmaceutical composition containing olmesartan medoxomil and amlodipine, which has improved dissolvability. Said composition contains (A) olmesartan medoxomil and (B) amlodipine as active ingredients and (C) a calcium-containing additive. A method of improving the dissolution properties of a pharmaceutical composition containing olmesartan medoxomil and amlodipine by using said composition is also provided.

Priority: JP20080064500 Applic. Date: 2008-03-13; WO2009JP53859 Applic. Date: 2009-03-02

Inventor: YADA SHUICHI [JP]; YANO HIDEKI [JP]; NAGAIKE TSUYOSHI [JP]; YOKOI MISATO [JP]


Application No.: US20110039804A1  Published: 17/Feb/2011

Title: Composition of Risedronate and Vitamin D3

Applicant/Assignee: LANDSTEINER SCIENTIFIC, S.A. DE C.V

Application No.: 12/520149   Filing Date: 09/Nov/2009

Abstract:

The present invention is focused on compositions that contain risedronate and vitamin D as active ingredients. This dose combines the pharmaceutical properties of risedronate, which avoids bone degradation, and those from vitamin D, which fixates calcium to the bone, which are used for treating postmenopausal osteoporosis.

Priority: WO2006MX00151 Applic. Date: 2006-12-20

Inventor: ARANDA FUENTES JOAQUIN [MX]; HERNANDEZ PALMA ELIZABETH [MX]


Application No.: US20110039825A1  Published: 17/Feb/2011

Title: LIGANDS OF ALPHA-ADRENOCEPTORS, DOPAMINE, HISTAMINE, IMIDAZOLINE AND SEROTONIN RECEPTORS AND THEIR USE

Applicant/Assignee: ALLA CHEM, LLC

Application No.: 12/810013   Filing Date: 19/Dec/2008

Abstract:

The invention relates to novel ligands the broad spectrum of biological activity of which includes simultaneously [alpha]-adrenoceptors, dopamine receptors, histamine receptors, imidazoline receptors and serotonin receptors, among them serotonin 5-HT7 receptors, which are compounds of general formula 1 in the form of free bases, geometrical isomers, racemic mixtures or individual optical isomers, pharmaceutically acceptable salts and/or hydrates, wherein: R1 is a substituent of amino group, selected from hydrogen, optionally substituted C1-C4 alkyl, acyl, heterocyclyl, alkoxycarbonyl, substituted sulfonyl

R2 is a substituent of cyclic system, selected from hydrogen, halogen, optionally substituted C1-C4 alkyl, CF3, CN, alkoxy, alkoxycarbonyl, carboxyl, heterocyclyl or substituted sulfonyl

Ar is optionally substituted aryl not necessarily annalated with heterocyclyl, or optionally substituted aromatic heterocyclyl

W is optionally substituted (CH2)m group, optionally substituted CH-CH group, optionally substituted CH2-CH-CH group, C[identical to]C group, SO2 group

n=1, 2

m=1, 2, 3

solid line accompanied by dotted line, i.e. may represent single or double bond. The invention also relates to active ingredients, pharmaceutical compositions comprising the said ligands as active ingredients

to novel medicaments useful for treatment of diseases and conditions of central nervous system (CNS) of humans and warm-blooded animals.

Priority: RU20070147347 Applic. Date: 2007-12-21; RU20070147349 Applic. Date: 2007-12-21; RU20070147351 Applic. Date: 2007-12-21; RU20070147352 Applic. Date: 2007-12-21; RU20070147355 Applic. Date: 2007-12-21; RU20070147356 Applic. Date: 2007-12-21; RU20070147358 Applic. Date: 2007-12-21; RU20070147361 Applic. Date: 2007-12-21; RU20070147363 Applic. Date: 2007-12-21; RU20070147365 Applic. Date: 2007-12-21; RU20070147367 Applic. Date: 2007-12-21; RU20070147368 Applic. Date: 2007-12-21; RU20070147370 Applic. Date: 2007-12-21; RU20070147371 Applic. Date: 2007-12-21; RU20070147372 Applic. Date: 2007-12-21; RU20070147374 Applic. Date: 2007-12-21; WO2008RU00780 Applic. Date: 2008-12-19

Inventor: IVASHCHENKO ANDREY ALEXANDROVICH [RU]; IVASHCHENKO VASILIEVICH [US]; LAVROVSKY YAN VADIMOVICH [US]; MITKIN OLEG DMITRIEVICH [RU]; SAVCHUK NIKOLAY FILIPPOVICH [US]; TKACHENKO SERGEY YEVGENIEVICH [US]; OKUN ILYA MATUSOVICH [US]


Application No.: US20110039897A1  Published: 17/Feb/2011

Title: LIQUID FORMULATION FOR DEFERIPRONE WITH PALATABLE TASTE

Applicant/Assignee: APOTEX TECHNOLOGIES INC

Application No.: 12/989127   Filing Date: 25/Apr/2008

Abstract:

An oral pharmaceutical liquid formulation comprising deferiprone and a taste masking composition, said taste masking composition comprising an effective amount of a sweetener (such as sucralose) per litre of liquid composition, an effective amount of a thickening and suspension aid, (for example hydroxyethylcellulose), per litre of liquid composition, an effective amount of a humectant (such as glycerin) per litre of liquid composition, and an effective amount of at least one flavoring agent, wherein a final form of said taste-masked pharmaceutical has a substantially non-bitter and palatable taste.

Priority: WO2008CA00784 Applic. Date: 2008-04-25

Inventor: SPINO MICHAEL [CA]; HUI ANITA [CA]; YANG CIHUA [CA]; KABIR MOHAMMED N [CA]


Application No.: US20110044971A1  Published: 24/Feb/2011

Title: METHOD AND COMPOSITION FOR TREATING A SERATONIN RECEPTOR-MEDIATED CONDITION

Applicant/Assignee:

Application No.: 12/747912   Filing Date: 13/Dec/2008

Abstract:

A method and composition for treating serotonin receptor-mediated conditions.

Priority: US20070013377P Applic. Date: 2007-12-13; WO2008US86734 Applic. Date: 2008-12-13

Inventor: POLYMEROPOULOS MIHAEL H [US]; BAROLDI PAOLO [US]; WOLFGANG CURT [US]


Application No.: US20110045046A1  Published: 24/Feb/2011

Title: GLYCOPEPTIDES AND METHODS OF MAKING AND USING THEM

Applicant/Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Application No.: 12/918155   Filing Date: 26/Feb/2009

Abstract:

In one embodiment, the invention provides glycopeptides (or carbohydrate-peptide conjugates) comprising TACAs that direct against (e.g., bind specifically to) cytotoxic T lymphocytes (CTLs) or helper T cells for, e.g., CTL- or T-helper-based immunotherapy of carcinomas, and methods for making and using the glycopeptides of the invention. In one embodiment, the invention provides novel glycopeptides comprising tumor-derived carbohydrate or tumor-derived epitopes that specifically bind to major histocompatibility (MHC) class I molecules on cytotoxic T lymphocytes (CTLs) or MHC molecules on helper T cells, and methods for using same, e.g., as a vaccine, including a pan-cancer vaccine.

Priority: US20080031387P Applic. Date: 2008-02-26; US20080038832P Applic. Date: 2008-03-24; WO2009US35340 Applic. Date: 2009-02-26

Inventor: FRANCO ALESSANDRA [US]


Application No.: US20110045062A1  Published: 24/Feb/2011

Title: FORMULATION

Applicant/Assignee:

Application No.: 12/939450   Filing Date: 04/Nov/2010

Abstract:

This invention relates to a formulation comprising a dipeptidylpeptidase IV (DPP-IV) inhibitor preferably vildagliptin and metformin, to tablets comprising such formulations and to processes for the preparation thereof.

Priority: US2008-067346 Applic. Date: 2008-03-19; WO2006US37198 Applic. Date: 2006-09-25; US20050722624P Applic. Date: 2005-09-29

Inventor: JOSHI YATINDRA [US]; KOWALSKI JAMES [US]; LAKSHMAN JAY PARTHIBAN [US]; ROYCE ALAN EDWARD [US]; TONG WEI-QIN [US]; VASANTHAVADA MADHAV [US]


Application No.: US20110045068A1  Published: 24/Feb/2011

Title: PHARMACEUTICAL FORMULATIONS FOR THE ORAL ADMINISTRATION OF PPI

Applicant/Assignee:

Application No.: 12/734491   Filing Date: 07/Nov/2008

Abstract:

The present invention relates to pharmaceutical formulations comprising a layer of compressed granules to facilitate the administration of oral PPI.

Priority: IT2007FI00253 Applic. Date: 2007-11-09; WO2008EP65127 Applic. Date: 2008-11-07

Inventor: VALDUCCI ROBERTO [IT]; ALIGHIERI TIZIANO [IT]; AVANESSIAN SEROZH [IT]


Application No.: US20110045079A1  Published: 24/Feb/2011

Title: DRY POWDERS OF CELLULAR MATERIAL

Applicant/Assignee: PRESIDENT AND FELLOWS OF HARVARD COLLEGE

Application No.: 12/681652   Filing Date: 06/Oct/2008

Abstract:

Methods and compositions of spray drying cellular material are provided that allow preservation of the cellular material. In one aspect, the cellular material is spray dried with a quantity of excipient. In another aspect, the cellular material is spray dried using a cryoprotectant.

Priority: US20070997923P Applic. Date: 2007-10-05; WO2008US78979 Applic. Date: 2008-10-06

Inventor: EDWARDS DAVID A [US]


Application No.: US20110045082A1  Published: 24/Feb/2011

Title: AGGLOMERATES BY CRYSTALLISATION

Applicant/Assignee:

Application No.: 12/748167   Filing Date: 26/Mar/2010

Abstract:

The present invention describes novel agglomerates in crystalline form of [beta]-lactum compounds, Furthermore, a process for the preparation of said agglomerates, wherein a solution or suspension of at least one [beta]-lactum compound in a solvent is mixed with one or more anti-solvents has been described.

Priority: EP19990201034 Applic. Date: 1999-04-01; US2005-290185 Applic. Date: 2005-11-30; US2002-937834 Applic. Date: 2002-02-13; WO2000EP02917 Applic. Date: 2000-04-03

Inventor: BOOIJ JOHANNES [NL]; LEFFERTS GEERTRUIDA AGEETH [NL]


Application No.: US20110045090A1  Published: 24/Feb/2011

Title: FORMULATIONS OF FLIBANSERIN

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: 12/867097   Filing Date: 11/Feb/2009

Abstract:

The present invention provides pharmaceutical release systems comprising an therapeutically effective amount of flibanserin.

Priority: EP20080101599 Applic. Date: 2008-02-13; WO2009EP00941 Applic. Date: 2009-02-11

Inventor: BRICKL ROLF-STEFAN [DE]; BONI JULIA [DE]; WAGNER KARL GERHARD [DE]


Application No.: US20110045097A1  Published: 24/Feb/2011

Title: SOLID PHARMACEUTICAL COMPOSITION COMPRISING IRBESARTAN

Applicant/Assignee: KRKA, D.D. NOVO MESTO

Application No.: 12/160206   Filing Date: 05/Jan/2007

Abstract:

The present invention concerns preferably surfactant-free solid pharmaceutical formulations comprising, as an active ingredient, at least one of irbesartan and pharmaceutically acceptable salts thereof, and at least one disintegrant. Preferably, the active ingredient comprises irbesartan hydrochloride. Also, the present invention is directed to a process for the manufacture of such formulations, including a wet granulation process (A) and a direct granulation process (B).

Priority: EP20060000329 Applic. Date: 2006-01-09; WO2007EP00074 Applic. Date: 2007-01-05

Inventor: VRBINC MIHA [SI]; JAKSE RENATA [SI]; BEVEC FRANCI [SI]; ZUPANCIC SILVO [SI]


Application No.: US20110046038A1  Published: 24/Feb/2011

Title: Polypeptide-Polymer Conjugates and Methods of Use Thereof

Applicant/Assignee:

Application No.: 12/933655   Filing Date: 26/Mar/2009

Abstract:

The present invention provides polypeptide-polymer conjugates. A subject polypeptide-polymer conjugate is useful in a variety of applications, cations, which are also provided.

Priority: US20080040556P Applic. Date: 2008-03-28; WO2009US38446 Applic. Date: 2009-03-26

Inventor: HEALY KEVIN EDWARD [US]; WALL SAMUEL T [NO]; SAHA KRISHANU [US]


Application No.: US20110046218A1  Published: 24/Feb/2011

Title: CRYSTALLINE BASE OF ESCITALOPRAM AND ORODISPERSIBLE TABLETS COMPRISING ESCITALOPRAM BASE

Applicant/Assignee: H. LUNDBECK A/S

Application No.: 12/916750   Filing Date: 01/Nov/2010

Abstract:

The present invention relates to the crystalline base of the well known antidepressant drug escitalopram, S-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile, formulations of said base, a process for the preparation of purified salts of escitalopram, such as the oxalate, using the base, the salts obtained by said process and formulations containing such salts, and a process for the preparation of purified escitalopram free base or salts of escitalopram, such as the oxalate, using the hydrobromide, the salts obtained by said process and formulations containing such salts. Finally the present invention relates to an orodispersible tablet having a hardness of at least 22 N and an oral-disintegration time of less than 120 s and comprising an active pharmaceutical ingredient adsorbed onto a water soluble filler wherein the active pharmaceutical ingredient has a melting point in the range of 40-100 DEG C., as well as a method for making such an orodispersible tablet.

Priority: US2006-425522 Applic. Date: 2006-06-21; US20050693214P Applic. Date: 2005-06-22

Inventor: DANCER ROBERT [DK]; PETERSEN HANS [DK]; NIELSEN OLE [DK]; ROCK MICHAEL HAROLD [DK]; ELIASEN HELLE [DK]; LILJEGREN KEN [DK]


Application No.: US20110046599A1  Published: 24/Feb/2011

Title: Multi-Day Delivery Of Biologically Active Substances

Applicant/Assignee:

Application No.: 12/665977   Filing Date: 26/Jun/2008

Abstract:

Compositions and methods for modifying biologically active substances to achieve multi-day delivery of such substances, particularly through oral or parenteral administration, are disclosed. The compositions include the biologically active substance conjugated to a carrier having a suitably long half life, typically more than one day, wherein the conjugate optionally contains a spacer linking the carrier to the biologically active substance. Pharmaceutical formulations of the conjugates are also disclosed, as are methods of extending delivery of a single dose of a biologically active substance for more than one day.

Priority: US20070937604P Applic. Date: 2007-06-27; US20070958914P Applic. Date: 2007-07-09; US20070959298P Applic. Date: 2007-07-12; WO2008US07983 Applic. Date: 2008-06-26

Inventor: KYDONIEUS AGIS [US]


Application No.: US20110052616A1  Published: 03/Mar/2011

Title: Biological materials and uses thereof

Applicant/Assignee: HELPERBY THERAPEUTICS LIMITED

Application No.: 12/918789   Filing Date: 25/Feb/2009

Abstract:

The present invention concerns a peptide molecule or a nucleic acid molecule, for use in medicine and, in particular, for use in preventing or treating a non-cancerous condition or relieving pain in a patient. The invention also relates to a pharmaceutical composition comprising the peptide or nucleic acid molecule of the invention and methods of treatment thereof.

Priority: GB20080003369 Applic. Date: 2008-02-25; WO2009GB00522 Applic. Date: 2009-02-25

Inventor: COATES ANTHONY ROBERT MILNES [GB]; RIFFO-VASQUEZ YANIRA [GB]; TORMAY PETER [GB]


Application No.: US20110052640A1  Published: 03/Mar/2011

Title: HYPOALLERGENIC HYBRID PROTEINS OF MAJOR GROUP 1 AND 2 MITE ALLERGENS FOR USE IN THE TREATMENT OF ALLERGIES

Applicant/Assignee: BIAL INDUSTRIAL FARMACEUTICA, S.A

Application No.: 12/934418   Filing Date: 24/Mar/2009

Abstract:

The present invention refers to recombinant ADN molecules coding to hybrids polypeptides of different allergens from D. pteronyssinus useful for the prevention and treatment of allergies, particularly allergies caused by mites. Specifically, the invention describes hybrid proteins composed of fragments of allergens Derp p 1 y Derp p 2 with hypoallergenic characteristics and maintain their immunogenic capacity, being particularly useful for the treatment of allergy. The invention also describes the production methods of these polypeptides in heterologous expression systems. Besides, the invention describes efficient purification methods of these hybrid proteins.

Priority: ES20080000827 Applic. Date: 2008-03-25; WO2009IB05114 Applic. Date: 2009-03-24

Inventor: ASTURIAS ORTEGA JUAN ANDRES [ES]; IBARROLA LOPEZ DE DAVALILLO INAKI [ES]; ARILLA RODRIGUEZ MARIA CARMEN [ES]; MARTINEZ GARATE ALBERTO [ES]


Application No.: US20110052670A1  Published: 03/Mar/2011

Title: IDENTIFICATION OF A PLURIPOTENT PRE-MESENCHYMAL, PRE-HEMATOPOIETIC PROGENITOR CELL

Applicant/Assignee: UNIVERSITY OF SOUTHERN CALIFORNIA

Application No.: 12/828488   Filing Date: 01/Jul/2010

Abstract:

The present invention provides a molecular marker for the identification of pluripotent pre-mesenchymal, pre-hematopoietic stem cells. The invention further provides primitive progenitor cells identified by the molecular marker. Such cells have the potential to differentiate into both mesenchymal and hematopoietic phenotypes, as determined by a proliferative response to inductive growth factors and cytokines, and by their morphologic and cytochemical features.

Priority: US2003-404714 Applic. Date: 2003-03-31; US2000-619865 Applic. Date: 2000-07-20; US19990144786P Applic. Date: 1999-07-20

Inventor: HALL FREDERICK L [US]; GORDON ERLINDA M [US]


Application No.: US20110052681A1  Published: 03/Mar/2011

Title: Pharmaceutical compositions of entacapone co-micronized with sugar alcohols

Applicant/Assignee:

Application No.: 12/865783   Filing Date: 06/Feb/2009

Abstract:

The present invention relates to pharmaceutical compositions comprising entacapone or pharmaceutically acceptable salts thereof along with one or more sugar alcohols

wherein the entacapone is co-micronized with one or more sugar alcohols. The invention also relates to processes of making such compositions.

Priority: IN2008MU00264 Applic. Date: 2008-02-06; WO2009IB50490 Applic. Date: 2009-02-06

Inventor: KAPOOR RITESH [IN]; MATE SANJAY [IN]; TALWAR MUNISH [IN]; JAIN GIRISH KUMAR [IN]


Application No.: US20110052684A1  Published: 03/Mar/2011

Title: PHARMACEUTICAL COMPOSITION

Applicant/Assignee: BIOVAIL LABORATORIES INTERNATIONAL S.R.L

Application No.: 12/864453   Filing Date: 28/Jan/2009

Abstract:

The present invention relates to a pharmaceutical composition comprising a tablet core comprising a combination of actives selected from the group consisting of bupropion hydrochloride and escitalopram oxalate, bupropion hydrobromide and citalopram hydrochloride, bupropion hydrobromide and escitalopram oxalate, and bupropion hydrobromide and quetiapine fu-marate, and at least one pharmaceutically acceptable excipient, and a control-releasing coat surrounding the tablet core, wherein said composition surprisingly provides for a synchronous release of the combination of active agents in-vitro. The once-daily pharmaceutical composition surprisingly also provides for enhanced absorption of bupropion hydrobromide when administered to a subject in need of such administration.

Priority: US20080023951P Applic. Date: 2008-01-28; WO2009EP50924 Applic. Date: 2009-01-28

Inventor: WALSH EDWIN [IE]; JACKSON GRAHAM [BB]; OBEREGGER WERNER [CA]; JIN XIAOPIN [CA]


Application No.: US20110053844A1  Published: 03/Mar/2011

Title: LIQUID FORMULATION OF G-CSF CONJUGATE

Applicant/Assignee:

Application No.: 12/675749   Filing Date: 27/Aug/2008

Abstract:

The present invention relates to a liquid pharmaceutical composition comprising a granulocyte colony stimulating factor polypeptide conjugated with a polymer, the composition having a pH value in the range of 4.5 to 5.5. The composition further comprises a surfactant and optionally one or more other pharmaceutically acceptable excipients. Further, the composition of the invention is free from tartaric acid or salts thereof and from succinic acid and salts thereof as buffering agents and does not contain amino acids as stabilizer. The composition has a good storage stability and is especially useful for the prophylaxis and treatment of disorders and medical indications where granulocyte colony stimulating factor preparations are considered as useful remedies.

Priority: EP20070115047 Applic. Date: 2007-08-27; WO2008EP61232 Applic. Date: 2008-08-27

Inventor: HINDERER WALTER [DE]; SCHECKERMANN CHRISTIAN [DE]


Application No.: US20110053848A1  Published: 03/Mar/2011

Title: PRODRUG COMPRISING A DRUG LINKER CONJUGATE

Applicant/Assignee: ASCENDIS PHARMA AS

Application No.: 12/865693   Filing Date: 30/Jan/2009

Abstract:

The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising a drug linker conjugate D-L, wherein -D is an amine containing biologically active moiety

and -L is a non-biologically active linker moiety -L1 represented by formula (I), wherein the dashed line indicates the attachment to the amine of the biologically active moiety and wherein R1, R1a, R2, R2a, R3, R3a, X, X1, X2, X3 have the meaning as indicated in the description and the claims and wherein L1 is substituted with one to four groups L2-Z and optionally further substituted, provided that the hydrogen marked with the asterisk in formula (I) is not replaced by a substituent

wherein L2 is a single chemical bond or a spacer

and Z is a carrier group. The invention also relates to A-L, wherein A is a leaving group, pharmaceutical composition comprising said prodrugs and their use as medicaments.

Priority: EP20080150973 Applic. Date: 2008-02-01; EP20080170872 Applic. Date: 2008-12-05; WO2009EP51079 Applic. Date: 2009-01-30

Inventor: CLEEMANN FELIX [DE]; HERSEL ULRICH [DE]; KADEN SILVIA [DE]; RAU HARALD [DE]; WEGGE THOMAS [DE]


Application No.: US20110053986A1  Published: 03/Mar/2011

Title: RESPIRATORY DISEASE TREATMENT

Applicant/Assignee:

Application No.: 12/850318   Filing Date: 04/Aug/2010

Abstract:

There is provided a pharmaceutical composition that is adapted for pulmonary administration by inhalation, which composition comprises a glitazone, such as pioglitazone or rosiglitazone, and one or more pharmaceutically acceptable carriers and/or excipients, and wherein the glitazone content of the composition consists of at least 95% by weight of the 5R enantiomer and less than 5% by weight of the 5S enantiomer. There is also provided a use and kit.

Priority: GB20080014488 Applic. Date: 2008-08-07; GB20080023568 Applic. Date: 2008-12-24; GB20090013672 Applic. Date: 2009-08-05; WO2009GB01920 Applic. Date: 2009-08-05

Inventor: FINCH HARRY [GB]; FOX CRAIG [GB]; SAJAD MOHAMMED [GB]; VAN NIEL MONIQUE BODIL [GB]; FORREST ANDREW [GB]


Application No.: US20110059193A1  Published: 10/Mar/2011

Title: METHOD FOR OBTAINING AN EXTRACT OF CRANBERRY MARC THAT CAN BE USED IN PARTICULAR IN THE PREVENTION AND TREATMENT OF CONDITIONS SUCH AS CARIES, GINGIVITIS OR SORE THROATS

Applicant/Assignee: TOURNAY BIOTECHNOLOGIES, SAS

Application No.: 12/990975   Filing Date: 05/May/2009

Abstract:

A a method for obtaining an extract prepared from cranberry (genus Vaccinium macrocarpon and/or Vaccinium oxycoccus) marc, with a view to obtaining a product that, provided in various galenical forms or other, has, owing to the high concentration of proanthocyanidins, in particular type A proanthocyanidins, therein, many therapeutic qualities and properties that can be exploited in particular in the field of dental care and prevention and oral hygiene, and also in the field of the prevention of viral or bacterial infections of the oropharynx in humans and animals. It also relates to this extract and to uses thereof.

Priority: FR20080002463 Applic. Date: 2008-05-05; WO2009FR00523 Applic. Date: 2009-05-05

Inventor: TOURNAY DAVID [FR]; TOURNAY MICHAEL [FR]


Application No.: US20110059997A1  Published: 10/Mar/2011

Title: SUBSTITUTED CYCLOALCANO[e AND d] PYRAZOLO [1,5-a]PYRIMIDINES/ANTAGONISTS OF SEROTONIN 5-HT6 RECEPTORS AND METHODS FOR PRODUCTION AND THE USE THEREOF

Applicant/Assignee:

Application No.: 12/863192   Filing Date: 23/Jan/2009

Abstract:

The invention relates to substituted 2-alkylsulfanyl-3-(arylsulfonyl)-cycloalkyl[e and d]pyrazolo[1,5-a]pyrimidines, to serotonin 5-HT6 receptor antagonists, to novel drug substances and pharmaceutical compositions, comprising the said conpounds as active ingredients, to novel medicaments and methods for treatment and prophylaxis of CNS diseases of humans and warm blooded animals pathogenesis of which is associated with 5-HT6 receptors. In general formulas 1 and 2 R1 represents hydrogen or C1-C3 alkyl

R2 represents C1-C3 alkyl

R3 represents hydrogen, one or more optionally identical halogens, C1-C3 alkyl or hydroxyl optionally substituted with C1-C3 alkyl

n represents the whole numbers 1, 2 or 3.

Priority: RU20080102154 Applic. Date: 2008-01-24; RU20080137217 Applic. Date: 2008-09-17; WO2009IB50275 Applic. Date: 2009-01-23

Inventor: IVASHCHENKO ANDREY ALEXANDROVICH [RU]; IVASHCHENKO ALEXANDER VASILIEVICH [US]; SAVCHUK NIKOLAY FILIPPOVICH [US]


Application No.: US20110060008A1  Published: 10/Mar/2011

Title: PHARMACEUTICAL COMPOSITION CONTAINING ACETYLCHOLINE ESTERASE INHIBITOR AND METHOD FOR THE PREPARATION THEREOF

Applicant/Assignee:

Application No.: 12/666508   Filing Date: 26/Jun/2008

Abstract:

A pharmaceutical composition for oral administration comprising donepezil or pharmaceutically acceptable salt thereof, and an effective amount of pH dependent excipient as a taste masking agent, to suppress the release of donepezil in the pH environment of the oral cavity and increase the release of donepezil in acidic environment.

Priority: GR20070100405 Applic. Date: 2007-06-26; WO2008GR00049 Applic. Date: 2008-06-26

Inventor: MURPANI DEEPAK [GR]; PATERAKIS PANAGIOTIS [GR]


Application No.: US20110060016A1  Published: 10/Mar/2011

Title: Oral dosage form containing a pde 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient

Applicant/Assignee: NYCOMED GMBH

Application No.: 12/876996   Filing Date: 07/Sep/2010

Abstract:

Disclosed is a method of treatment of COPD by oral administration of roflumilast.

Priority: DE20021007160 Applic. Date: 2002-02-20; EP20020003811 Applic. Date: 2002-02-20; US2006-501836 Applic. Date: 2006-08-10; US2004-505138 Applic. Date: 2004-08-19; WO2003EP01650 Applic. Date: 2003-02-19

Inventor: DIETRICH RANGO [DE]; NEY HARTMUT [DE]; EISTETTER KLAUS [DE]


Application No.: US20110064714A1  Published: 17/Mar/2011

Title: FACTOR VIIA-POLYSIALIC ACID CONJUGATE HAVING PROLONGED IN VIVO HALF-LIFE

Applicant/Assignee: BAXTER HEALTHCARE S.A, BAXTER INTERNATIONAL INC

Application No.: 12/877425   Filing Date: 08/Sep/2010

Abstract:

The present invention relates to a proteinaceous construct comprising plasmatic or recombinant factor VIIa (FVIIa) or biologically active derivatives thereof, which are bound to a carbohydrate moiety comprising 1-4 sialic acid units, wherein the in vivo half-life of the proteinaceous construct is substantially prolonged in the blood of a mammal, as compared to the in vivo half-life of a FVIIa molecule not bound to a carbohydrate moiety. The invention also provides a method for controlling bleeding in a mammal having a bleeding disorder due to functional defects or deficiencies of FVIIa, FVIII, or FIX. The invention also provides a method for controlling bleeding in a mammal during surgery or trauma.

Priority: US2007-956634 Applic. Date: 2007-12-14; US20060875217P Applic. Date: 2006-12-15

Inventor: PETER TURECEK [AT]; JUERGEN SIEKMANN [AT]; FRIEDRICH SCHEIFLINGER [AT]; MICHEL CANAVAGGIO [AT]; CANAVAGGIO MARIE-CHRISTINE [AT]


Application No.: US20110064806A1  Published: 17/Mar/2011

Title: SOLID COMPOSITIONS COMPRISING AN OXADIAZOANTHRACENE COMPOUND AND METHODS OF MAKING AND USING THE SAME

Applicant/Assignee: TRANSTECH PHARMA, INC

Application No.: 12/874455   Filing Date: 02/Sep/2010

Abstract:

The invention provides solid compositions comprising (S)-3-(4'-Cyano-biphenyl-4-yl)-2-{[(3S,7S)-3-[4-(3,4-dichloro-benzyloxy)-phenyl]-1-methyl-2-oxo-6-((S)-1-phenyl-propyl)-2,3,5,6,7,8-hexahydro-1H-4-oxa-1,6-diaza-anthracene-7-carbonyl]-amino}-propionic acid (OC-1) or a salt thereof and methods of making and using those compositions. The invention also provides the monohydrochloride salt of (S)-3-(4'-Cyano-biphenyl-4-yl)-2-{[(3S,7S)-3-[4-(3,4-dichloro-benzyloxy)-phenyl]-1-methyl-2-oxo-6-((S)-1-phenyl-propyl)-2,3,5,6,7,8-hexahydro-1H-4-oxa-1,6-diaza-anthracene-7-carbonyl]-amino}-propionic acid.

Priority: US20090241655P Applic. Date: 2009-09-11

Inventor: POLISETTI DHARMA RAO [US]; BENJAMIN ERIC [US]; QUADA JR JAMES C [US]; THORSTEINSSON THORSTEINN [US]


Application No.: US20110064864A1  Published: 17/Mar/2011

Title: Food Additive for Ruminants Based on Eugenol and Cinnamaldehyde

Applicant/Assignee:

Application No.: 11/883600   Filing Date: 03/Feb/2006

Abstract:

The invention concerns a composition based on a mixture of eugenol and cinnamaldehyde, as food additive for feeding ruminants. The composition may be incorporated in a food additive, or a salt block. The eugenol and the cinnamaldehyde may be natural or identical natural constituents. Administering the composition or the food additive increases meat production and milk production.

Priority: FR20050001489 Applic. Date: 2005-02-03; WO2006FR00253 Applic. Date: 2006-02-03

Inventor: GAUTIER FRANCOIS [FR]; KAMEL CHRISTOPHER [FR]; CALSAMIGLIA SERGIO [ES]; DOANE PERRY [US]


Application No.: US20110065630A1  Published: 17/Mar/2011

Title: USE OF A OCTREOTIDE AS A THERAPEUTIC AGENT

Applicant/Assignee:

Application No.: 12/677293   Filing Date: 09/Sep/2008

Abstract:

The present invention is directed to the use of the peptide compound D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-L-threoninol as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-L-threoninol optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.

Priority: EP20070017752 Applic. Date: 2007-09-11; WO2008EP07598 Applic. Date: 2008-09-09

Inventor: BEVEC DORIAN [DE]; CAVALLI FABIO [CH]; CAVALLI VERA [CH]; BACHER GERALD [DE]


Application No.: US20110065680A1  Published: 17/Mar/2011

Title: Metal Complexes

Applicant/Assignee:

Application No.: 12/921794   Filing Date: 10/Mar/2009

Abstract:

A method for synthesizing a complex having the formula: [L3MO3]'' wherein L3 represents a tridentate ligand, M represents a metal selected from Tc an Re, and n is a charge from -2 to +1, the method comprising: a) reaction of pertechnetate or perrhenate with a reducing agent and L3, or b) reaction of pertechnetate or perrhenate with a Lewis acid and L3, wherein the synthesis (a) or (b) is carried out in an aqueous medium.

Priority: GB20080004406 Applic. Date: 2008-03-10; WO2009GB00650 Applic. Date: 2009-03-10

Inventor: ALBERTO ROGER [CH]; BRABAND HENRIK [CH]


Application No.: US20110065751A1  Published: 17/Mar/2011

Title: Improved pharmaceutical composition containing a selective estrogen receptor modulator and method for the preparation thereof

Applicant/Assignee: PHARMATHEN S.A

Application No.: 12/739545   Filing Date: 24/Nov/2010

Abstract:

The present invention relates to a pharmaceutical formulation of solid dosage forms comprising a therapeutically effective amount of a selective estrogen receptor modulator, and especially Raloxifene or a pharmaceutical acceptable salt thereof, in combination with a super disintegrant such as Primojel, and a process for the preparation thereof by wet granulation.

Priority: WO2007EP08955 Applic. Date: 2007-10-16

Inventor: KARAVAS EVANGELOS [GR]; KOUTRIS EFTHIMIOS [GR]; BIKIARIS DIMITRIOS [GR]; SAMARA VICKY [GR]; KALASKANI ANASTASIA [GR]; STATHAKI ELENI [GR]


Application No.: US20110065800A1  Published: 17/Mar/2011

Title: FORMULATIONS FOR CATHEPSIN K INHIBITORS

Applicant/Assignee:

Application No.: 12/992124   Filing Date: 06/May/2009

Abstract:

The instant invention relates to pharmaceutical compositions containing cathepsin K inhibitors. Also disclosed are processes for making said pharmaceutical compositions.

Priority: US20080127630P Applic. Date: 2008-05-14; WO2009US42924 Applic. Date: 2009-05-06

Inventor: FAN HAIHONG [US]; MAHJOUR MAJID [US]; MOSER JUSTIN [US]; REGE BHAGWANT [US]


Application No.: US20110070249A1  Published: 24/Mar/2011

Title: IMMUNIZING COMPOSITION AND METHOD FOR INDUCING AN IMMUNE RESPONSE AGAINST THE Beta-SECRETASE CLEAVAGE SITE OF AMYLOID PRECURSOR PROTEIN

Applicant/Assignee: RAMOT AT TEL-AVIV UNIVERSITY LTD

Application No.: 12/961248   Filing Date: 06/Dec/2010

Abstract:

The present invention is directed to an immunizing composition containing an antigenic product such as a multiple antigen peptide system (MAPS) or a filamentous bacteriophage displaying an A[beta]PP epitope spanning the [beta]-secretase cleavage site of A[beta]PP and a method for inducing an immune response against the [beta]-secretase cleavage site of A[beta]PP using this immunizing composition. The present invention is also directed to antibodies against the [beta]-secretase cleavage site of A[beta]PP and their use in a method for inhibiting the formation of amyloid [beta].

Priority: US2007-695948 Applic. Date: 2007-04-03; US2004-506665 Applic. Date: 2004-09-07; WO2003US06388 Applic. Date: 2003-03-04; US20020361344P Applic. Date: 2002-03-05

Inventor: SOLOMON BEKA [IL]


Application No.: US20110070299A1  Published: 24/Mar/2011

Title: DELAYED RELEASE PHARMACEUTICAL COMPOSITION OF DULOXETINE

Applicant/Assignee: ALPHAPHARM PTY LTD

Application No.: 12/863882   Filing Date: 09/Jan/2009

Abstract:

A pharmaceutical composition comprising duloxetine or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipient(s) characterised in that the duloxetine has a D90 particle size of 2 to 40 [mu]m.

Priority: AU20080900332 Applic. Date: 2008-01-25; WO2009AU00028 Applic. Date: 2009-01-09

Inventor: MOONEY BRETT ANTONY [AU]; KERAMIDAS PANAGIOTIS [AU]; FERGUSON PHILLIP JOHN [AU]


Application No.: US20110070302A1  Published: 07/Oct/2010

Title: COATED PHARMACEUTICAL OR NUTRACEUTICAL PREPARATION WITH ACCELERATED CONTROLLED ACTIVE SUBSTANCE RELEASE

Applicant/Assignee: EVONIK ROEHM GMBH

Application No.: 12/742263   Filing Date: 01/Feb/2008

Abstract:

The present invention relates to pharmaceutical or nutraceutical preparations comprising a) a core containing a pharmaceutically or nutraceutically active substance

and b) a controlling layer surrounding the core comprising i) 55 to 92% by weight based on the total weight of (meth)acrylic copolymers present in the layer of one or a mixture of a plurality of (meth)acrylate copolymers composed of 80 to 98% by weight based on the weight of the (meth)acrylic copolymer of structural units derived from Ci to C4 alkyl esters of (meth)acrylic acid and 2 to 20% by weight based on the weight of the (meth)acrylic copolymer of structural units derived from (meth)acrylate monomers with a quaternary ammonium group in the alkyl radical

and ii) 8 to 45% by weight based on the total weight of (meth)acrylic copolymers present in the layer of one or a mixture of a plurality of (meth)acrylate copolymers composed of more than 5 to 59% by weight based on the weight of the copolymer of structural units derived from acrylic acid or methacrylic acid, and to tablets and capsules containing same.

Priority: IN2008CH00094 Applic. Date: 2008-01-10; WO2008EP51240 Applic. Date: 2008-02-01

Inventor: RAVISHANKAR HEMA [IN]; PETEREIT HANS-ULRICH [DE]; BODINGE SHRADDA [IN]


Application No.: US20110071138A1  Published: 24/Mar/2011

Title: PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PREMATURE EJACULATION

Applicant/Assignee: YUHAN CORPORATION

Application No.: 12/993418   Filing Date: 19/May/2009

Abstract:

The present invention provides an oral pharmaceutical composition for the treatment of premature ejaculation, and the composition provides the effective and excellent treatment of premature ejaculation as well as reduced side effects like nausea, vomiting, drowsiness, sedation effect, awakening effect, and weight-loss etc.

Priority: KR20080046199 Applic. Date: 2008-05-19; WO2009KR02636 Applic. Date: 2009-05-19

Inventor: SEOL HYUN UK [KR]; LEE YOUNG SUNG [KR]; KIM YOUNG HUN [KR]; KIM KYEONG BAE [KR]; SEO JEONG MIN [KR]; AHN KYOUNG KYU [KR]


Application No.: US20110071157A1  Published: 24/Mar/2011

Title: Role of N-2-Hydroxy-Ethyl-Piperazine-N'-2-Ethane Sulfonic Acid (HEPES) in Pain Control and Reversal of Demyelinization Injury

Applicant/Assignee: NORTH TEXAS MEDICAL ASSOCIATES

Application No.: 12/885404   Filing Date: 17/Sep/2010

Abstract:

Compositions and therapeutic uses of HEPES and derivatives in the treatment of pain associated with cancers and side-effects including post-chemotherapy cognitive impairment are disclosed herein. HEPES is also used to treat neurodegenerative and neurological diseases, demyelinization injuries, and side-effects and withdrawal symptoms associated with benzodiazepines, anti-depressants, and other neurological agents.

Priority: US20090243464P Applic. Date: 2009-09-17

Inventor: DANHOF IVAN E [US]


Application No.: US20110071169A1  Published: 24/Mar/2011

Title: Preparation of polymorphic form of lapatinib ditosylate

Applicant/Assignee: MAI DE LTD

Application No.: 12/806466   Filing Date: 14/Aug/2010

Abstract:

The present invention is directed to two novel polymorph form (Form A and Form B) of lapatinib ditosylate, wherein Form A is the hydrate ditosylate salt of lapatinib, and Form B is anhydrate ditosylate salt of lapatinib. The present invention is further directed to amorphous form of lapatinib ditosylate and its solid dispersion. The present invention further provides processes for the preparation of Form A, Form B, Amorphous form and solid dispersion of lapatinib ditosyalte, and a pharmaceutical composition comprising the said forms. Form A and Form B were characterized by X-RPD, DSC, TGA and FT-IR, and can be prepared from recrystallizing lapatinib ditosylate in a mixture of tetrahydrofuran (THF) and water.

Priority: US20090275120P Applic. Date: 2009-08-26

Inventor: HUANG HUI MIN HE [US]; YANG HU [US]


Application No.: US20110076296A1  Published: 31/Mar/2011

Title: TLR3 Agonist Compositions

Applicant/Assignee: INNATE PHARMA S.A

Application No.: 12/988815   Filing Date: 22/Apr/2009

Abstract:

The present invention relates generally to the fields of medicine. More specifically, the present invention relates to improved TLR3 agonists. The present invention provides novel dsRNA such as polyAU composition useful in the treatment of TLR3 related diseases, uses and preparations thereof.

Priority: US20080047969P Applic. Date: 2008-04-25; US20090154229P Applic. Date: 2009-02-20; WO2009IB06036 Applic. Date: 2009-04-22

Inventor: AUBIN ERIC [FR]; BELMANT CHRISTIAN [FR]; GAUTHIER LAURENT [FR]; MOREL YANNIS [FR]; PATUREL CARINE [FR]; BREGEON DELPHINE [FR]


Application No.: US20110077272A1  Published: 31/Mar/2011

Title: PULMONARY FORMULATIONS OF TRIPTANS

Applicant/Assignee: VECTURA LIMITED

Application No.: 12/865340   Filing Date: 02/Feb/2009

Abstract:

A pharmaceutical composition includes triptans, such as sumatriptan, and may be used in therapy. The composition may be administered via the inhaled route.

Priority: GB20080002024 Applic. Date: 2008-02-01; GB20080006156 Applic. Date: 2008-04-04; GB20080006283 Applic. Date: 2008-04-07; WO2009GB00265 Applic. Date: 2009-02-02

Inventor: MAIN MARK JONATHAN [DE]


Application No.: US20110077304A1  Published: 31/Mar/2011

Title: 1-AMINOCYCLOHEXANE DERIVATIVES FOR THE TREATMENT OF COCHLEAR TINNITUS.

Applicant/Assignee: MERZ PHARMA GMBH & CO., KGAA

Application No.: 12/733646   Filing Date: 10/Sep/2008

Abstract:

The present invention relates to the treatment of an individual afflicted with cochlear tinnitus comprising administering to the individual an effective amount of a 1-amino-alkylcyclohexane derivative.

Priority: EP20070253630 Applic. Date: 2007-09-12; EP20080004776 Applic. Date: 2008-03-14; EP20080004777 Applic. Date: 2008-03-14; EP20080004778 Applic. Date: 2008-03-14; US20070993396P Applic. Date: 2007-09-12; US20080066931P Applic. Date: 2008-02-25; US20080067026P Applic. Date: 2008-02-25; US20080067083P Applic. Date: 2008-02-25; WO2008EP07421 Applic. Date: 2008-09-10

Inventor: ELLERS-LENZ BARBARA [DE]; ROSENBERG TANJA [DE]; KRUGER HAGEN [DE]; AL THAUS MICHAEL [DE]


Application No.: US20110081377A1  Published: 07/Apr/2011

Title: AEROSOLIZED GENETIC VACCINES AND METHODS OF USE

Applicant/Assignee: THE UNITED STATES, AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES

Application No.: 12/887286   Filing Date: 21/Sep/2010

Abstract:

The present invention generally features methods for the mucosal delivery of immunogenic compositions and methods for treating or preventing diseases featuring such immunogenic compositions. In particular embodiments, the immunogenic compositions are genetic vaccines formulated as aerosols.

Priority: WO2009US01754 Applic. Date: 2009-03-20; US20080038534P Applic. Date: 2008-03-21

Inventor: ROEDERER MARIO [US]; RAO SRINIVAS [US]; NABEL GARY J [US]; ANDREWS CHARLA A [US]


Application No.: US20110081389A1  Published: 07/Apr/2011

Title: COMPOSITION COMPRISING A MIXTURE OF ACTIVE PRINCIPLES, AND METHOD OF PREPARATION

Applicant/Assignee: ETHYPHARM

Application No.: 12/947551   Filing Date: 16/Nov/2010

Abstract:

Active principle-based coated particle, in which both the core and the coating contain active principle, includes a core which contains a first active principle while the coating contains a second active principle, which is different in nature.

Priority: FR20030001308 Applic. Date: 2003-02-05; US2004-544311 Applic. Date: 2004-01-21; WO2004EP50035 Applic. Date: 2004-01-21; US20030447198P Applic. Date: 2003-02-13

Inventor: CHENEVIER PHILIPPE [CA]; MARECHAL DOMINIQUE [CA]


Application No.: US20110081411A1  Published: 07/Apr/2011

Title: Orally Administered Corticosteroid Compositions

Applicant/Assignee:

Application No.: 12/896005   Filing Date: 01/Oct/2010

Abstract:

The present invention is directed to orally administered corticosteroid compositions. The present invention also provides a method for treating a condition associated with inflammation of the gastrointestinal tract in an individual. The method comprises administering to an individual in need thereof a pharmaceutical composition of the present invention.

Priority: US20090247642P Applic. Date: 2009-10-01

Inventor: PERRETT STEPHEN [US]; COHEN FREDRIC JAY [US]; VENKATESH GOPI [US]


Application No.: US20110085994A1  Published: 14/Apr/2011

Title: Sunscreen Compositions

Applicant/Assignee: WYETH LLC

Application No.: 12/902802   Filing Date: 12/Oct/2010

Abstract:

The present invention provides a taste-masked sunscreen composition comprising at least one sunscreen and a spider ester wherein the sunscreen and the spider ester are in intimate association. A method of making the taste-masked sunscreen composition is provided.

Priority: US20090250615P Applic. Date: 2009-10-12

Inventor: PATEL BHALCHANDRA SOMABHAI [US]; DICKERSON JAY ROBERTS [US]; AGISIM GARY ROBERT [US]; KENNY RICHARD JOHN [US]


Application No.: US20110086019A1  Published: 14/Apr/2011

Title: POLYPEPTIDES, ANTIBODY VARIABLE DOMAINS AND ANTAGONISTSMETHODS FOR

Applicant/Assignee: DOMANTIS LIMITED

Application No.: 12/663509   Filing Date: 03/Jun/2008

Abstract:

The invention relates to anti-TNFR1 polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for as therapeutics and/or prophylactics that are likely to encounter proteases when administered to a patient, for example for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient, as well as for treating inflammatory disease, such as arthritis or COPD.

Priority: GB20070024331 Applic. Date: 2007-12-13; US20070933632P Applic. Date: 2007-06-06; WO2008GB50400 Applic. Date: 2008-06-03

Inventor: ENEVER CAROLYN [GB]; JESPERS LAURENT [GB]; PUPECKA MALGORZATA [GB]; TOMLINSON IAN [GB]; SEPP ARMIN [GB]


Application No.: US20110086069A1  Published: 14/Apr/2011

Title: PHARMACEUTICAL FORMULATIONS OF NITRITE AND USES THEREOF

Applicant/Assignee: THERAVASC, LLC

Application No.: 12/904791   Filing Date: 14/Oct/2010

Abstract:

The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO2-). The pharmaceutical compositions of the invention are useful, for example, for the treatment of chronic tissue ischemia.

Priority: US20090251483P Applic. Date: 2009-10-14

Inventor: KEVIL CHRISTOPHER [US]; GIORDANO ANTHONY [US]; FLANAGAN DOUGLAS R [US]; CONSTANTINIDES PANAYIOTIS P [US]


Application No.: US20110086070A1  Published: 14/Apr/2011

Title: Orally disintegrating compositions of rhein or diacerein

Applicant/Assignee:

Application No.: 12/934122   Filing Date: 26/Sep/2008

Abstract:

The invention relates to orally disintegrating pharmaceutical compositions comprising rhein or diacerein, or salts or esters or prodrugs thereof, and processes for preparing such compositions.

Priority: IN2008MU00597 Applic. Date: 2008-03-24; IN2008MU00598 Applic. Date: 2008-03-24; WO2008IB53925 Applic. Date: 2008-09-26

Inventor: TALWAR MUNISH [IN]; DABRE RAHUL [IN]; KAPOOR RITESH [IN]; VERMA HIMANSHU [IN]; JAIN NITIN [IN]; JAIN GIRISH KUMAR [IN]


Application No.: US20110086092A1  Published: 14/Apr/2011

Title: PHARMACUETICAL TABLETS CONTAINING A PLURALITY OF ACTIVE INGREDIENTS

Applicant/Assignee: ACCU-BREAK TECHNOLOGIES, INC

Application No.: 12/376802   Filing Date: 08/Aug/2007

Abstract:

Described are stable compressed pharmaceutical dosage forms, such as tablets, layered so that incompatible active ingredients can be included in a single dosage form, and such that carry-over and intermixing are minimized in the manufacture process.

Priority: WO2007US75469 Applic. Date: 2007-08-08; US20060836429P Applic. Date: 2006-08-08

Inventor: KAPLAN ALLAN S [US]; SOLOMON LAWRENCE [US]


Application No.: US20110086097A1  Published: 14/Apr/2011

Title: Manufacture process for the preparation of an iron containing phosphate adsorbent

Applicant/Assignee:

Application No.: 12/997447   Filing Date: 12/Jun/2009

Abstract:

The present invention relates to a new manufacture process for producing an iron containing phosphate adsorbent, in particular to a process for manufacturing and isolating an iron(III)-based phosphate adsorbent which exhibits valuable pharmacological properties.

Priority: EP20080158263 Applic. Date: 2008-06-13; WO2009EP57307 Applic. Date: 2009-06-12

Inventor: KAUFMANN DANIEL [CH]; BIERI NICOLE [CH]; MEIER ULRICH [CH]; THAKUR RANJIT [CH]; ZENCAK ZDENEK [CH]; HARTMANN CHRISTA [CH]; MEYER ANDREAS [DE]


Application No.: US20110086102A1  Published: 14/Apr/2011

Title: DELAYED RELEASE COMPOSITIONS

Applicant/Assignee: TEVA PHARMACEUTICAL INDUSTRIES LTD

Application No.: 12/578434   Filing Date: 13/Oct/2009

Abstract:

The present invention provides delayed release pharmaceutical compositions comprising an active pharmaceutical ingredient, e.g. mycophenolate sodium, and an enteric polymer, and methods for preparing the same. Preferably, the pharmaceutical compositions do not contain a coating.

Priority:

Inventor: SILVER DAVID ISAAC [IL]; HRAKOVSKY JULIA [IL]; SOLOMONOVICH ROEY [IL]; ARIELI DAFNA [IL]


Application No.: US20110086871A1  Published: 14/Apr/2011

Title: RIFAXIMIN COMPOSITIONS AND METHOD OF USE

Applicant/Assignee: ALFA WASSERMANN, S.P.A

Application No.: 12/955607   Filing Date: 29/Nov/2010

Abstract:

Forms of rifaximin (INN) antibiotic, such as the poorly crystalline form named rifaximin [gamma] are described, along with the production of medicinal preparations containing rifaximin for oral and topical use.

Priority: IT2003MI02144 Applic. Date: 2003-11-07; US2008-119630 Applic. Date: 2008-05-13; US2007-873841 Applic. Date: 2007-10-17; US2005-135651 Applic. Date: 2005-05-24; WO2004EP12490 Applic. Date: 2004-11-04

Inventor: VISCOMI GIUSEPPE CLAUDIO [IT]; CAMPANA MANUELA [IT]; BRAGA DARIO [IT]; CONFORTINI DONATELLA [IT]; CANNATA VINCENZO [IT]; RIGHI PAOLO [IT]; ROSINI GOFFREDO [IT]


Application No.: US20110091431A1  Published: 21/Apr/2011

Title: COMPOSITIONS AND METHODS COMPRISING PEDIOCOCCUS FOR REDUCING AT LEAST ONE SYMPTOM ASSOCIATED WITH AUTISM SPECTRUM DISEASE IN A PERSON DIAGNOSED WITH AN AUTISM SPECTRUM DISEASE

Applicant/Assignee: PROTHERA, INC

Application No.: 12/901225   Filing Date: 08/Oct/2010

Abstract:

Compositions, methods, etc., comprising Pediococcus and at least one other probiotic microbial organism that reduce one or more symptoms of an autism spectrum disorder such as autism. The compositions can be used, for example, as dietary supplements, food additives, and pharmaceutical preparations.

Priority: US20090250220P Applic. Date: 2009-10-09

Inventor: OLMSTEAD STEPHEN F [US]


Application No.: US20110091536A1  Published: 21/Apr/2011

Title: COMPOSITIONS COMPRISING EUPHORBIA PROSTRATA AND PROCESS OF PREPARATION THEREOF

Applicant/Assignee: PANACEA BIOTEC LTD

Application No.: 12/995436   Filing Date: 28/May/2009

Abstract:

Oral pharmaceutical compositions comprising dry extract of Euphorbia prostrata from about 0.1% to about 99% by weight wherein the effective average particle size of the dry extract of Euphorbia prostrata is not more than about 500 microns with pharmaceutically acceptable excipient(s) and process(s) for the preparation of such compositions useful for the treatment of anorectal disease and colonic diseases such as hemorrhoids, fissures, cracks, fistulas, abscesses, inflammatory bowel disease and the like are provided. Further, the pharmaceutical compositions of the present invention provides for the administration of a therapeutically and/or prophylactically effective amount of the Euphorbia prostrata wherein the compositions possess properties to control inflammation, prevent capillary bleeding and fragility in mammalians, particularly human beings. Furthermore, the compositions preferably provides a release of not less than about 50% of the dry extract of Euphorbia prostrata in first 15 minutes and not less than about 80% of dry extract of Euphorbia prostrata after total dissolution study of about 60 minutes when tested in accordance with the dissolution method described herein employing physiological pH range of about 2 to about 7.5 optionally with surfactant(s). Preferably the compositions of the present invention are in the form of tablets, minitablets, powders, capsules, pellets, granules, beads, compacts and the like. The present invention also provides and prophylactic and/or therapeutic methods of using such compositions for the treatment of anorectal diseases including hemorrhoids and colonic diseases.

Priority: IN2008DE01312 Applic. Date: 2008-05-30; WO2009IN00308 Applic. Date: 2009-05-28

Inventor: JAIN RAJESH [IN]; SINGH SUKHJEET [IN]; BHASIN SHILPA [IN]


Application No.: US20110091547A1  Published: 21/Apr/2011

Title: Pharmaceutical Compositions Comprising Brivaracetam

Applicant/Assignee: UCB PHARMA, S.A

Application No.: 12/993704   Filing Date: 28/May/2009

Abstract:

The present invention relates to a pharmaceutical composition comprising brivaracetam as active ingredient, the invention relates specifically to a prolonged release formulation.

Priority: EP20080009919 Applic. Date: 2008-05-30; WO2009EP56570 Applic. Date: 2009-05-28

Inventor: EECKMAN FREDERIC [BE]; BERWAER MONIQUE [BE]; FANARA DOMENICO [BE]


Application No.: US20110091558A1  Published: 21/Apr/2011

Title: Pharmaceutical Compositions of Entacapone, Levodopa and Carbidopa with Improved Bioavailability

Applicant/Assignee: WOCKHARDT RESEARCH CENTRE

Application No.: 12/865745   Filing Date: 06/Feb/2009

Abstract:

The present invention relates to single oral dose pharmaceutical compositions comprising a combination of entacapon, levodopa and carbidopa, or salts thereof along with one or more sugar alcohols, wherein the entacapone is co-micronized with one or more sugar alcohols. The composition of the invention exhibits bioequivalence to commercially available entacapone, levodopa and carbidopa combination formulation marketed under the trade name Stalcvo200 TM . The invention also relates to processes for making such compositions.

Priority: IN2008MU00262 Applic. Date: 2008-02-06; IN2008MU00263 Applic. Date: 2008-02-06; WO2009IB50486 Applic. Date: 2009-02-06

Inventor: TALWAR MUNISH [IN]; KAPOOR RITESH [IN]; MASHALKAR MANOJ [IN]; JAIN GIRISH KUMAR [IN]


Application No.: US20110091583A1  Published: 21/Apr/2011

Title: ANTIALLERGIC MARINE BIOPOLYMERS

Applicant/Assignee: MARINOMED BIOTECHNOLOGIE GMBH

Application No.: 12/992424   Filing Date: 30/Jun/2009

Abstract:

The present invention relates to pharmaceutical compositions based on carrageenan as an active ingredient, for use as a medicament in the prophylactic or therapeutic treatment of allergic conditions or diseases, with the proviso that the carrageenan comprises iota- and/or kappa-carrageenan and is substantially free of lambda carrageenan. Typically, the invention relates to liquid formulations, gels and dry powder compositions comprising iota- and/or kappa-carrageenan and, optionally, one or more non-carrageenan therapeutic agents for administration to the respiratory tract, the gastrointestinal tract or the eyes. The compositions of the invention have been found to be efficacious in the prevention and treatment of type I allergies and additionally, may exert an adjuvant function upon combined mucosal administration with non-carrageenan therapeutic agents.

Priority: US20080129507P Applic. Date: 2008-07-01; WO2009EP04696 Applic. Date: 2009-06-30

Inventor: GRASSAUER ANDREAS [AT]; PRIESCHL-GRASSAUER EVA [AT]


Application No.: US20110092444A1  Published: 21/Apr/2011

Title: LARGE SCALE PREPARATION OF ALPHA-1 PROTEINASE INHIBITOR AND USE THEREOF

Applicant/Assignee:

Application No.: 12/972736   Filing Date: 20/Dec/2010

Abstract:

A pharmaceutical preparation containing a purified, active API in the form of a ready to use sterile solution that optionally includes an excipient, diluent or a carrier. At least 90% to 95% of the API is active and is present at a concentration between about 1% to about 10%. The pH of the preparation is in the range of 6.5-7.5 and the preparation is preferably devoid of a protein stabilizer. The API is stable for at least 3 months when stored at a temperature of between 20 DEG C. to 25 DEG C. and is stable for a minimum of at least 12 months, at least 21 months, or at least 36 months when the pharmaceutical composition is stored at a temperature of between 2 DEG C. to 8 DEG C. The composition is formulated to be administered intravenously or by inhalation.

Priority: IL20030158053 Applic. Date: 2003-09-22; US2005-572523 Applic. Date: 2005-06-23; WO2004IL00881 Applic. Date: 2004-09-22; US20030503902P Applic. Date: 2003-09-22

Inventor: BAUER SHABTAI [IL]


Application No.: US20110092471A1  Published: 21/Apr/2011

Title: USE OF THE COMBINATION OF CICLESONIDE AND ANTIHISTAMINES FOR THE TREATMENT OF ALLERGIC RHINITIS

Applicant/Assignee: NYCOMED GMBH

Application No.: 12/973414   Filing Date: 20/Dec/2010

Abstract:

The subject matter of this application relates to the combination of ciclesonide with an antihistamine.

Priority: EP20020019406 Applic. Date: 2002-08-30; US2005-524821 Applic. Date: 2005-02-18; WO2003EP09622 Applic. Date: 2003-08-29

Inventor: MARX DEGENHARD [DE]; MUELLER HELGERT [DE]


Application No.: US20110092598A1  Published: 21/Apr/2011

Title: Driectly Compressible High Functionality Granular Microcrystalline Cellulose Based Excipient, Manufacturing Process and Use Thereof

Applicant/Assignee:

Application No.: 12/600369   Filing Date: 07/Oct/2008

Abstract:

An improved excipient comprising substantially homogeneous particles of a compressible, high functionality granular microcrystalline cellulose based excipient is provided. The improved excipient comprises microcrystalline cellulose, a binder and a disintegrant, and is formed by spraying a homogeneous slurry of the components. The excipient provides enhanced flowability/good flow properties, excellent/high compactibility, and increased API loading and blendability as compared to the individual components, and as compared to conventional excipients formed from the same materials. The improved excipient has strong intraparticle bonding bridges between the components, resulting in a unique structural morphology including significant open structures or hollow pores. The presence of these pores provides a surface roughness that is the ideal environment for improved blending with an API.

Priority: US20070978866P Applic. Date: 2007-10-10; WO2008US11555 Applic. Date: 2008-10-07

Inventor: DEORKAR NANDU [US]; FARINA JAMES [US]; MIINEA LILIANA [US]; RANDIVE SAMEER [IN]


Application No.: US20110092602A1  Published: 21/Apr/2011

Title: RAPIDLY DISINTEGRATING ORAL COMPOSITIONS OF TRAMADOL

Applicant/Assignee:

Application No.: 12/937861   Filing Date: 24/Apr/2009

Abstract:

The present invention relates to a stable taste masked orally disintegrating pharmaceutical composition of tramadol comprising of 3% to 30% w/w of tramadol, 2% to 30% w/w of an ion exchange resin, 0.01 to about 2% w/w of binder and pharmaceutically acceptable excipients to equal 100% w/w, wherein the binder used is gelatin.

Priority: IN2008MU00915 Applic. Date: 2008-04-25; WO2009IN00251 Applic. Date: 2009-04-24

Inventor: LADDHA NITIN SHIVCHARAN [IN]; KULKARNI SUSHRUT K [IN]; ROY SUNILENDU BUSHAN [IN]


Application No.: US20110097401A1  Published: 28/Apr/2011

Title: METHODS FOR TREATING GASTROINTESTINAL DISORDERS

Applicant/Assignee: MERITAGE PHARMA, INC

Application No.: 12/814335   Filing Date: 11/Jun/2010

Abstract:

Provided herein are compositions and formulations suitable for the treatment of gastrointestinal disorders. Also provided are methods for treating, preventing, or alleviating disorders of the gastrointestinal tract, for example, those involving the esophagus.

Priority: US20090186777P Applic. Date: 2009-06-12

Inventor: PHILLIPS ELAINE [US]; HILL MALCOLM [US]; SIMPSON ADAM [US]


Application No.: US20110097414A1  Published: 28/Apr/2011

Title: PHARMACEUTICAL COMPOSITIONS COMPRISING ADSORBATE OF FENOFIBRATE

Applicant/Assignee:

Application No.: 12/528627   Filing Date: 26/Feb/2008

Abstract:

The present invention provides a pharmaceutical composition comprising adsorbate of fenofibrate or salt thereof or fenofibrate adsorbed on a pharmaceutically acceptable adsorbent and optionally one or more pharmaceutically acceptable excipients. The invention also relates to processes for the preparation of such compositions.

Priority: IN2007MU00370 Applic. Date: 2007-02-26; IN2007MU00777 Applic. Date: 2007-04-20; IN2007MU00778 Applic. Date: 2007-04-20; IN2007MU01489 Applic. Date: 2007-08-02; IN2007MU01490 Applic. Date: 2007-08-02; IN2007MU01491 Applic. Date: 2007-08-02; WO2008IB00414 Applic. Date: 2008-02-26

Inventor: SANDAL ROSHAN LAL [IN]; THAKKAR VIKRANT [IN]; GUNDU RAMAKANT KASHINATH [IN]; DABRE RAHUL SUDHAKAR [IN]; MURALI NARAYANAN [IN]; JAIN GIRISH KUMAR [IN]


Application No.: US20110098334A1  Published: 28/Apr/2011

Title: NOVEL CRYSTALLINE FORM OF CALCIUM ZOFENOPRIL

Applicant/Assignee: GENERICS [UK] LIMITED

Application No.: 12/671328   Filing Date: 08/Aug/2008

Abstract:

The present invention relates to a novel anhydrous crystalline form of zofenopril calcium of formula (I), chemically known as (4S)-1-[(2S)-3-(benzoylthio)-2-methylpropionyl]-4-(phenylthio)-L-proline calcium salt or hemi-calcium salt. The present invention further relates to a process for the preparation of the new crystalline form of zofenopril calcium, its use in pharmaceutical compositions and the use of the new crystalline form and compositions in the treatment of hypertension and various other diseases.

Priority: GB20070015626 Applic. Date: 2007-08-10; WO2008GB50683 Applic. Date: 2008-08-08

Inventor: BECKER AXEL [GB]


Application No.: US20110104262A1  Published: 05/May/2011

Title: Topical Combinations Comprising an Antimycotic Agent and an Antiviral Agent

Applicant/Assignee: CIPLA LIMITED

Application No.: 12/988155   Filing Date: 16/Apr/2009

Abstract:

There is provided a pharmaceutical composition comprising an antimycotic agent and an antiviral agent, useful for prophylaxis and/or treatment of an associated infection and/or disease and a method of manufacturing thereof.

Priority: IN2008MU00862 Applic. Date: 2008-04-16; WO2009GB00975 Applic. Date: 2009-04-16

Inventor: LULLA AMAR [IN]; MALHOTRA GEENA [IN]


Application No.: US20110104266A1  Published: 05/May/2011

Title: MULTIMICROPARTICULATE PHARMACEUTICAL FORMS FOR ORAL ADMINISTRATION

Applicant/Assignee: FLAMEL TECHNOLOGIES

Application No.: 13/004701   Filing Date: 11/Jan/2011

Abstract:

The object of the present invention is to minimize the risks of dose dumping associated with the concomitant consumption of alcohol and certain modified-release pharmaceutical or dietetic forms. The invention relates to an oral form comprising microparticles of the reservoir type for the modified release of at least one active principle (AP), characterized in that it is resistant to immediate dumping of the dose of AP in the presence of alcohol. In particular, the oral form according to the invention is characterized in that the time taken to release 50% of the AP in an alcoholic solution is not reduced more than 3-fold relative to the time taken to release 50% of the AP in an alcohol-free aqueous medium. The form comprises an agent 13, which is a pharmaceutically acceptable compound whose hydration or solvation rate or capacity is greater in an alcohol-free aqueous medium than in alcoholic solution.

Priority: US2001-130047 Applic. Date: 2011-01-11; US2007-707054 Applic. Date: 2007-02-16; US20060773657P Applic. Date: 2006-02-16

Inventor: GUIMBERTEAU FLORENCE [FR]; DARGELAS FREDERIC [FR]


Application No.: US20110104267A1  Published: 05/May/2011

Title: Pharmaceutical compositions of antiretrovirals

Applicant/Assignee: AUROBINDO PHARMA LIMITED

Application No.: 11/919161   Filing Date: 24/Apr/2006

Abstract:

The present invention relates to the stable pharmaceutical dosage forms of combination of antiretroviral agents. More particularly, the present invention relates to stable pharmaceutical dosage forms of Lamivudine, Zidovudine and Nevirapine, prepared by granulation technology.

Priority: IN2005CH00464 Applic. Date: 2005-04-25; WO2006IB01210 Applic. Date: 2006-04-24

Inventor: HANJAGI UMESH MUTT [IN]


Application No.: US20110104268A1  Published: 05/May/2011

Title: GALENIC APPLICATIONS OF SELF-EMULSIFYING MIXTURES OF LIPIDIC EXCIPIENTS

Applicant/Assignee: AVENTIS PHARMA S.A

Application No.: 12/870250   Filing Date: 27/Aug/2010

Abstract:

A subject-matter of the invention is novel pharmaceutical formulations which make it possible to improve the intestinal absorption of orally administered active principles, their process of preparation and the application of lipid excipients in combination with one or more surfactants and one or more cosurfactants for inhibiting efflux pumps.

Priority: FR20040008269 Applic. Date: 2004-07-27; US2005-572402 Applic. Date: 2005-07-20; WO2005FR01853 Applic. Date: 2005-07-20

Inventor: PACHOT JEAN [FR]; SEGOT CHICQ SERGE [FR]


Application No.: US20110104271A1  Published: 05/May/2011

Title: Microcrystalline Cellulose and Calcium Phosphate Compositions Useful as Pharmaceutical Excipients

Applicant/Assignee: FMC CORPORATION

Application No.: 12/917991   Filing Date: 02/Nov/2010

Abstract:

Compositions containing calcium phosphate and microcrystalline cellulose are useful as excipients in the preparation of solid dosage forms containing active pharmaceutical ingredients, particularly those prepared by processes involving multiple compaction steps. The recompactibility performance of such compositions is improved through the use of calcium phosphate having a relatively small particle size, e.g., a median particle size of not more than about 20 microns or not more than about 10 microns.

Priority: US20090258390P Applic. Date: 2009-11-05

Inventor: THOORENS GREGORY [BE]; LECLERCQ BRUNO [BE]; RUSZKAY THOMAS [US]


Application No.: US20110104274A1  Published: 05/May/2011

Title: NOVEL COMPOSITION AND USES THEREOF, IN PARTICULAR COSMETIC USES, FOR TREATING SKIN DEHYDRATION

Applicant/Assignee: COMPAGNIE GERVAIS DANONE

Application No.: 12/445245   Filing Date: 12/Oct/2007

Abstract:

The present invention relates to the use of a combination comprising gamma-linolenic acid and at least one green tea polyphenol, in which the ratio of the gamma-linolenic acid to the green tea polyphenol ranges from approximately 1 to approximately 10, for increasing the in vitro and ex vivo differentiation of keratinocytes.

Priority: FR20060009039 Applic. Date: 2006-10-13; WO2007FR01677 Applic. Date: 2007-10-12

Inventor: TRAN QUANG-KHAI [FR]; RONDEAU PASCALE [FR]; SAINT NENIS THIERRY [FR]; SAMSON-VILLEGER SANDRINE [FR]


Application No.: US20110104288A1  Published: 05/May/2011

Title: Microcrystalline Cellulose and Calcium Phosphate Compositions Useful as Pharmaceutical Excipients

Applicant/Assignee: FMC CORPORATION

Application No.: 12/917904   Filing Date: 02/Nov/2010

Abstract:

Coprocessed compositions containing calcium phosphate and microcrystalline cellulose are useful as excipients in the preparation of solid dosage forms containing active pharmaceutical ingredients, particularly those prepared by processes involving multiple compaction steps. Such compositions may be obtained by preparing aqueous slurries of microcrystalline cellulose and calcium phosphate and drying such slurries to produce particulate products. The coprocessed products exhibit improved compactibility, as compared to dry physical blends of the same components.

Priority: US20090258391P Applic. Date: 2009-11-05

Inventor: THOORENS GREGORY [BE]; LECLERCQ BRUNO [BE]; RUSZKAY THOMAS [US]


Application No.: US20110105594A1  Published: 05/May/2011

Title: PALATABLE NUTRITIONAL COMPOSITION COMPRISING A NUCLEOTIDE AND/OR A NUCLEOSIDE AND A TASTE MASKING AGENT

Applicant/Assignee: N.V. NUTRICIA

Application No.: 12/809431   Filing Date: 22/Dec/2008

Abstract:

The present invention relates to the use of a taste masking agent selected from the group of cellulose

starch

xanthan gum

gellan gum

alginate

galactomannans such as fenugreek, guar gum, tara gum, locust bean gum, and cassia gum

gum karaya

gum tragacanth

carrageenan

and mixture thereof, for improving one or more of mouth feel, taste, aftertaste and smell of a liquid aqueous nutritional composition comprising a nucleotide and/or a nucleoside. It also relates to a nutritional composition comprising an unsavoury nucleotide and/or a nucleoside component, having improved sensory characteristics such as improved mouth feel, taste, aftertaste and smell. In particular, it relates to a composition comprising said un-savoury nucleotide and/or a nucleoside component, in particular comprising an uridine-containing nucleotide and/or a nucleoside in combination with an unsavoury edible oil, such as a fish oil.

Priority: EP20070123811 Applic. Date: 2007-12-20; WO2008NL50124 Applic. Date: 2008-03-04; WO2008NL50843 Applic. Date: 2008-12-22

Inventor: DE KORT ESTHER JACQUELINE [NL]; GROENENDIJK MARTIN [NL]; KAMPHUIS PATRICK JOSEPH GERARDUS HENDRIKUS [NL]


Application No.: US20110110880A1  Published: 12/May/2011

Title: NICOTINE LOZENGE COMPOSITIONS

Applicant/Assignee:

Application No.: 12/990049   Filing Date: 30/Apr/2009

Abstract:

The present invention relates to nicotine lozenge compositions comprising reduced levels of buffering agents from traditional nicotine lozenges and which provide optimal oral pH and prompt nicotine absorption in a smaller, more convenient dosage form.

Priority: US20080049515P Applic. Date: 2008-05-01; WO2009US42190 Applic. Date: 2009-04-30

Inventor: CHEN LI-LAN [US]


Application No.: US20110111006A1  Published: 12/May/2011

Title: CONVENIENTLY IMPLANTABLE SUSTAINED RELEASE DRUG COMPOSITIONS

Applicant/Assignee: RAMSCOR, INC

Application No.: 13/006801   Filing Date: 14/Jan/2011

Abstract:

This invention provides for biocompatible and biodegradable syringeable liquid, implantable solid, and injectable gel pharmaceutical formulations useful for the treatment of systemic and local disease states.

Priority: US2001-130068 Applic. Date: 2011-01-14; US2007-826833 Applic. Date: 2007-07-18; US2005-236426 Applic. Date: 2005-09-27; US20040614484P Applic. Date: 2004-10-01; US20050709665P Applic. Date: 2005-08-19

Inventor: WONG VERNON G [US]; WOOD LOUIS L [US]


Application No.: US20110111019A1  Published: 12/May/2011

Title: Novel Method for Producing Nanocapsules in the Absence of an Organic Solvent, and Nanocapsules Produced Thereby

Applicant/Assignee: UNIVERSITE CLAUDE BERNARD LYON I

Application No.: 12/988380   Filing Date: 14/Apr/2009

Abstract:

The invention relates to a method for preparing an aqueous suspension of nanocapsules comprising an oily core surrounded by a polymeric shell, in which method the following phases are mixed: a) a first phase, called an oily phase, comprising: a hydrophobic polymer, an oil or a mixture of oils, at least one active ingredient, and a surfactant TA1, this oily phase being brought to a temperature T1 higher than the melting point of the hydrophobic polymer, the hydrophobic polymer being miscible, at this temperature T1, with the mixture of the surfactant TA1 and the oil or mixture of oils, and the active ingredient being miscible, soluble or solubilized in the mixture of the surfactant TA1 and the oil or mixture of oils

b) a second phase, called a polar phase, comprising a hydrophilic polymer in the form of a hydrogel in an aqueous solution containing a surfactant TA2, in such a way as to obtain the formation of the nanocapsules in an aqueous suspension.

Priority: FR20080052648 Applic. Date: 2008-04-18; WO2009FR50680 Applic. Date: 2009-04-14

Inventor: PIROT FABRICE [FR]; FALSON FRANCOISE [FR]


Application No.: US20110111023A1  Published: 12/May/2011

Title: PREVENTION OF TYPE 1 DIABETES BY ADMINISTRATION OF GLIADIN

Applicant/Assignee: KOBENHAVNS UNIVERSITET

Application No.: 12/675314   Filing Date: 10/Sep/2008

Abstract:

The invention herein is related to intranasal or other mucosal administration of gliadin, or parts thereof, to prevent the development of type 1 diabetes. This environmental antigen, which may have etiological role in the development of diabetes in genetically predisposed individuals, has been successfully applied in the prevention of disease.

Priority: US20070993327P Applic. Date: 2007-09-11; US20080075055P Applic. Date: 2008-06-24; WO2008EP62008 Applic. Date: 2008-09-10

Inventor: BUSCHARD KARSTEN [DK]; FUNDA DAVID [CZ]; FUNDOVA PETRA [CZ]; HANSEN AXEL KORNERUP [DK]


Application No.: US20110111024A1  Published: 12/May/2011

Title: PHARMACEUTICAL COMPOSITIONS AND ORAL DOSAGE FORMS OF A LEVODOPA PRODRUG AND METHODS OF USE

Applicant/Assignee: XENOPORT, INC

Application No.: 12/941971   Filing Date: 08/Nov/2010

Abstract:

Pharmaceutical compositions and oral dosage forms of (2R)-2-phenylcarbonyloxypropyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate mesylate and methods of treating diseases comprising orally administering such pharmaceutical compositions and dosage forms are disclosed.

Priority: US20090259567P Applic. Date: 2009-11-09

Inventor: MAO CHEN [US]; PARGAONKAR NIKHIL [US]; MAUER LAURA E [US]; MA SARINA GRACE HARRIS [US]


Application No.: US20110112024A1  Published: 12/May/2011

Title: FACTOR VIII POLYMER CONJUGATES

Applicant/Assignee: BAXTER HEALTHCARE S.A, BAXTER INTERNATIONAL INC

Application No.: 13/010607   Filing Date: 20/Jan/2011

Abstract:

The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same.

Priority: US2007-130106 Applic. Date: 2011-01-20; US2010-684456 Applic. Date: 2010-01-08; US2008-184567 Applic. Date: 2008-08-01; US2007-729625 Applic. Date: 2007-03-29; US20060787968P Applic. Date: 2006-03-31; US20060790239P Applic. Date: 2006-04-06

Inventor: TURECEK PETER [AT]; SIEKMANN JUERGEN [AT]


Application No.: US20110112025A1  Published: 12/May/2011

Title: FACTOR VIII POLYMER CONJUGATES

Applicant/Assignee: BAXTER HEALTHCARE S.A, BAXTER INTERNATIONAL INC

Application No.: 13/010610   Filing Date: 20/Jan/2011

Abstract:

The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same.

Priority: US2010-684456 Applic. Date: 2010-01-08; US2008-184567 Applic. Date: 2008-08-01; US2007-729625 Applic. Date: 2007-03-29; US20060787968P Applic. Date: 2006-03-31; US20060790239P Applic. Date: 2006-04-06

Inventor: TURECEK PETER [AT]; SIEKMANN JUERGEN [AT]


Application No.: US20110112026A1  Published: 12/May/2011

Title: FACTOR VIII POLYMER CONJUGATES

Applicant/Assignee: BAXTER HEALTHCARE S.A, BAXTER INTERNATIONAL INC

Application No.: 13/010616   Filing Date: 20/Jan/2011

Abstract:

The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same.

Priority: US2010-684456 Applic. Date: 2010-01-08; US2008-184567 Applic. Date: 2008-08-01; US2007-729625 Applic. Date: 2007-03-29; US20060787968P Applic. Date: 2006-03-31; US20060790239P Applic. Date: 2006-04-06

Inventor: TURECEK PETER [AT]; SIEKMANN JUERGEN [AT]


Application No.: US20110112027A1  Published: 12/May/2011

Title: FACTOR VIII POLYMER CONJUGATES

Applicant/Assignee: BAXTER HEALTHCARE S.A, BAXTER INTERNATIONAL INC

Application No.: 13/010622   Filing Date: 20/Jan/2011

Abstract:

The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same.

Priority: US2010-684482 Applic. Date: 2010-01-08; US2008-184567 Applic. Date: 2008-08-01; US2007-729625 Applic. Date: 2007-03-29; US20060787968P Applic. Date: 2006-03-31; US20060790239P Applic. Date: 2006-04-06

Inventor: TURECEK PETER [AT]; SIEKMANN JUERGEN [AT]


Application No.: US20110112028A1  Published: 12/May/2011

Title: FACTOR VIII POLYMER CONJUGATES

Applicant/Assignee: BAXTER HEALTHCARE S.A, BAXTER INTERNATIONAL INC

Application No.: 13/010625   Filing Date: 20/Jan/2011

Abstract:

The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same.

Priority: US2010-684509 Applic. Date: 2010-01-08; US2008-184567 Applic. Date: 2008-08-01; US2007-729625 Applic. Date: 2007-03-29; US20060787968P Applic. Date: 2006-03-31; US20060790239P Applic. Date: 2006-04-06

Inventor: TURECEK PETER [AT]; SIEKMANN JUERGEN [AT]


Application No.: US20110112041A1  Published: 12/May/2011

Title: Treatment of Male-Pattern Baldness by Local Induction of the Metabolic Defect of Fabry Disease

Applicant/Assignee: BAYLOR RESEARCH INSTITUTE

Application No.: 12/896591   Filing Date: 01/Oct/2010

Abstract:

Compositions comprising inhibitors of lysosomal enzyme alpha-galactosidase A and their use to favor hair growth or to prevent hair loss are disclosed in the instant invention. The topical use of the composition of the instant invention directly inhibits scalp enzyme activity and is used in the treatment for male pattern baldness (androgenic alopecia) in men and women.

Priority: US20090247894P Applic. Date: 2009-10-01

Inventor: SCHIFFMANN RAPHAEL [US]


Application No.: US20110112199A1  Published: 12/May/2011

Title: PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE

Applicant/Assignee: PATHOLOGICA LLC

Application No.: 12/837753   Filing Date: 16/Jul/2010

Abstract:

Disclosed herein are new oral pharmaceutical compositions of MGBG and related polyamine analogs, polyamine biosynthesis inhibitors, polyamine inhibitors of AMD-I and regulators of osteopontin, and their application for the treatment of disease.

Priority: US20090226060P Applic. Date: 2009-07-16; US20090290095P Applic. Date: 2009-12-24

Inventor: MCKEARN JOHN [US]; BLITZER JEREMY [US]


Application No.: US20110117186A1  Published: 19/May/2011

Title: INTRAVENOUS INFUSION OF CURCUMIN AND A CALCIUM CHANNEL BLOCKER

Applicant/Assignee:

Application No.: 12/949897   Filing Date: 19/Nov/2010

Abstract:

Compositions and methods for treating systemic diseases by intravenous administration of formulations of synthesized curcumin (diferuloylmethane) and concomitantly a calcium channel blocker to human subjects with neoplastic and neurodegenerative diseases are disclosed herein. The diseases are treated by prolonged administration of sub-optimal doses of liposomal curcumin or polymeric nanocurcumin or the sustained release curcumin from PLGA nanocurcumin at dosages below systemic hemolytic thresholds concomitantly with or without calcium channel blockers.

Priority: US20090262745P Applic. Date: 2009-11-19

Inventor: HELSON LAWRENCE [US]


Application No.: US20110117189A1  Published: 19/May/2011

Title: OPHTHALMIC COMPOSITIONS FOR TREATING PATHOLOGIES OF THE POSTERIOR SEGMENT OF THE EYE

Applicant/Assignee: S.I.F.I. SOCIETA' INDUSTRIA FARMACEUTICA ITALIANAS.P.A

Application No.: 13/003143   Filing Date: 08/Jul/2008

Abstract:

New compositions for ophthalmic use for the prevention and therapy of pathologies of the posterior segment of the eye. These compositions utilize xanthan gum as an active principle carrier, and can be advantageously administered as liquid-gel eye drops on the surface of the eye and optionally used in combination with other therapies for the treatment of the same pathologies.

Priority: WO2008IT00456 Applic. Date: 2008-07-08

Inventor: MAZZONE MARIA GRAZIA [IT]; CIVIALE CLAUDINE [IT]; CUFFARI FRANCESCO [IT]


Application No.: US20110117190A1  Published: 19/May/2011

Title: Pharmaceutical Formulations

Applicant/Assignee: GLAXO GROUP LIMITED

Application No.: 12/741596   Filing Date: 07/Nov/2008

Abstract:

The present invention is directed to novel pharmaceutically acceptable polymeric compositions suitable for melt extrusion and injection moulding of single or multi-component pharmaceutical dosage forms comprising a plurality of drug substance containing sub-units, being capsule compartments and/or solid sub-units comprising a solid matrix of a polymer which contains a drug substance, the sub-units being connected together in the assembled dosage form.

Priority: US20070986383P Applic. Date: 2007-11-08; WO2008IB03872 Applic. Date: 2008-11-01

Inventor: BROWN ADRIAN [GB]; GORRINGE LEE J [GB]; MCALLISTER STEPHEN MARK [GB]; MATTHEWS WAYNE M [GB]; RUSSELL DANIELLE GENEVIEVE REBECCA [GB]


Application No.: US20110117192A1  Published: 19/May/2011

Title: CARBIDOPA/LIPODOPA GASTRORETENTIVE DRUG DELIVERY

Applicant/Assignee: INTEC PHARM LTD

Application No.: 12/937955   Filing Date: 17/Apr/2009

Abstract:

A gastroretentive drug formulation for the sustained release of an active agent in the gastrointestinal tract comprises an internal layer or compartment comprising an active agent and one or more pharmaceutical excipients, of which at least one is a polymer and two membranes forming together an envelope around the inner membrane, each membrane comprising at least one polymeric combination of an enteric polymer which is not soluble in gastric juice, and an hydrophilic swelling polymer, and at least one plasticizer.

Priority: US20080046261P Applic. Date: 2008-04-18; US20080120051P Applic. Date: 2008-12-04; WO2009IB05691 Applic. Date: 2009-04-17

Inventor: NAVON NADAV [IL]; MOOR EYTAN [IL]; KIRMAYER DAVID [IL]; KLUEV ELENA [IL]; CARNI GIORA [IL]


Application No.: US20110117193A1  Published: 19/May/2011

Title: ANTIRETROVIRAL DRUG FORMULATIONS FOR TREATMENT OF CHILDREN EXPOSED TO HIV/AIDS

Applicant/Assignee: DUQUESNE UNIVERSITY OF THE HOLY SPIRIT

Application No.: 12/863111   Filing Date: 16/Jan/2009

Abstract:

The present disclosure provides fast disintegrating formulations for the treatment of human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) in patients such as neonatal, perinatal and pediatric children. Neonatal and perinatal formulations provide for the prevention or reduction of incidence of mother to child transmission of HIV. Also provided are formulations and methods for treating pediatric children having HIV/AIDS. The orally administered fast disintegrating formulations are in granule and tablet form and are specially formulation for children to increase adherence to treatment protocols.

Priority: US20080021790P Applic. Date: 2008-01-17; WO2009US31285 Applic. Date: 2009-01-16

Inventor: ADEYEYE MOJI C [US]; ESSEKU FREDRICK [US]; JOSHI ANAJALI [US]


Application No.: US20110117196A1  Published: 19/May/2011

Title: Analgetic dosage forms that are resistant to parenteral and inhalation dosing and have reduced side effects

Applicant/Assignee:

Application No.: 12/930805   Filing Date: 18/Jan/2011

Abstract:

The invention provides a novel solid pharmaceutical dosage form which includes an opiate, an opiate antagonist admixed with the analgetic (opiate agonist) and an amount of a hydrocolloid containing excipient which is effective to form a non-injectable slurry when the dosage form is contacted with water. In addition the dosage form contains pure naloxone in enteric coated form which is designed to release in the colon to prevent or relieve constipation. Thus the formulation, because of the enteric coated naloxone and the hydrocolloid excipient(s), has reduced side effects as compared with formulations which do not contain these features.

Priority: US2004-762714 Applic. Date: 2004-01-22

Inventor: GORDON MAXWELL [US]


Application No.: US20110118364A1  Published: 19/May/2011

Title: PHARMACEUTICAL COMPOSITIONS OF NANOPARTICLES CONTAINING ACTIVE INGREDIENTS

Applicant/Assignee:

Application No.: 13/002036   Filing Date: 30/Jun/2009

Abstract:

This invention concerns a manufacturing process for nanoparticles composted of biodegradable polymers and active ingredients with therapeutic, cosmetic, veterinary, and alimentary applications, and a composition which contains said nanoparticles, which are used in products for animals, including humans. The process consists of emulsifying the hydrosoluble substances to form a w/o emulsion

dissolving the non-emulsionable substances, liposoluble polymer or polymer/compounds in organic solvents

mixing the w/o emulsion and the organic solution of the hydrophobics to form a pre-emulsioned mixture

adding the pre-emulsioned mixture, with the assistance of an injector system, to an aqueous emulsifier solution under ultradispersion to form the final emulsion

leading the final emulsion to evaporation, then centrifuge, freeze, and lyophilize. One variation of the method takes place when the hydrosoluble emulsioned compounds and the liposoluble polymer or polymer/compounds solution are injected separately over the aqueous emulsifying solution. The process of the invention allows nanoparticles of active ingredients to be obtained with a rigorous control over the size of the particle, preserving the active characteristics of the encapsulated compounds.

Priority: BR2008PI02233 Applic. Date: 2008-06-30; WO2009BR00192 Applic. Date: 2009-06-30

Inventor: LINS DANTAS FABIO MOYSES [BR]


Application No.: US20110123575A1  Published: 26/May/2011

Title: MODIFIED RELEASE NIACIN FORMULATIONS

Applicant/Assignee: DR. REDDY'S LABORATORIES LTD, DR. REDDY'S LABORATORIES, INC

Application No.: 12/995718   Filing Date: 02/Jun/2009

Abstract:

Modified release pharmaceutical formulations comprising niacin in a non-swellable core, and processes for preparation of the formulations.

Priority: IN2008CH01345 Applic. Date: 2008-06-02; IN2009CH01145 Applic. Date: 2009-05-18; WO2009US45927 Applic. Date: 2009-06-02

Inventor: VOOTURI RAJESH [IN]; SINGARE DHANAJAY [IN]; DAMLE SHANTANU YESHWANT [IN]; KARATGI PRADEEP JAIRAO [IN]; MARELLA SESHA SAI [IN]; BHAGWATWAR HARSHAL PRABHAKAR [IN]; KHANNA ISH KUMAR [US]; PILLAI RAVIRAJ SUKUMAR [IN]


Application No.: US20110123608A1  Published: 26/May/2011

Title: PHARMACEUTICAL FORMULATION

Applicant/Assignee: SMITHKLINE BEECHAM LIMITED

Application No.: 12/952677   Filing Date: 23/Nov/2010

Abstract:

The present invention is directed to pharmaceutically acceptable polymeric compositions suitable for injection molding of single or multi-component pharmaceutical dosage forms comprising a plurality of drug substance containing sub-units, being capsule compartments and/or solid sub-units comprising a solid matrix of a polymer which contains a drug substance, the sub-units being connected together in the assembled dosage form by a weld between parts of the assembled dosage form.

Priority: GB20010002342 Applic. Date: 2001-01-30; US2004-470439 Applic. Date: 2004-01-20; WO2002US02698 Applic. Date: 2002-01-30

Inventor: MCALLISTER STEPHEN MARK [GB]; RABY JR RONALD K [US]; BROWN ADRIAN [GB]; CLARKE ALLAN J [US]


Application No.: US20110123610A1  Published: 26/May/2011

Title: EXTENDED RELEASE COMPOSITIONS CONTAINING TOLTERODINE AND PROCESS FOR PREPARING THE SAME

Applicant/Assignee: MICRO LABS LIMITED

Application No.: 12/951965   Filing Date: 22/Nov/2010

Abstract:

The present invention is directed to an extended release pharmaceutical composition such as tablets and capsules, and in particular to a matrix tablet composition comprising a therapeutically effective quantity of Tolterodine or pharmaceutical acceptable salts thereof incorporated in a hydrophobic matrix comprising water insoluble polymer and wax and a method for the preparation thereof.

Priority: IN2009CH02880 Applic. Date: 2009-11-23

Inventor: KSHIRSAGAR RAJESH [IN]; MUNDADE SACHIN [IN]; SHINDE GANESH [IN]; KAMBLE PRAVIN [IN]; SONAWANE SANDIP [IN]; MUDDA SM [IN]


Application No.: US20110123631A1  Published: 26/May/2011

Title: ORAL COMPOSITIONS OF CLINDAMYCIN

Applicant/Assignee:

Application No.: 13/055004   Filing Date: 10/Sep/2008

Abstract:

A taste masked pharmaceutical composition of clindamycin, or a pharmaceutically acceptable salt(s), hydrate(s), solvate(s) and physiologically functional derivative(s) and precursors thereof, which includes all polymorphic forms, whether crystalline or amorphous comprising polyhydric alcohol(s)

and one or more other pharmaceutically acceptable excipient(s). A process for preparation of a taste masked pharmaceutical composition of clindamycin or a pharmaceutically acceptable salt(s) thereof the said process comprising the steps of a) dry mixing clindamycin, polyhydric alcohol and other pharmaceutically acceptable excipient(s) to get a dry mixture

b) granulating the dry mixture above with a granulating liquid prepared by mixing the suitable pharmaceutically acceptable excipient(s) with aqueous/non-aqueous fluid to obtain a wet mass

c) drying the wet mass to obtain the discrete particles

d) lubricating the discrete particles obtained with a suitable lubricating agent and/or flavour(s).

Priority: WO2008IN00579 Applic. Date: 2008-09-10; IN2008KO01242 Applic. Date: 2008-07-22

Inventor: WALZADE KALPANA [IN]; KULKARNI RAJESH [IN]; KULKARNI SHIRISHKUMAR [IN]


Application No.: US20110123652A1  Published: 26/May/2011

Title: SELF-EMULSIFYING ACTIVE SUBSTANCE FORMULATION AND USE OF THIS FORMULATION

Applicant/Assignee:

Application No.: 12/899227   Filing Date: 06/Oct/2010

Abstract:

The present invention relates to self-emulsifying formulations based on an active ingredient component and a formulation base with a lipid component and with a binder component and to the use of this formulation as dosage form in the life science sector. The invention also describes a process for producing self-emulsifying formulations by mixing the formulation components to form a plastic mixture and, where appropriate, to manufacture the formulations as dosage form advantageously by use of melt extrusion. The formulations spontaneously form emulsions in water or aqueous media.

Priority: DE20001026698 Applic. Date: 2000-05-30; US2002-296451 Applic. Date: 2002-11-25; WO2001EP06116 Applic. Date: 2001-05-29

Inventor: BERNDL GUNTHER [DE]; BREITENBACH JOERG [DE]; ROSENBERG JOERG [DE]; HEGER ROBERT [DE]; STADLER MICHAEL [DE]; WILKE PETER [DE]


Application No.: US20110123692A1  Published: 26/May/2011

Title: CRYSTALLIZATION OF POLYOL COMPOSITIONS, CRYSTALLINE POLYOL COMPOSITION PRODUCT AND USE THEREOF

Applicant/Assignee: DANISCO SWEETENERS OY

Application No.: 12/914317   Filing Date: 28/Oct/2010

Abstract:

The present invention relates to microcrystallized polyol comprising at least two polyols, wherein said polyols are selected from the group consisting of maltitol, xylitol and lactitol and wherein said composition contains at least 35% by weight of each of at least two of said polyols microcrystallized together into a solid microcrystalline product. The present invention also relates to a process for the microcrystallization of polyols into a polyol composition. The microcrystallized polyol composition can be used in confectionery, foodstuffs, oral hygiene products and pharmaceuticals and in dietetic products.

Priority: FI20020001312 Applic. Date: 2002-07-03; US2005-517692 Applic. Date: 2005-07-05; WO2003FI00533 Applic. Date: 2003-07-02

Inventor: EROMA OLLI-PEKKA [FI]; NYGREN JOHANNA [FI]; HEIKKILA HEIKKI [FI]; SORENSEN PER BO [DK]; SARKKI MARJA-LEENA [FI]; FAIRS IAN [GB]; GROS HAKAN [FI]


Application No.: US20110124694A1  Published: 26/May/2011

Title: BIOAVAILABLE COMPOSITIONS OF METAXALONE AND PROCESSES FOR PRODUCING THE SAME

Applicant/Assignee: MUTUAL PHARMACEUTICAL COMPANY, INC

Application No.: 13/020347   Filing Date: 03/Feb/2011

Abstract:

Pharmaceutical compositions comprising metaxalone which demonstrate improved dissolution and bioavailability characteristics compared to the commercially available product, and methods of producing them are provided. In a preferred embodiment, a dosage form comprising metaxalone and at least one inactive powder excipient is bioequivalent to its commercially available counterpart (Skelaxin TM 400-mg tablets) after oral administration to fasting or non-fasting human subjects, while at the same time displaying faster drug dissolution rates than the Skelaxin TM tablets as demonstrated from three different dissolution tests. In another preferred embodiment, a dosage form comprising metaxalone, at least one inactive powder excipient and a nonvolatile liquid is significantly more bioavailable than the commercially available Skelaxin TM 400-mg tablets after oral administration to fasting human subjects.

Priority: US2009-466544 Applic. Date: 2009-05-15; US2005-075170 Applic. Date: 2005-03-08; US20040551257P Applic. Date: 2004-03-08

Inventor: SPIREAS SPIRIDON [US]


Application No.: US20110124730A1  Published: 26/May/2011

Title: ORAL PHARMACEUTICAL SUSPENSION COMPRISING PARACETAMOL AND IBUPROFEN

Applicant/Assignee: WOCKHARDT RESEARCH CENTRE

Application No.: 12/811187   Filing Date: 03/Jan/2008

Abstract:

The present invention relates to an oral pharmaceutical suspension comprising paracetamol and ibuprofen. The invention also relates to a method of treating perioperative or postoperative pain by administering to a subject a therapeutically effective amount of oral pharmaceutical suspension comprising paracetamol and Ibuprofen.

Priority: WO2008IB00005 Applic. Date: 2008-01-03

Inventor: ATKINSON HARTLEY [NZ]; KIELY AUSTIN [IE]


Application No.: US20110129485A1  Published: 02/Jun/2011

Title: Modified Galectin-2 and Uses Thereof

Applicant/Assignee: THE UNIVERSITY OF QUEENSLAND

Application No.: 12/992662   Filing Date: 18/May/2009

Abstract:

An isolated modified galectin-2 protein comprising a mutation and/or modification which improves one or more properties of said isolated modified galectin-2 are provided. More particularly, the mutation of galectin-2 is substitution of cysteine 57, preferably with a methionine residue. Modification of an isolated galectin-2 includes a modification of cysteine 75. Modification includes chemical modification by PEGylation or alkylation. Also provided are isolated nucleic acid, genetic constructs comprising said isolated nucleic acids, antibodies, compositions and methods of modulating an immune response that may be useful in therapeutic and/or prophylactic treatment of disease, disorders or considers which involve an immune response is mediated by one or more cytokines or other soluble immunomodulators and/or the immune response is mediated by one or more cells of the immune system.

Priority: AU20080902459 Applic. Date: 2008-05-19; WO2009AU00621 Applic. Date: 2009-05-18

Inventor: WANG HUI [AU]; MIDDELBERG ANTON P J [AU]; HE LIZHONG [AU]


Application No.: US20110129530A1  Published: 02/Jun/2011

Title: Compressible-Coated Pharmaceutical Compositions and Tablets and Methods of Manufacture

Applicant/Assignee: EURAND, INC

Application No.: 12/956543   Filing Date: 30/Nov/2010

Abstract:

There is provided a method for preparing a pharmaceutical composition comprising compressible coated, taste-masked and/or controlled-release coated drug-containing particles, rapidly-dispersing microgranules comprising a disintegrant and a sugar alcohol, a saccharide, or a mixture thereof, and other optional, pharmaceutically acceptable excipients wherein the orally disintegrating tablet (ODT) or rapidly dispersing tablet (RDT) composition having acceptable tableting, organoleptic, and pharmacokinetic properties.

Priority: US20090265213P Applic. Date: 2009-11-30

Inventor: VENKATESH GOPI M [US]; LAI JIN-WANG [US]; CLEVENGER JAMES M [US]; KRAMER CRAIG [US]


Application No.: US20110130370A1  Published: 02/Jun/2011

Title: Pharmaceutical composition comprising a strontium salt, vitamin D and A cyclodextrin

Applicant/Assignee: LES LABORATORIES SERVIER

Application No.: 12/927733   Filing Date: 23/Nov/2010

Abstract:

A pharmaceutical composition comprising a strontium salt, vitamin D and a cyclodextrin.

Priority: FR20090005706 Applic. Date: 2009-11-27

Inventor: BRIAULT GILLES [FR]; QUENAULT XAVIER [FR]; POIRIER CECILE [FR]; PEAN JEAN-MANUEL [FR]


Application No.: US20110130434A1  Published: 02/Jun/2011

Title: MODIFIED RELEASE RAMIPRIL COMPOSITIONS AND USES THEREOF

Applicant/Assignee: PANACEA BIOTEC LTD

Application No.: 13/055778   Filing Date: 28/Jul/2009

Abstract:

The invention relates to a modified release pharmaceutical composition comprising ramipril or pharmaceutically acceptable salts thereof and pharmaceutically acceptable excipient(s) wherein pharmaceutical composition is bioequivalent to conventional immediate release formulation of ramipril administered twice daily. The invention further relates to a modified release pharmaceutical composition comprising: an immediate release component comprising ramipril or pharmaceutically acceptable salts thereof and a modified release component comprising ramipril or pharmaceutically acceptable salts thereof. The invention further relates to the process for the preparation of modified release pharmaceutical composition of ramipril.

Priority: IN2008MU01621 Applic. Date: 2008-07-30; WO2009IN00428 Applic. Date: 2009-07-28

Inventor: JAIN RAJESH [IN]; SINGH SARABJIT [IN]


Application No.: US20110132356A1  Published: 09/Jun/2011

Title: COMPOSITIONS FOR PULMONARY DELIVERY OF LONG-ACTING B2 ADRENERGIC RECEPTOR AGONISTS AND ASSOCIATED METHODS AND SYSTEMS

Applicant/Assignee: PEARL THERAPEUTICS, INC

Application No.: 12/790605   Filing Date: 28/May/2010

Abstract:

Compositions, methods and systems are provided for pulmonary delivery of long-acting muscarinic antagonists and long-acting [beta]2 adrenergic receptor agonists via a metered dose inhaler. In particular embodiments, the compositions include a suspension medium, active agent particles, and suspending particles, in which the active agent particles and suspending particles form a co-suspension within the suspension medium.

Priority: US20090182565P Applic. Date: 2009-05-29; US20090258172P Applic. Date: 2009-11-04; US20100309365P Applic. Date: 2010-03-01; US20100345536P Applic. Date: 2010-05-17

Inventor: VEHRING REINHARD [CA]; HARTMAN MICHAEL STEVEN [US]; SMITH ADRIAN EDWARD [US]; JOSHI VIDYA B [US]; DWIVEDI SARVAJNA KUMAR [US]


Application No.: US20110132357A1  Published: 09/Jun/2011

Title: COMPOSITIONS, METHODS & SYSTEMS FOR RESPIRATORY DELIVERY OF TWO OR MORE ACTIVE AGENTS

Applicant/Assignee: PEARL THERAPEUTICS, INC

Application No.: 12/790710   Filing Date: 28/May/2010

Abstract:

Compositions, methods and systems are provided for pulmonary or nasal delivery of two or more active agents via a metered dose inhaler. In one embodiment, the compositions include a suspension medium, active agent particles, and suspending particles, in which the active agent particles and suspending particles form a co-suspension within the suspension medium.

Priority: US20090182565P Applic. Date: 2009-05-29; US20090258172P Applic. Date: 2009-11-04; US20100309365P Applic. Date: 2010-03-01; US20100345536P Applic. Date: 2010-05-17

Inventor: VEHRING REINHARD [CA]; HARTMAN MICHAEL STEVEN [US]; LECHUGA-BALLESTEROS DAVID [US]; SMITH ADRIAN EDWARD [US]; JOSHI VIDYA B [US]; DWIVEDI SARVAJNA KUMAR [US]


Application No.: US20110135580A1  Published: 09/Jun/2011

Title: Novel Medicament Combinations for the Treatment of Respiratory Diseases

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: 12/301923   Filing Date: 09/May/2007

Abstract:

The present invention relates to new medicament combinations which contain in addition to one or more, preferably one, compound of general formula 1 wherein the groups A, B, X, R1, R2 and R3 may have the meanings given in the claims and specification, at least one anticholinergic 2 and at least one steroid 3, processes for preparing them and their use as pharmaceutical compositions.

Priority: EP20060114541 Applic. Date: 2006-05-24; EP20060115462 Applic. Date: 2006-06-14; WO2007EP54487 Applic. Date: 2007-05-09

Inventor: KONETZKI INGO [DE]


Application No.: US20110135623A1  Published: 09/Jun/2011

Title: Conjugates of a Cholinesterase Moiety and a Polymer

Applicant/Assignee: NEKTAR THERAPEUTICS

Application No.: 12/991402   Filing Date: 15/May/2009

Abstract:

Conjugates of a cholinesterase moiety and one or more nonpeptidic, water soluble polymers are provided. Typically, the nonpeptidic, water soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided, among other things, are compositions comprising conjugates, methods of making conjugates, and methods of administering compositions to a patient.

Priority: US20080127928P Applic. Date: 2008-05-16; WO2009US03035 Applic. Date: 2009-05-15

Inventor: BOSSARD MARY J [US]; ZAPPE HAROLD [US]; LEE SEOJU [US]; FERNANDO LAL AJITHA RATNAPALA [US]


Application No.: US20110135679A1  Published: 09/Jun/2011

Title: COMPOSITIONS FOR INDUCING IMMUNE RESPONSES

Applicant/Assignee: NOVARTIS AG

Application No.: 12/746723   Filing Date: 07/Dec/2008

Abstract:

The invention provides, inter alia, immunogenic compositions that comprise (a) a first antigen, (b) at least first and second adjuvants, wherein the first adjuvant comprises microparticles and wherein the second adjuvant comprises an imidazoquinoline compound, and (c) a pharmaceutically acceptable excipient, which compositions elicits an immune response when administered to a vertebrate subject. The invention also provides methods of producing immunogenic compositions and methods for using immunogenic compositions (e.g., for treatment), among other benefits.

Priority: US20070005704P Applic. Date: 2007-12-07; WO2008US85506 Applic. Date: 2008-12-04

Inventor: MALYALA PADMA [US]; O'HAGAN DEREK [US]; SINGH MANMOHAN [US]


Application No.: US20110135724A1  Published: 09/Jun/2011

Title: Ondansetron Orally Disintegrating Tablet Compositions for Prevention of Nausea and Vomiting

Applicant/Assignee: EURAND, INC

Application No.: 12/956249   Filing Date: 30/Nov/2010

Abstract:

This invention is related to a pharmaceutical composition in the patient-friendly orally disintegrating tablet form comprising a weakly basic, selective serotonin 5-HT3 blocking agent for the prevention of nausea and/or vomiting for up to 24 hrs postdosing in cancer patients prior to undergoing moderately emetogenic chemotherapy or partial or whole body radiotherapy or in subjects at moderate to high risk of postoperative or postdischarge nausea and/or vomiting prior to inpatient or outpatient ambulatory surgery. The unit dosage form comprising a multitude of immediate-release drug particles providing dissolution profiles similar to that of reference drug product, and one or more timed, pulsatile-release bead populations, comprising at least one organic acid, which solubilizes said weakly basic selective serotonin 5-HT3 blocking agent prior to releasing it into the hostile intestinal environment, wherein the blocking agent is practically insoluble, is capable of delivering said antiemetic agent in patients in need thereof in a sustained-released fashion to be suitable for a once-daily dosing regimen.

Priority: US20090265233P Applic. Date: 2009-11-30

Inventor: VENKATESH GOPI M [US]


Application No.: US20110135732A1  Published: 09/Jun/2011

Title: MULTIPLE PHASE CROSS-LINKED COMPOSITIONS AND USES THEREOF

Applicant/Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY

Application No.: 12/951221   Filing Date: 22/Nov/2010

Abstract:

The present invention is directed to pharmaceutical compositions, and method for preparing pharmaceutical compositions, comprising a cross-linked matrix physically entrapping at least one therapeutic agent. The matrix may comprise one or more phases in addition to an aqueous phase, such as a solid and/or oil phase. The matrix of the invention has at least one controlled release in-vivo kinetic profile, and may have additional profiles for the same agent. The matrix may also comprise more than one therapeutic agent, and each additional therapeutic agent may have one or more controlled release in-vivo kinetic profile.

Priority: US2006-434023 Applic. Date: 2006-05-15; US2001-883842 Applic. Date: 2001-06-18; US20000212511P Applic. Date: 2000-06-19

Inventor: STEIN STANLEY [US]; QIU BO [US]; SINKO PATRICK J [US]


Application No.: US20110136771A1  Published: 09/Jun/2011

Title: Orally Disintegrating Solid Dosage Forms Comprising Progestin and Methods of Making and Use Thereof

Applicant/Assignee:

Application No.: 12/958975   Filing Date: 02/Dec/2010

Abstract:

The present invention is directed to non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising progestin and methods of making and using the dosage forms to treat conditions in females in need thereof.

Priority: US2007-003234 Applic. Date: 2007-12-20; US20060875827P Applic. Date: 2006-12-20

Inventor: AHMED SALAH U [US]; SETHIA SUNDEEP [US]; CHOWDHURY TAHSEEN A [US]


Application No.: US20110136853A1  Published: 09/Jun/2011

Title: LIGAND WITH A BROAD SPECTRUM OF PHARMACOLOGICAL ACTIVITY, A PHARMACEUTICAL COMPOSITION, A MEDICINAL AGENT AND A METHOD OF TREATMENT

Applicant/Assignee:

Application No.: 13/059419   Filing Date: 03/Aug/2009

Abstract:

The present invention is directed to the novel ligand with wide range of pharmacological activity including activity to GPCR receptors, ion channels and monoamine transporters representing 3-methyl-9-benzyl-1,2,3,4-tetrahydrocarboline naphthalene-1,5-disulfonate of formula 1 The invention is also directed to the novel drug substance, Pharmaceutical formulation comprising the novel drug substance, and to the method for its preparation, to the novel medicaments, and method for treatment of CNS diseases including neurodegenerative diseases and cognitive disorders at humans and warm blooded animals.

Priority: RU20080134309 Applic. Date: 2008-08-22; WO2009RU00381 Applic. Date: 2009-08-03

Inventor: IVASCHENKO ANDREY ALEXANDROVICH [RU]; SAVCHUK NIKOLAY FILIPPVICH [US]; IVASHCHENKO ALEXANDER VASILIEVICH [US]


Application No.: US20110136883A1  Published: 09/Jun/2011

Title: GRANULATION OF ACTIVE PHARMACEUTICAL INGREDIENTS

Applicant/Assignee: LEK PHARMACEUTICALS D.D

Application No.: 12/937081   Filing Date: 08/Apr/2009

Abstract:

The present invention discloses a dry formulation or granulation comprising, in admixture, more than 50 wt. % of active pharmaceutical ingredient and from 1 to 10 wt. % of each of any nonaqueous excipient selected from liquid substances. In a preferred embodiment no water or lower alcohol has been added in any step of the preparation of the dry formulation or granulation, and the nonaqueous excipient selected from liquid substances is adsorbed to dryness by the active pharmaceutical ingredient and/or by a further solid excipient. Pharmaceutical formulations based on such dry formulation or granulation, and processes for the preparation thereof, are described as well. The dry formulations or granulations reliably and effectively further processed under dry conditions without requiring active drying, including e.g. briquetting, slugging, sieving, milling, tabletting, further fine granulating, direct compression, and the like.

Priority: EP20080154239 Applic. Date: 2008-04-09; EP20080162297 Applic. Date: 2008-08-13; WO2009EP54259 Applic. Date: 2009-04-08

Inventor: INJAC RADE [SI]; CESAR SARA [SI]


Application No.: US20110140298A1  Published: 16/Jun/2011

Title: METHOD AND APPARATUS OR DRY GRANULATION

Applicant/Assignee: ATACAMA LABS OY

Application No.: 12/941314   Filing Date: 08/Nov/2010

Abstract:

The invention provides, inter alia, a method for producing granules from a powder, characterized in that compaction force is applied to the powder to produce a compacted mass comprising a mixture of fine particles and granules and separating and removing fine particles and/or small granules from the other granules by entraining the fine particles and/or small granules in a gas stream. Also provided are apparatus for use in the process and tablets formed by compression of the resultant granules.

Priority: FI20060000990 Applic. Date: 2006-11-10; FI20060001146 Applic. Date: 2006-12-21; FI20070000521 Applic. Date: 2007-07-02; FI20080000346 Applic. Date: 2008-05-09; FI20080000347 Applic. Date: 2008-05-09; FI20080000348 Applic. Date: 2008-05-09; FI20080000349 Applic. Date: 2008-05-09; FI20080000350 Applic. Date: 2008-05-09; FI20080000351 Applic. Date: 2008-05-09; FI20080000352 Applic. Date: 2008-05-09; FI20080000353 Applic. Date: 2008-05-09; FI20080000354 Applic. Date: 2008-05-09; FI20080000355 Applic. Date: 2008-05-09; FI20080000356 Applic. Date: 2008-05-09; FI20080000357 Applic. Date: 2008-05-12; WO2009EP55627 Applic. Date: 2009-05-08; WO2009EP55628 Applic. Date: 2009-05-08; WO2009EP55629 Applic. Date: 2009-05-08; WO2009EP55630 Applic. Date: 2009-05-08; WO2009EP55631 Applic. Date: 2009-05-08; US2009-580558 Applic. Date: 2009-10-16; US2009-463186 Applic. Date: 2009-05-08; US2007-979530 Applic. Date: 2007-11-05

Inventor: POLITI GIOVANNI [FI]; HEILAKKA ERKKI [FI]


Application No.: US20110142889A1  Published: 16/Jun/2011

Title: COMPOSITIONS AND METHODS FOR ORAL DRUG DELIVERY

Applicant/Assignee: NOD PHARMACEUTICALS, INC

Application No.: 12/970637   Filing Date: 16/Dec/2010

Abstract:

The invention provides a pharmaceutical composition for oral drug delivery comprising a solid dosage form containing an effective amount of a therapeutic agent, a permeation enhancer and a pharmaceutically acceptable excipient and a bioadhesive layer containing a bioadhesive polymer, and optionally comprising an impermeable or semi-permeable layer having an opening capable of directing a unidirectional release of the therapeutic agent and the permeation enhancer from the solid dosage form. Methods of making and using the present pharmaceutical composition are also provided.

Priority: CN20091201248 Applic. Date: 2009-12-16; CN20102227045D Applic. Date: 2010-07-14; CN20101590909 Applic. Date: 2010-12-16; US20090287146P Applic. Date: 2009-12-16; US20100365916P Applic. Date: 2010-07-20

Inventor: LEE WILLIAM W [US]; LU FENG [CN]; YIN MIN [CN]


Application No.: US20110142905A1  Published: 16/Jun/2011

Title: COATED TABLETS WITH REMAINING DEGRADATION SURFACE OVER THE TIME

Applicant/Assignee: BIONEER A/S

Application No.: 13/058933   Filing Date: 14/Aug/2009

Abstract:

The present invention relates to a pharmaceutical composition for controlled delivery of at least one active ingredient into an aqueous phase, said pharmaceutical composition comprising: a tablet, preferably obtainable by compression, said tablet comprising said at least one active ingredient and optionally excipients

and a coating, applied on said tablet, said coating covering at least part of said tablet to impede the release of said at least one active ingredient from at least part of the surface of said tablet, said coating being applied in a manner allowing the release of said at least one active ingredient from said tablet after contacting said pharmaceutical composition with said aqueous phase, establishing one or more degradation surfaces of said tablet

wherein the first derivative of the area of each degradation surface with respect to time is larger than or equal to zero.

Priority: US20080088859P Applic. Date: 2008-08-14; WO2009DK50201 Applic. Date: 2009-08-14

Inventor: BAR-SHALOM DANIEL [DK]; NAELAPAEAE KAISA [DK]


Application No.: US20110142927A1  Published: 16/Jun/2011

Title: Nanoparticles for protein drug delivery

Applicant/Assignee:

Application No.: 12/931935   Filing Date: 15/Feb/2011

Abstract:

The invention discloses the nanoparticles composed of chitosan, poly-glutamic acid, and at least one anti-hemophilic factor or bioactive agent characterized with a positive surface charge and their enhanced permeability in oral drug delivery.

Priority: US2009-378976 Applic. Date: 2009-02-20; US2008-286504 Applic. Date: 2008-09-30; US2008-151230 Applic. Date: 2008-05-05; US2006-398145 Applic. Date: 2006-04-05; US2005-284734 Applic. Date: 2005-11-21; US2005-029082 Applic. Date: 2005-01-04; US20080204025P Applic. Date: 2008-12-31

Inventor: SUNG HSING-WEN [TW]; TU HOSHENG [US]


Application No.: US20110142929A1  Published: 16/Jun/2011

Title: SOLID PHARMACEUTICAL FORMULATIONS COMPRISING BIBW 2992

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: 12/995715   Filing Date: 05/Jun/2009

Abstract:

The present invention relates to a pharmaceutical dosage form containing the active substance BIBW 2992 as the dimaleate salt, providing an immediate release profile of the active substance, further, the invention relates to compacted intermediates comprising BIBW 2992 dimaleate salt (BIBW 2992 MA2) in form of a powder prepared using a combined roller compaction and sieving step from BIBW 2992 MA2, intermediate blends prepared from said compacted intermediate as well as solid oral formulations providing an immediate release profile of the active substance, made from said compacted intermediate or from said intermediate blends ready for use/ingestion, e.g. capsule and tablet formulations such as uncoated or film-coated tablets prepared by direct-compression, and methods for their production.

Priority: EP20080157800 Applic. Date: 2008-06-06; EP20090160297 Applic. Date: 2009-05-14; WO2009EP56944 Applic. Date: 2009-06-05

Inventor: MESSERSCHMID ROMAN [DE]; FRIEDL THOMAS [DE]


Application No.: US20110142930A1  Published: 16/Jun/2011

Title: Pharmaceutical Compositions of Atorvastatin

Applicant/Assignee: PFIZER INC

Application No.: 13/029714   Filing Date: 17/Feb/2011

Abstract:

A dry-granulated pharmaceutical composition comprising atorvastatin or a pharmaceutically acceptable salt thereof, as well as a dry-granulated pharmaceutical composition comprising atorvastatin or a pharmaceutically acceptable salt thereof in combination with at least one other active drug, methods for preparing said compositions, kits for containing such compositions, and a method of treating hypercholesterolemia and/or hyperlipidemia, osteoporosis, benign prostatic hyperplasia (BPH), and Alzheimer's disease using a therapeutically effective amount of the pharmaceutical composition.

Priority: US2009-423330 Applic. Date: 2009-04-14; US2004-828398 Applic. Date: 2004-04-20; US20030477917P Applic. Date: 2003-06-12; US20030477916P Applic. Date: 2003-06-12

Inventor: LUNER PAUL E [US]; WATERMAN KENNETH CRAIG [US]


Application No.: US20110142941A1  Published: 16/Jun/2011

Title: Nanoparticle and Polymer Formulations for Thyroid Hormone Analogs, Antagonists, and Formulations and Uses Thereof

Applicant/Assignee:

Application No.: 12/947389   Filing Date: 16/Nov/2010

Abstract:

Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric Nanoparticle form of thyroid hormone agonist, partial agonist or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed.

Priority: US2007-004979 Applic. Date: 2007-12-21; US20060876770P Applic. Date: 2006-12-22; US20070922113P Applic. Date: 2007-04-05; US20070936223P Applic. Date: 2007-06-18; US20070959006P Applic. Date: 2007-07-09; US20070967016P Applic. Date: 2007-08-30; US20070994895P Applic. Date: 2007-09-21; US20070000262P Applic. Date: 2007-10-23; US20070003935P Applic. Date: 2007-11-20

Inventor: DAVIS PAUL J [US]; MOUSA SHAKER A [US]


Application No.: US20110142943A1  Published: 16/Jun/2011

Title: TAMPER-RESISTANT PHARMACEUTICAL COMPOSITIONS OF OPIODS AND OTHER DRUGS

Applicant/Assignee: COLLEGIUM PHARMACEUTICAL, INC

Application No.: 12/965572   Filing Date: 10/Dec/2010

Abstract:

Tamper-resistant pharmaceutical compositions have been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opioids. The tamper-resistant compositions retard the release of drug, even if the physical integrity of the formulation is compromised (for example, by chopping with a blade or crushing) and the resulting material is placed in water, snorted, or swallowed. However, when administered as directed, the drug is slowly released from the composition as the composition is passes through the GI tract.

Priority: US2008-112937 Applic. Date: 2008-04-30; US2003-614866 Applic. Date: 2003-07-07; US2009-473073 Applic. Date: 2009-05-27; US2008-112993 Applic. Date: 2008-04-30; US20090285231P Applic. Date: 2009-12-10; US20020393876P Applic. Date: 2002-07-05; US20020436523P Applic. Date: 2002-12-23; US20030443226P Applic. Date: 2003-01-28; US20030463514P Applic. Date: 2003-04-15; US20030463518P Applic. Date: 2003-04-15

Inventor: RARIY ROMAN V [US]; FLEMING ALISON B [US]; HIRSH JANE C [US]; SAIM SAID [US]; VARANASI RAVI K [US]


Application No.: US20110144029A1  Published: 16/Jun/2011

Title: Model Systems and Materials for the Study and Treatment of Neurodegenerative Diseases

Applicant/Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

Application No.: 12/895763   Filing Date: 30/Sep/2010

Abstract:

The present invention provides models for studying the development of, and/or pathologies associated with neurodegenerative diseases, and agents that can modulate such development and/or pathologies.

Priority: US20090247307P Applic. Date: 2009-09-30

Inventor: D MELLO SANTOSH R [US]; GOUX WARREN J [US]


Application No.: US20110144050A1  Published: 16/Jun/2011

Title: SALTS OF HIV INHIBITOR COMPOUNDS

Applicant/Assignee: GILEAD SCIENCES, INC

Application No.: 12/999441   Filing Date: 07/Jul/2009

Abstract:

The invention is related to salts of anti-viral compounds, compositions containing such salts, and therapeutic methods that include the administration of such salts, as well as to processes and intermediates useful for preparing such salts.

Priority: US20080078989P Applic. Date: 2008-07-08; WO2009US49838 Applic. Date: 2009-07-07

Inventor: GRAETZ BENJAMIN R [US]; POLNIASZEK RICHARD [US]


Application No.: US20110144181A1  Published: 16/Jun/2011

Title: Pharmaceutical Compositions of Amorphous Atorvasta and Process for Preparing Same

Applicant/Assignee: WARNER-LAMBERT COMPANY LLC

Application No.: 13/034230   Filing Date: 24/Feb/2011

Abstract:

Solid pharmaceutical compositions containing atorvastatin are disclosed. The compositions include a solid dispersion of amorphous atorvastatin and one or more optional pharmaceutically acceptable excipients. The solid dispersion is prepared by mixing crystalline atorvastatin with a melt-processible polymer and an optional stabilizer and an optional plasticizer at a temperature sufficiently high to soften or melt the polymer and to melt or dissolve the crystalline atorvastatin in the polymer, thereby forming a dispersion of amorphous atorvastatin.

Priority: US2008-795438 Applic. Date: 2008-03-27; WO2005IB03661 Applic. Date: 2005-11-23; US20040632559P Applic. Date: 2004-12-02

Inventor: DYAR STEPHEN CRAIG [US]; LODAYA MAYUR P [US]; MOLLAN JR MATTHEW J [US]; SHAH UMANG [US]; SUN HEI JEN [US]; TEWELDEMEDHIN ZERI [US]


Application No.: US20110144207A1  Published: 16/Jun/2011

Title: ARYL ALKYL CARBOXYLIC ACID SALTS, PROCESS FOR PREPARATION AND DOSAGE FORMS

Applicant/Assignee: SHASUN CHEMICALS AND DRUGS LIMITED

Application No.: 13/058978   Filing Date: 14/Aug/2009

Abstract:

The invention particularly discloses a process for preparing aryl alkyl carboxylic acid salts by preparing aqueous alkali solution, adding aryl alkyl carboxylic acid to said alkali solution at a temperature ranging from 4 DEG to 121 DEG C. for obtaining a clear solution, preferably by heating and/or stirring and concentrating and cooling to obtain aryl alkyl carboxylic acid salt The invention therefore discloses solid oral dosage forms and compositions of aryl alkyl carboxylic acid salts which are free of organic solvent/so. The solid oral dose compositions of aryl alkyl carboxylic acid salts of the invention are prepared in situ from aryl alkyl carboxylic acids and bases to obtain aryl acid alkyl carboxylic acid sails in crystalline/powder form with or without the use of pharmaceutical excipients.

Priority: IN2008CH01977 Applic. Date: 2008-08-14; WO2009IB53592 Applic. Date: 2009-08-14

Inventor: CHODANKAR NANDKUMAR [IN]; BIYANI MILIND [IN]; MUTHUNARAYANAN MOHAN [IN]; RADHAKRISHNAN SELVARAJU [IN]; SANTHANAMPILLAI SATHISH KUMAR [IN]; NADAR RAJENDRAN PAUL [IN]; SUNDARAMURTHY VIVEKANANDAN [IN]; PRABU SAKTHIVEL LAKSHAMANA [IN]


Application No.: US20110150980A1  Published: 23/Jun/2011

Title: CGRP ANALOG

Applicant/Assignee: VASOGENIX PHARMACEUTICALS, INC

Application No.: 12/949565   Filing Date: 18/Nov/2010

Abstract:

Sequence modified calcitonin gene related peptide (CGRP) compounds are useful for treating heart failure, stroke, hemorrhagic shock, or migraine, improving renal function, preventing or delaying the advancement of heart failure into advanced stages, treating angina, controlling pulmonary hypertension, counteracting ischemia due to a myocardial infarction, preventing vasospasms during angioplasty, preventing reocclusion of blood vessels during and/or after angioplasty, stent insertion, or the implantation of a vascular grafts, and for treating male impotence and female sexual arousal disorder.

Priority: WO2009US03097 Applic. Date: 2009-05-19; US20080054337P Applic. Date: 2008-05-19

Inventor: SOUTHARD GEORGE LEE [US]; SOUTHARD JEFFREY LEE [US]


Application No.: US20110150989A1  Published: 23/Jun/2011

Title: Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans

Applicant/Assignee: MALLINKCKRODT INC

Application No.: 12/973962   Filing Date: 21/Dec/2010

Abstract:

Methods for producing stabilized solid dosage form pharmaceutical compositions are provided. In particular, methods for preparing protected granules containing morphinans, and solid dosage form pharmaceutical compositions produced using the morphinan-protected granules are provided.

Priority: US20090284651P Applic. Date: 2009-12-22

Inventor: PARK JAE HAN [US]; EISENHAUER TIFFANI [US]; DHANARAJAN ANISH [US]; GUPTA VISHAL K [US]; OVERHOLT STEPHEN [US]


Application No.: US20110151014A1  Published: 23/Jun/2011

Title: MICROCRYSTALLINE CELLULOSE AND CALCIUM CARBONATE COMPOSITIONS USEFUL AS RECOMPACTIBLE PHARMACEUTICAL EXCIPIENTS

Applicant/Assignee: FMC CORPORATION

Application No.: 12/962992   Filing Date: 08/Dec/2010

Abstract:

Coprocessed compositions containing microcrystalline cellulose and calcium carbonate, wherein the weight ratio of microcrystalline cellulose to calcium carbonate is relatively high, are useful as excipients in the preparation of solid dosage forms containing active pharmaceutical ingredients, particularly those prepared by processes involving multiple compaction steps. Such compositions may be obtained, for example, by preparing aqueous slurries or wet masses of microcrystalline cellulose and calcium carbonate and drying such slurries or wet masses to produce particulate products. The coprocessed products exhibit improved recompactibility, as compared to coprocessed products having lower microcrystalline cellulose:calcium carbonate weight ratios or as compared to physical dry blends of the two excipients.

Priority: US20090289061P Applic. Date: 2009-12-22

Inventor: THOORENS GREGORY [BE]; LECLERCQ BRUNO [BE]; RUSZKAY THOMAS [US]


Application No.: US20110152766A1  Published: 23/Jun/2011

Title: IMPLANT WITH COATING

Applicant/Assignee:

Application No.: 12/961931   Filing Date: 07/Dec/2010

Abstract:

One embodiment of the invention relates to an implant with a coating containing at least one active pharmaceutical substance. The inventive implant is characterized in that the coating is covered by a protective layer comprising or containing one or more materials from the group including shellac, vinylpyrrolidone-vinyl acetate copolymer, vinyl acetate-crotonic acid copolymer, vinyl acetate-vinyl propionate-crotonic acid terpolymer, methylvinyl ether-maleic anhydride copolymer, vinylpyrrolidone-dimethylaminoethyl acrylate copolymer, polyvinylpyrrolidone, polyvinyl acetate, polycrotonic acid, polyvinyl propionate, polymethylvinyl ether, polymaleic anhydride and polydimethylaminoethyl acrylate.

Priority: US20090288347P Applic. Date: 2009-12-21

Inventor: HOFMANN ANDREAS [DE]; BORCK ALEXANDER [DE]; TITTELBACH MICHAEL [DE]


Application No.: US20110152840A1  Published: 23/Jun/2011

Title: METHODS FOR REDUCING THE OCCURRENCE OF PRETERM DELIVERY AND OTHER PREGNANCY-RELATED CONDITIONS

Applicant/Assignee: DRUGTECH CORPORATION

Application No.: 12/971900   Filing Date: 17/Dec/2010

Abstract:

The present invention relates to methods and kits for reducing the occurrence of preterm delivery and other pregnancy-related conditions in pregnant female subjects exhibiting one or more risk factors for preterm delivery and other pregnancy-related conditions. For example, the present invention relates to methods for reducing the occurrence of preterm delivery in a pregnant female subject having no history of preterm delivery and exhibiting one or more risk factors for preterm delivery (e.g., smoking during pregnancy). The methods and kits provide for the administration of a steroid hormone to the pregnant female subject.

Priority: US20090289572P Applic. Date: 2009-12-23

Inventor: LEE CHANG [US]; BIRCH ROBERT [US]


Application No.: US20110158906A1  Published: 30/Jun/2011

Title: TARGETED BLOCK COPOLYMER MICELLES

Applicant/Assignee: MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V

Application No.: 12/673472   Filing Date: 13/Aug/2008

Abstract:

The present invention provides a micelle comprising an amphiphilic block copolymer, said amphiphilic block copolymer consisting of (a) a hydrophobic polymer attached to the 5' end of a first nucleic acid molecule, wherein said first nucleic acid molecule is hybridized with a second nucleic acid molecule, wherein a targeting unit capable of selectively binding to a specific cell type and/or tissue is attached to the 5' end of said second nucleic acid molecule

and/or (b) a hydrophobic polymer attached to the 3' end of a first nucleic acid molecule, wherein said first nucleic acid molecule is hybridized with a second nucleic acid molecule, wherein a targeting unit capable of selectively binding to a specific cell type and/or tissue is attached to the 3' end of said second nucleic acid molecule.

Priority: EP20070015900 Applic. Date: 2007-08-13; WO2008EP06663 Applic. Date: 2008-08-13

Inventor: MUELLEN KLAUS [DE]; ALEMDAROGLU FIKRI E [DE]; HERRMANN ANDREAS [DE]; ALEMDAROGLU N CEREN [DE]; LANGGUTH PETER [DE]


Application No.: US20110159033A1  Published: 30/Jun/2011

Title: WEST NILE VIRUS VACCINE

Applicant/Assignee: BOEHRINGER INGELHEIM VETMEDICA, INC

Application No.: 12/937504   Filing Date: 31/Aug/2009

Abstract:

The invention provides for immunogenic compositions against West Nile Virus. The immunogenic compositions, in alternate embodiments, also include other equine pathogens. The West Nile Virus composition of the present invention advantageously provides for protection against North American Dominant West Nile Virus strains or isolates.

Priority: US20080093081P Applic. Date: 2008-08-29; US20080117086P Applic. Date: 2008-11-21; WO2009US55564 Applic. Date: 2009-08-31

Inventor: HENNESSY KRISTINA J [US]; HAYES PHILLIP WAYNE [US]


Application No.: US20110159052A1  Published: 30/Jun/2011

Title: TAXANES COVALENTLY BOUNDED TO HYALURONIC ACID OR HYALURONIC ACID DERIVATIVES

Applicant/Assignee:

Application No.: 13/011172   Filing Date: 21/Jan/2011

Abstract:

The present invention relates to water-soluble taxanes covalently bounded to hyaluronic acid or hyaluronic acid derivatives, and in particular to paclitaxel and docetaxel, useful for the preparation of pharmaceutical compositions to be used in the field of oncology, in the treatment of autoimmune disorders and of restenosis. The invention also relates to the process for preparing taxanes covalently bounded to hyaluronic acid or hyaluronic acid derivates by direct synthesis between molecules of hyaluronic acid and of taxane or by indirect synthesis by the introduction of a spacer between the hyaluronic acid derivative and the taxane.

Priority: IT2002PD00271 Applic. Date: 2002-10-18; US2005-531853 Applic. Date: 2005-04-18; WO2003EP11239 Applic. Date: 2003-10-10

Inventor: DELUCA GILDA [IT]; BETTOLO RINALDO MARINI [IT]; MIGNECO LUISA MARIA [IT]


Application No.: US20110159080A1  Published: 30/Jun/2011

Title: COMPOSITION COMPRISING LIPOSOME-ENTRAPPED DOXORUBICIN AND METHODS OF ADMINISTRATION

Applicant/Assignee:

Application No.: 12/995820   Filing Date: 03/Jun/2009

Abstract:

Patients suffering from cancer, such as ovarian cancer, may be treated by administering an effective combined amount of a liposomal-entrappeddoxorubicin, an alkylating antineoplastic agent, and a vascular endothelial growth factor inhibitor. In one embodiment, patients suffering from ovarian cancer are treated by administering an effective combined amount of the liposome-entrapped doxorubicin product DOXIL, carboplatin and bevacizumab.

Priority: US20080058391P Applic. Date: 2008-06-03; WO2009US46075 Applic. Date: 2009-06-03

Inventor: LOWERY COLIN [US]


Application No.: US20110159084A1  Published: 30/Jun/2011

Title: RALOXIFENE PHARMACEUTICAL FORMULATIONS

Applicant/Assignee: DR. REDDY'S LABORATORIES LTD, DR. REDDY'S LABORATORIES, INC

Application No.: 12/936804   Filing Date: 02/Apr/2009

Abstract:

Pharmaceutical formulations comprising raloxifene or its salts, esters, polymorphs, isomers, hydrates, solvates, or derivatives thereof having defined particle sizes. Also described are processes for preparing formulations and methods of using such formulations.

Priority: IN2008CH00834 Applic. Date: 2008-04-02; US20080075507P Applic. Date: 2008-06-25; WO2009US39273 Applic. Date: 2009-04-02

Inventor: ALAGARSAMY ALAGUMURUGAN [IN]; RAMBABU BOORUGU [IN]; REDDY PALLEMPALLI SIVA [IN]; VENUGOPAL KUMARAN [IN]; KUMAR BHASIN RAKESH [IN]


Application No.: US20110159085A1  Published: 30/Jun/2011

Title: ABT-263 CAPSULE

Applicant/Assignee: ABBOTT LABORATORIES

Application No.: 12/974154   Filing Date: 21/Dec/2010

Abstract:

A pharmaceutical capsule comprises a shell having encapsulated therewithin a liquid solution of ABT-263 or a pharmaceutically acceptable salt thereof in a substantially non-ethanolic carrier that comprises as pharmaceutically acceptable excipients (a) at least one phospholipid, (b) at least one solubilizing agent for the at least one phospholipid, selected from the group consisting of glycols, glycerides and mixtures thereof, (c) at least one non-phospholipid surfactant and (d) at least one sulfur-containing antioxidant. The capsule is useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

Priority: US20090289289P Applic. Date: 2009-12-22

Inventor: TONG PING [US]; ZHOU DELIANG [US]; ZHANG GEOFF G Z [US]; HEEMSTRA KATHERINE R [US]; FISCHER CRISTINA M [US]; CATRON NATHANIEL D [US]; SCHMITT ERIC A [US]; SANZGIRI YESHWANT D [US]


Application No.: US20110159086A1  Published: 30/Jun/2011

Title: PHARMACEUTICAL FORMULATION COMPRISING A CB1-RECEPTOR COMPOUND IN A SOLID SOLUTION AND/OR SOLID DISPERSION

Applicant/Assignee: LABORATORIOS DEL DR. ESTEVE, S.A

Application No.: 13/056366   Filing Date: 27/Jul/2009

Abstract:

The present invention relates to a pharmaceutical formulation comprising 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-(cis-2,6-dimethylpiperidin-1-yl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide as racemate or (S)-enantiomer or mixtures thereof in a solid solution and/or solid dispersion.

Priority: EP20080384010 Applic. Date: 2008-07-28; WO2009EP05425 Applic. Date: 2009-07-27

Inventor: SOLER RANZANI LUIS [ES]; CASADEVALL PUJALS GEMMA [ES]; SANTANACH DELISAU ANGEL [ES]


Application No.: US20110159087A1  Published: 30/Jun/2011

Title: Crosslinked Polymers

Applicant/Assignee:

Application No.: 13/060624   Filing Date: 02/Sep/2009

Abstract:

Disclosed herein are pharmaceutical compositions comprising wet granulated bile acid sequestrants having the general Formula I shown, and their process of preparation. The present invention also discloses process for preparation of Colesevelam hydrochloride, an antilipemic agent.

Priority: IN2008MU01860 Applic. Date: 2008-09-02; WO2009IN00483 Applic. Date: 2009-09-02

Inventor: SATHE DHANANJAY GOVIND [IN]; MONDKAR HARISH KASHINATH [IN]; RAO MANTRIPRAGADA NARAYAN [IN]; PATIL SAMADHAN DAULAT [IN]; JADHAV TANAJI SHAMRAO [IN]; OMRAY ASHOK [IN]; CHOUDHARY VARSHA SHASHANK [IN]; BHIDE YOGESH SHARAD [IN]


Application No.: US20110159092A1  Published: 30/Jun/2011

Title: EXTENDED RELEASE PHARMACEUTICAL COMPOSITION COMPRISING LINEZOLID AND PROCESS FOR PREPARING THE SAME

Applicant/Assignee: MICRO LABS LIMITED

Application No.: 12/980776   Filing Date: 29/Dec/2010

Abstract:

The present invention provides an extended release pharmaceutical composition suitable for once daily dosing comprising Linezolid or pharmaceutically acceptable salt, derivative, prodrug, metabolite and polymorph thereof and one or more pharmaceutically acceptable excipients and a process of preparing the same. The present invention further provides a method of treating bacterial infections in a mammal comprising administering an extended release, pharmaceutical composition suitable for once daily dosing comprising Linezolid capable of maintaining T>MIC for at least 24 hours. The present invention further provides an extended release pharmaceutical composition suitable for once daily dosing comprising Linezolid so that upon oral administration the maximum concentrations (Cmax) of Linezolid in plasma are statistically significantly lower than the immediate release formulation given twice daily, and area under the plasma concentration-time curve (AUC) and the minimum plasma concentrations are maintained over 24 hours.

Priority: IN2009CH03193 Applic. Date: 2009-12-29

Inventor: KSHIRSAGAR RAJESH [IN]; MUNDADE SACHIN [IN]; SHINDE GANESH [IN]; KAMBLE PRAVIN [IN]; MUDDA SM [IN]; DHANURE SHIVANAND [IN]


Application No.: US20110159094A1  Published: 30/Jun/2011

Title: EXTENDED RELEASE COMPOSITIONS FOR HIGH SOLUBILITY, HIGH PERMEABILITY ACTIVE PHARMACEUTICAL INGREDIENTS

Applicant/Assignee:

Application No.: 12/978631   Filing Date: 27/Dec/2010

Abstract:

A novel composition comprising a tablet, comprising a highly soluble active pharmaceutical ingredient, which is then coated with a coating. The core is preferably a tablet. The coating preferably comprises any type of suitable extended release polymer, with the proviso that the polymer does not comprise an enteric polymer.

Priority: US20090290178P Applic. Date: 2009-12-25

Inventor: ONN LIAT [IL]; AVRAMOFF AVI [IL]


Application No.: US20110159096A1  Published: 30/Jun/2011

Title: 1-(1H-1,2,4-Triazol-1-YL)Butan-2-OL Derivative For Pharmaceutical Use, and The Use Of a 1-(1H-1,2,4-Triazol-1-YL)Butan-2-OL Derivative With Substantially Undefined Crystal Shape For Preparing Said 1-(1H-1,2,4-Triazol-1-YL)Butan-2-OL Derivative

Applicant/Assignee: MEDICHEM, S.A

Application No.: 12/842540   Filing Date: 23/Jul/2010

Abstract:

The present invention relates to voriconazole, processes of preparing voriconazole, and pharmaceutical compositions and therapeutic uses thereof. In particular, the present invention also relates to voriconazole prepared from voriconazole having a substantially undefined shape and/or crystal habit. The invention further relates to voriconazole having a modified sphericity factor and/or specific surface area and/or Sauter diameter compared to voriconazole known from the prior art.

Priority: US20090290929P Applic. Date: 2009-12-30

Inventor: DURAN LOPEZ ERNESTO [ES]; CONTRERAS LASCORZ JUAN [ES]


Application No.: US20110160120A1  Published: 30/Jun/2011

Title: Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders

Applicant/Assignee: SYNERGY PHARMACEUTICALS INC

Application No.: 13/010267   Filing Date: 20/Jan/2011

Abstract:

The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition, including Crohn's disease and ulcerative colitis, and cancer.

Priority: US2008-133344 Applic. Date: 2008-06-04; US20070933194P Applic. Date: 2007-06-04

Inventor: SHAILUBHAI KUNWAR [US]; JACOB GARY S [US]


Application No.: US20110160141A1  Published: 30/Jun/2011

Title: Neurotrophic Peptides

Applicant/Assignee:

Application No.: 13/044323   Filing Date: 09/Mar/2011

Abstract:

The present invention relates to a neurotrophic peptide having an amino acid sequence of VGDGGLFEKKL (SEQ ID NO:1), EDQQVHFTPTEG (SEQ ID NO:2) or IPENEADGMPATV (SEQ ID NO:3), and comprising an adamantyl group at the C- and/or N-terminal end.

Priority: EP20070450050 Applic. Date: 2007-03-16; US2009-531616 Applic. Date: 2009-09-16; WO2008EP02106 Applic. Date: 2008-03-17

Inventor: MOESSLER HERBERT [AT]; IQBAL KHALID [US]; GRUNDKE-IQBAL INGE [US]


Application No.: US20110160153A1  Published: 30/Jun/2011

Title: Methods and Compositions for Treating Blood Circulation Disorders

Applicant/Assignee:

Application No.: 12/651251   Filing Date: 31/Dec/2009

Abstract:

Methods for preparing improved Panax Notoginseng saponin fraction from a Sanchi extract and its use in pharmaceutical compositions for treating or preventing a blood circulation disorder.

Priority:

Inventor: LAN GUIHUA [CN]; CHEN PENG [CN]; LAN FENG [CN]; FANG SONG [CN]


Application No.: US20110160156A1  Published: 30/Jun/2011

Title: Pharmaceutical Composition for the Eradication of Helicobacter Pylori and Preparation Method Thereof

Applicant/Assignee: SYNMOSA BIOPHARMA CORPORATION

Application No.: 12/816650   Filing Date: 16/Jun/2010

Abstract:

The present invention relates to a pharmaceutical composition and its preparation method for the eradication of Helicobacter pylorif in the forms of effervescent tablet, suspension or powder. The pharmaceutical composition comprises an effective dose of [beta]-lactam antibiotic, an effective dose of macrolide antibiotic, an effective dose of antacid such as proton pump inhibitor and H2 blocker, and a pharmaceutical acceptable carrier. An effective dose of alkaline substance such as carbonate or bicarbonate can be added to increase the pH of the stomach when the PPI antacid is used, which can protect the degradation of acid-labile antibiotics or PPI to further increase the bioavailability of the pharmaceutical composition for the purpose of Helicobacter pylori eradication.

Priority: TW20090146646 Applic. Date: 2009-12-31

Inventor: LIN CHIH-HUI [TW]; CHOU JUI-MING [TW]; PAO LI-HENG [TW]; CHANG CHIA-WEN [TW]; LIN CHIA-YI [TW]; LEE AN-LONG [TW]


Application No.: US20110160213A1  Published: 30/Jun/2011

Title: PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS

Applicant/Assignee: GLENMARK PHARMACEUTICALS, S.A

Application No.: 12/525049   Filing Date: 31/Jan/2008

Abstract:

The present invention relates to the pharmaceutical compositions, more particularly to the pharmaceutical compositions comprising novel phosphodiesterase type 4 (PDE4) inhibitors, and their use in treating allergic and inflammatory disorders.

Priority: IN2007MU00190 Applic. Date: 2007-02-01; US20070890693P Applic. Date: 2007-02-20; WO2008IB00217 Applic. Date: 2008-01-31

Inventor: DHUPPAD ULHAS [IN]; ARRA GANGA SRINIVAS [IN]


Application No.: US20110165069A1  Published: 07/Jul/2011

Title: METHODS FOR RADIOLABELING MACROMOLECULES

Applicant/Assignee: THE AUSTRALIAN NATIONAL UNIVERSITY

Application No.: 12/989312   Filing Date: 23/Apr/2009

Abstract:

The present invention relates to a method for preparing a radiolabeled macromolecule, the method comprising contacting a macromolecule with a carbon encapsulated nanoparticle composite having a radioactive particulate core in an aqueous medium comprising a pH selected to promote short-range attractive forces between the nanoparticles and the macromolecule by attenuating repulsive electrostatic forces.

Priority: AU20080902063 Applic. Date: 2008-04-24; WO2009AU00508 Applic. Date: 2009-04-23

Inventor: STEPHENS ROSS WENTWORTH [AU]; SENDEN TIMOTHY JOHN [AU]; KING DAVID WALLACE [AU]


Application No.: US20110165078A1  Published: 07/Jul/2011

Title: SPECIFIC BINDING MEMBERS AGAINST SYNAPTOPHYSIN

Applicant/Assignee: THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN

Application No.: 12/974899   Filing Date: 21/Dec/2010

Abstract:

The present invention provides specific binding members that bind synaptophysin and which comprise: an antibody VH domain selected from the group consisting of the C1-3 VH domain (SEQ ID NO. 2) and a VH domain comprising a VH CDR3 with the amino acid sequence of SEQ ID NO. 12 and optionally one or more VH CDR's with an amino acid sequence selected from SEQ ID NO. 10 and SEQ ID NO. 11

and/or an antibody VL domain selected from the group consisting of the C1-3 VL domain (SEQ ID NO. 4) and a VL domain comprising one or more VL CDR's with an amino acid sequence selected from SEQ ID NO. 13, SEQ ID NO. 14 and SEQ ID NO. 15. The invention further provides related materials such as nucleic acids, kits and compositions, and also methods of use of the binding member, for instance in targeting entities to hepatic stellate cells which are implicated in liver fibrosis.

Priority: GB20040007059 Applic. Date: 2004-03-29; GB20040016402 Applic. Date: 2004-07-22; US2006-547368 Applic. Date: 2006-10-20; WO2005GB01190 Applic. Date: 2005-03-29

Inventor: WRIGHT MATTHEW [GB]; PORTER ANDY [GB]


Application No.: US20110165237A1  Published: 07/Jul/2011

Title: Protein Hydrolysate Excipients

Applicant/Assignee: WYETH

Application No.: 13/043669   Filing Date: 09/Mar/2011

Abstract:

A pharmaceutical composition comprising an effective amount of a pharmaceutical active and up to about 99.8% wt/wt water soluble protein hydrolysate to total weight of composition is provided. Whey protein hydrolysate is exemplary of a suitable soluble protein hydrolysate. A method for preparing such a composition is also provided.

Priority: US2006-354974 Applic. Date: 2006-02-16

Inventor: MARK WILLIAM ANTONIO [US]; HALL LLOYD THOMAS [US]


Application No.: US20110165239A1  Published: 07/Jul/2011

Title: PHARMACEUTICAL COMPOSITIONS OF ATORVASTATIN

Applicant/Assignee:

Application No.: 13/062891   Filing Date: 21/Sep/2009

Abstract:

The present invention provides stable pharmaceutical compositions comprised of atorvastatin and sodium bicarbonate or L-arginine. The compositions are prepared as bulk drug compositions and also as oral dosage units, such as tablets or capsules. The compositions are useful for preparation of monolithic and bi-layer tablets containing atorvastatin as the only active agent or combined with one or more additional active agents. The compositions are useful for treating hypercholesterolemia and related conditions.

Priority: US20080194037P Applic. Date: 2008-09-24; WO2009US57647 Applic. Date: 2009-09-21

Inventor: ALANI LAMAN [US]; GHOSH SOUMOJEET [US]


Application No.: US20110165240A1  Published: 07/Jul/2011

Title: GALENICAL FORMULATIONS OF ORGANIC COMPOUNDS

Applicant/Assignee:

Application No.: 13/063955   Filing Date: 22/Sep/2009

Abstract:

The present invention relates to a pharmaceutical oral fixed dose combination comprising a) a therapeutically effective amount of Aliskiren, or a pharmaceutically acceptable salt thereof, b) a therapeutically effective amount of Amlodipine, or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical oral fixed dose combination shows an in vitro dissolution of component (a) of 60% or less after 10 minutes and 98% or less after 20 minutes, and a dissolution profile of component (b) of 50% or more after 20 minutes, and 70% or more after 30 minutes at pH 2, said pharmaceutical oral fixed dose combination being bioequivalent, or close to reaching bioequivalence, to a free dose combination of Aliskiren and Amlodipine.

Priority: US20080098945P Applic. Date: 2008-09-22; WO2009US57750 Applic. Date: 2009-09-22

Inventor: VALAZZA STEPHEN [US]; WAGNER ROBERT F [US]; VIPPAGUNTA SUDHA [US]


Application No.: US20110165252A1  Published: 07/Jul/2011

Title: MEMANTINE FORMULATIONS

Applicant/Assignee: FOREST LABORATORIES HOLDINGS LIMITED

Application No.: 13/050139   Filing Date: 17/Mar/2011

Abstract:

The present invention relates to pharmaceutical compositions prepared from equant-shaped crystals of memantine, such as orally dissolving formulations, e.g., tablets (ODTs) and films (ODFs), and to methods of treating conditions, including childhood behavioral disorders (e.g., autism) and Alzheimer's disease by administering the same.

Priority: US2009-412447 Applic. Date: 2009-03-27; US20080040171P Applic. Date: 2008-03-28

Inventor: DEDHIYA MAHENDRA G [US]; SARKAR RANAJOY [US]


Application No.: US20110165253A1  Published: 07/Jul/2011

Title: NICOTINE-CONTAINING GRANULATE

Applicant/Assignee: SIEGFRIED LTD

Application No.: 13/058769   Filing Date: 16/Sep/2009

Abstract:

A dust-reduced nicotine-containing granulate comprising a homogenous mixture of nicotine or a pharmaceutically acceptable nicotine derivative and an excipient, the granulate having a particle size of at least 150 [mu]m. Method for the preparation of a dust-reduced nicotine-containing granulate, and use of the nicotine-containing granulate for the preparation of pharmaceutical products.

Priority: EP20080016336 Applic. Date: 2008-09-17; WO2009EP06676 Applic. Date: 2009-09-16

Inventor: ROEHRICH TILLMANN [CH]


Application No.: US20110165271A1  Published: 07/Jul/2011

Title: ANTITUMORAL TERPENOID PHARMACEUTICAL COMPOSITION 'ABISILIN' EXHIBITING ANGIOGENESIS-INHIBITING ACTION

Applicant/Assignee:

Application No.: 12/922338   Filing Date: 14/Mar/2008

Abstract:

The invention relates to medicine and the chemical and pharmaceutical industry and to agent for treating diseases caused by angiogenesis regulation disorders, in particular to a method for treating oncological diseases of different genesis by inducing angiogenesis inhibition which is secondary to the direct antitumoral, anti-reccurant and anti-metastatic action as well as by the associated activation of the apoptosis endogenous system. The invention uses a novel peroral medicinal form 'Abisilin', comprising ingredients relating to the class of natural terpene compounds (isoprenoids), produced from coniferous threes of a Pinaceue family, which medicinal form contains: sesquiterpenoids (3-6%), neutral diterpenoids (11-15%), diterpene acids (22-28%), triterpene acids (8-16%), unsaturated and saturated fatty acids (0.1-0.3%), phenolic compounds (0.1-0.2%), monoterpenoids being the rest, wherein the bornyl acetate content is equal to not less that 10.0% of the total terpene composition. It is expected that the use of the novel peroral medicinal form 'Abisilin', the substance of which exhibits immunomodulating, antibacterial, antiinfiammatory, anesthetic, wound-healing and other pharmacologically-significant actions, is free of contra-indications and toxic effects and can be used together with different agents, provides a novel therapeutic approach and enhances the efficiency of treatment of oncological and many other diseases caused by angiogenesis process disorders.

Priority: WO2008RU00147 Applic. Date: 2008-03-14

Inventor: MAKSIMOVNA PINIGINA NINA [RU]; ANATOLIEVNA LATSERUS LUDMILA [RU]; URIEVICH BARYSHNIKOV ANATOLY [RU]; MIHAILOVICH KOZLOV ALEKSEY [RU]; SERGEEVNA SMIRNOVA ZOYA [RU]; IRSHATOVNA MAGANOVA FANIA [RU]


Application No.: US20110166087A1  Published: 07/Jul/2011

Title: PHARMACEUTICAL COMPOSITION FOR USE IN TREATING SEXUALLY TRANSMITTED INFECTIONS

Applicant/Assignee:

Application No.: 13/062182   Filing Date: 04/Sep/2009

Abstract:

The present invention relates to a solid oral pharmaceutical composition comprising fluconazole, tinidazole and clindamycin or a pharmaceutically acceptable salt thereof, wherein the content of pharmaceutically acceptable excipients is significantly lower than the content of the active principles, the use of said composition for oral administration with therapeutic activity for treating sexually transmitted infections.

Priority: MX20080011321 Applic. Date: 2008-09-04; WO2009IB06738 Applic. Date: 2009-09-04

Inventor: GARCIA SALGADO LOPEZ RAUL [MX]; ARZOLA PANIAGUA ANGELICA [MX]; PABLO SENOSIAIN PELAEZ JUAN [MX]; BARRANCO HERNANDEZ GUSTAVO [MX]


Application No.: US20110166225A1  Published: 07/Jul/2011

Title: ORAL LIQUID COMPOSITIONS OF RHEIN OR DIACEREIN

Applicant/Assignee:

Application No.: 12/989966   Filing Date: 23/Sep/2008

Abstract:

The invention relates to liquid pharmaceutical compositions for oral administration comprising rhein or diacerein, or salts or esters or prodrugs thereof and processes for preparing such compositions.

Priority: IN2008MU00952 Applic. Date: 2008-04-30; WO2008IB53858 Applic. Date: 2008-09-23

Inventor: VERMA HIMANSHU [IN]; DABRE RAHUL [IN]; JAIN GIRISH KUMAR [IN]

Clck to enlarge and view details
US Applications Published in 2012
US Applications Published in 2010
...or use our Search Engine to
search for patent documents by
number.
Search for anything. Simply
type the words in the box..